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It is not known whether pancreatic cancers evolve from a single or multiple cells, or 
from a particular pancreatic lineage.  However, in the Pdx1-Cre; LSL-KrasG12D; LSL-
Tp53R172H mouse model of pancreatic cancer, all pancreatic lineages are susceptible 
to express mutant KRas and p53. Hence, such mouse model implies a scenario of 
maximal heterogeneity of cancer cell origins.  On this basis, I isolated seven sub-
clones of heterogeneous mouse pancreatic cancer cells from a single tumour; each of 
them had a distinct morphology and gene expression profile.  Notably, they 
possessed different intrinsic phospho-SMADs downstream of the TGFβ receptor 
(phospho-SMAD2/3) or the BMP receptor (Phospho-SMAD1/5/8).  I discovered that 
SMAD4, a co-SMAD which is frequently found to be lost in pancreatic caner tissues, 
upregulated HNF4α via the classical BMP-SMAD1 pathway, when cells were 
experiencing metabolic stress upon deprivation of serum, or in the presence of excess 
thymidine. Under serum starvation at a hypoglycemic-like glucose concentration, the 
HNF4α-expressing sub-clones appeared to be more able to sustain an unstressed 
morphology than other non-HNF4α-expressing sub-clones. Immunohistochemical 
staining on pancreatic cancer sections revealed nuclear co-localization of SMAD4 
and HNF4α in human (half of the cases) and in mouse samples.  As a secondary 
project conducted during characterization of cells, I also found that three of the sub-
clones more robustly proliferated under anchorage independent conditions, and they 
relied on the MEK-ERK pathway and the canonical Wnt pathway, to a different 
degree. Both studies demonstrate for the first time in primary cell culture that 
pancreatic cancer cells within a tumour could be highly heterogeneous in terms of 
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1.1 Overview of pancreatic cancer 
 
1.1.1 Risk factors of sporadic pancreatic cancer 
Pancreatic cancer in most cases interchangeably refers to pancreatic adenocarcinoma 
(Hruban et al., 2006).  It is one of the most lethal types of cancer, with an overall 5-year 
survival rate below 5% (reviewed by Hidalgo, 2010).  In the UK, pancreatic cancer ranks 
fifth for the deaths caused among other cancers (Figure 1A).  Another type of cancer in the 
pancreas is insulinoma, which is rare, non-ductal and arises in the beta cells of the endocrine 
pancreas.   
 
One main reason for the deadliness of pancreatic cancer is the difficulties in early detection.  
Owing to the retroperitoneal location of the pancreas, the pancreas is largely inaccessible for 
routine sampling, or radiographic and endoscopic screening (reviewed by Leach 2004) 
(Figure 1B).  Moreover, since pancreatic cancer causes few symptoms at early stages, 
diagnosis is often found when patients have undergone abdominal computed tomography 
(CT) scans for other reasons.  Hence, people who show symptoms attributable to pancreatic 
cancer, such as mid-back pain, obstructive jaundice and weight loss, may have reached more 
advanced, metastatic stages of the disease (reviewed by Vincent et al., 2011).  In addition, 
metastases are very common in regional lymph nodes, the liver, and other distant sites 
(Hruban et al., 2006).   
 
Pancreatic cancer is predominantly a disease of the elderly that it is rare before the age of 40, 
and the median age at diagnosis is 73 years (Villeneuve et al., 2000).  So far, only cigarette-
smoking has been identified as a preventable and statistically important cause (reviewed by 
Li et al., 2004), and as many as one in four cases of pancreatic cancer may be attributable to 
smoking (Lowenfels et al., 2006).  Other risk factors include diets high in meats and fat, low 
serum folate levels, obesity, chronic pancreatitis and long-standing diabetes mellitus 
(Lowenfels et al., 2006; Michaud et al., 2002, 2001; Everhart et al., 2006).  About 25% of 
patients with pancreatic cancer have diabetes mellitus at diagnosis and roughly another 40% 
1




Figure 1 (A) Ranking by the number of deaths caused by different cancer types in 2010 
(Source: Cancer Research UK website).  (B) - Location of the pancreas in the human body 
(Source: the New York Times).  (C) - Top: Gross appearance of pancreatic cancer excised 
from a surgery. bottom: low magnification of H&E staining of pancreatic cancer (Source: 




have impaired glucose tolerance (Chari et al 2008; Pannala et al., 2008; reviewed by Vincent 
et al., 2011).   
 
1.1.2 Familial pancreatic cancer 
Familial pancreatic cancer is defined as a patient having at least a pair of first-degree 
relatives diagnosed with the disease.  It accounts for up to 10% of pancreatic cancer cases 
(reviewed by Vincent et al., 2011).  Screenings do identify precancerous lesions in many 
individuals with strong family histories of pancreatic cancer (Szafranska et al., 2008; Li et 
al., 2010; reviewed by Vincent et al., 2011).  The risk for developing pancreatic cancer 
increases with the number of first-degree relatives diagnosed with pancreatic cancer, 
potentially attributed to autosomal dominant inheritance of a rare allele (Klein et al. 2004).  
A number of genes alterations have been found to be more closely related to familial than to 
sporadic pancreatic cancer, such as Brca2 (reviewed by Maitra & Hruban 2008).   
 
Nevertheless, individuals with germ-line Brca2 gene mutations do not always have a strong 
family history of cancer.  A demographic study reveals that in 41 patients with apparently 
sporadic pancreatic cancer, 4 patients have a Brca2 mutation but none has a family history of 
pancreatic cancer (Goggins et al., 1996).  This suggests the presence of additional modifiers 
in determining an individual’s susceptibility to familial pancreatic cancer.  In one family, the 
4q32-34 locus has been linked to the development of diabetes, pancreatic exocrine 
insufficiency, and pancreatic cancer with a penetrance approaching 100% (Eberle et al. 
2002).  However, it is not yet known which gene is associated with this syndrome.   
 
1.1.3 Clinical pathology and precursor lesions 
Pancreatic cancer is clinically classified into resectable (without spread to the nearby blood 
vessels or any distant tissues), borderline resectable, locally advanced (tumour cells present 
in nearby blood vessels) and metastatic disease (distant metastasis often with ascites).  Most 
of the primary tumours develop in the head of the pancreas (reviewed by Hidalgo 2011).   
 
In the operating theatre, pancreatic cancer often appears to be a firm, highly sclerotic mass 
(Hruban et al., 2006) (Figure 1C).  The edges of these cancers are poorly defined, with long 
tongues of carcinoma extending beyond the main tumour (Hruban et al., 2006).  At the light-
3
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microscopic level, pancreatic cancer is composed of an infiltrating gland-forming neoplastic 
epithelium with an intense desmoplastic reaction.  This desmoplastic reaction is usually so 
intense that only a minority of the cells in the mass formed by pancreatic cancer are actually 
neoplastic cells (Hruban et al., 2006).   
 
1.1.4 Precursor lesions 
Three types of pre-malignant lesions are believed to be the tipping points of pancreatic 
cancer progression, including the frequently observed Pancreatic Intraepithelial Neoplasia 
(PanIN), the intraductal papillary mucinous neoplasm (IPMN) and the mucinous cystic 
neoplasm (MCN).  PanINs are neoplastic lesions in the small (<5 mm) pancreatic ducts 
(Hruban et al., 2001; 2004).  They are observed in about 30% of specimens from clinical 
pancreatic samples of elderly patients (reviewed by Hezel et al., 2006).   
 
PanINs look like dyplastic growth of the pancreatic ducts, and are classified into three 
stages, starting with stage-I having the appearance of a columnar, mucinous epithelium and 
with increasing architectural disorganization and nuclear atypia through stages II and III 
(Figure 2A, B).  The high-grade PanINs eventually transform into pancreatic cancer with 
invasion of tumour cells into the basement membrane (reviewed by Hezel et al., 2006).   
 
Patients with PanINs often end up with pancreatic cancer, and PanINs are frequently found 
in the pancreatic parenchyma adjacent to infiltrating adenocarcinomas (Bart et al., 1998).  
Consistent with this, PanINs harbour many of the gene mutations found in pancreatic cancer 
(Maitra et al., 2005, 2006, reviewed by Maitra & Hruban 2008).   These mutations will be 
discussed in the next section.  Furthermore, telomere shortening occurs early in PanIN-1 
lesions, and this may contribute to the accumulation of chromosomal abnormalities (van 
Heek et al., 2002; reviewed by Maitra & Hruban 2008).   
 
In contrast, MCNs and IPMNs lesions are less frequently observed.  MCNs are large mucin-
producing epithelial cystic lesions that harbour an “ovary-like” stroma with dysplasia and 
focal regions of invasion.  The vast majority of MCNs arise in women (reviewed by Hruban 
et al., 2006; reviewed by Maitra & Hruban 2008).  The genetic basis of MCN has not been 
defined.  IPMNs resemble PanINs at the cellular level but grow into larger cystic and 
4
Normal Pancreatic Duct PanIN1a 
PanIN1b PanIN2 
PanIN3 Adenocarcinoma 
Figure 2 (H&E staining, top) - Morphology of early-to-late grade PanIN lesions, 
compared with normal pancreatic ducts and adenocarcinoma (Bottom) - An 
Illustration of pancreatic cancer progression, corresponding to the H&E staining 
shown in (A), and with respect to the timing of most frequently altered genes 





sometimes papillary structures (reviewed by Hezel et al., 2006).  Loss of the Stk11 gene 
product (Liver Kinase B1, LKB1) is very common (reviewed by Maitra & Hruban 2008).   
 
1.1.5 Genetic alterations in PanIN lesions 
Much effort has been spent in investigating the underlying genetic aberrations in patients and 
in detecting these lesions in patients.  Kras activating-mutations (more than 90% of patients) 
and telomere shortening occur early in low-grade PanIN (van Heek et al., 2002), whereas 
inactivations of Cdkn2a (more than 90%), Tp53 (more than 90%), Dpc4 (about 50%), and 
Brca2 (in familial pancreatic cancer) occur in advanced PanINs and invasive carcinomas 
(Hruban et al., 2002, 2008).  Many of these hot-spot mutations have been knocked into 
mouse models, resulting in tumour formation (to be discussed in later chapters).  Progress 
has also been made recently using improved endoscopic ultrasound to detect lesions as small 
as 1cm diameter.  In a clinical trial in the USA (NCT00438906), both improved endoscopic 
ultrasound (93%) and MRI (81%) demonstrated much stronger detection frequency in 
patients than CT (27%) (Canto et al., 2010, reviewed by Vincent et al., 2011).   
 
1.1.6 Current and potential drugs against pancreatic cancer  
Gemcitabine is the current routine treatment for patients with advanced pancreatic cancer.  It 
is a nucleoside analogue in which the hydrogen atoms on the 2' carbon of deoxycytidine are 
replaced by fluorine atoms, hence, being able to block DNA replication.  However, 
Gemcitabine alone alleviates symptoms only in a few patients with advanced tumours 
(reviewed by Vincent et al., 2011).  Therefore, many additional drugs in combination with 
Gemcitabine have been used to increase elimination of pancreatic cancer cells in patients.   
 
Since pancreatic tumours are often poorly vascularized and bounded by a relatively thicker 
stroma than other cancers, one treatment strategy is to increase cancer cells’ exposure to 
drugs, such as controllably increasing vasculature within the cancer, which has been shown 
effective in a mouse model study by using a hedgehog pathway inhibitor (Olive et al., 2009).  
To date, the hedgehog pathway inhibitor GDC-0449 (Genentech Inc., USA) is on phase-2 
clinical trial in the USA, in combination with Gemcitabine and the nanoparticle formulation 
of paclitaxel, in patients with metastatic pancreatic cancer (NCT01088815) (reviewed by 
Vincent et al., 2011).   
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1.1.7 Heterogeneity and clonal evolution 
Several studies using DNA sequencing and mathematical modelling with patient samples 
have shown that pancreatic cancer cells within a tumour are highly heterogeneous.   The 
major driver genes are mutated before the development of invasive adenocarcinoma, and 
further heterogeneity arises in different metastases due to continuing genetic instability 
(Campbell et al., 2010).  The metastatic cells evolve at about one in a million pancreatic 
cancer cells in the primary tumour (Haeno et al., 2012).   
 
Pancreatic cancer grows at an exponential rate (Haeno et al., 2012); a precursor neoplastic 
clone may take 10 years to become a malignant clone, plus five more years to acquire 
metastatic potential, and patients often die in two years thereafter (Yachida et al., 2010).  
Nevertheless, the studies also revealed that 13.8% patients died with only locally advanced 
tumour; if these patients did not die of obstructions, physiological problems or exaggerated 
responses to therapies, their primary tumours may intrinsically lack the factors to acquire 
metastatic potential (Haeno et al., 2012; reviewed by Tuveson 2012).   
 
1.1.8 Possible origins of pancreatic cancer cells 
Pancreatic cancer (ductal adenocarcinoma) on histology often resembles pancreatic duct 
cells, displaying cuboidal shape, tubular structures, and ductal antigen expression (Solcia et 
al. 1995).  Hence, pancreatic cancer is widely thought to have arisen from neoplastic ductal 
cells (reviewed by Hezel et al., 2006).  Despite such similarity to duct cells, the cell of origin 
(that receives the first oncogenic hit) for pancreatic cancer, and in fact for most solid 
malignant tumours, has never been directly identified.   
 
One hypothesis is that cancer precursors arise from adult stem cells, which are thought to 
have unique potential to self-renew and differentiate into multiple lineages when necessary, 
such as when there is a need for tissue-repair under stress or upon tissue damage (reviewed 
by Hezel et al., 2006).  However, such adult stem cell has not been identified in the pancreas, 
and developmental studies have found that the majority of β cells in vivo are generated by 
replication of existing β cells rather than formation of new β cells from stem cells (Dor et al. 




1.1.9 Multiple pancreatic lineages are susceptible to cancer in mice 
Mouse model studies have indicated that multiple cell types in the pancreas can give rise to 
pancreatic cancer, depending on the nature of carcinogenic stress.  For example, Gidekel 
Friedlander et al., 2009 showed that Pdx1-CreER; LSL-KrasG12D/+ mice develop mPanIN and 
ductal metaplasia as in Pdx1-Cre; LSL-KrasG12D/+ (Hingorani et al., 2003; 2005).  In contrast, 
the procarboxypeptidase-A1 (CPA1)-expressing acinar cells (proCPA1-CreER), and insulin-
expressing cells (Rip-CreER), were inefficiently transformed by KRasG12D/+ (Gidekel 
Friedlander et al., 2009).  Nevertheless, upon induction of chronic pancreatitis and 
inflammation by *caerulin, the insulin-positive cells were transformed into mPanINs, and 
into tumours if Tp53 or Ink4A/Arf was deleted simultaneously (Gidekel Friedlander et al., 
2009).   
 
This suggests that only a subpopulation of cells along the PDX1-positive acinar lineage are 
susceptible to transformation by mutant KRas, in the absence of prior tissue injury. While 
insulin-expressing endocrine β-cells may be sensitive to transformation under damaging 
stress.  Such subpopulations of highly-susceptible PDX1-positive cells are likely to be acinar 
cells that do not express CPA1.  This observation is supported by other mouse models 
showing loss of acinar cells after direct damage or apparent transdifferentiation, and 
accompanied by duct-like, proliferative structures (Hruban et al. 2006).  Furthermore, 
targeting the KrasG12D allele to the population of elastase-expressing acinar cells (mature 
acinar cells) resulted in formation of mPanINs and adenocarcinomas upon caerulein-induced 
pancreatitis (Guerra et al., 2007).  On the other hand, differentiated ductal cells are unlikely 
to be the proximate cell of origin for pancreatic adenocarcinoma in mouse, as expression of 
KrasG12D/+ under the control of the Cytokeratin-19 (CK-19) promoter, which includes the 
mature ductal epithelium lineage, did not cause mPanINs or neoplasia, but only periductal 
lymphocytic infiltration (Brembeck et al., 2005).   
 
In conclusion with these mouse models, acinar cells that do not express CPA1 are more 
likely to be transformed by mutant KRas.  Although pancreatic cancer have a duct-like 
appearance, pancreatic duct cells do not appear to be the source of cancer evolution; rather, if 
the pancreas is injured and inflamed, multiple cell types would become susceptible to cancer 




*[Caerulin is a ten amino-acid oligopeptide that stimulates expression of intercellular 
adhesion molecule-1 (ICAM-1) in pancreatic cells, via increased NF-κB inflammatory 
activity (Zaninovic et al., 2000).  Cell-surface ICAM-1 in turn promotes neutrophil adhesion 
onto acinar cells and enhances inflammation (Zaninovic et al., 2000). 
 
1.2 Ras GTPases and their mutants 
As KRasG12D is the primary driver for pancreatic cancer in the Pdx1-Cre mouse model used 
in my study, I am going to present the background and recent findings in some of the 
signaling pathways downstream of KRas.  
 
1.2.1 An Overview of the Ras GTPases 
The Ras proteins are monomeric GTPases that act as binary switches to regulate multiple 
cellular processes, such as proliferation, survival, differentiation and cell cycle entry.  They 
lie at the cross-road of many signaling pathways.  One main function of Ras is to couple, or 
uncouple, cell surface receptors to intracellular effector-pathways, by cycling between ‘on’ 
and ‘off’ conformations that are conferred by the binding to GTP or GDP, respectively 
(reviewed by Pylayeva-Gupta et al., 2011).  Such ‘on-off’ transition is regulated by guanine 
nucleotide exchange factors (GEFs), which promote the activation of Ras proteins by 
stimulating GDP for GTP exchange, and by GTPase-activating proteins (GAPs), that 
accelerate Ras-mediated GTP hydrolysis (reviewed by Pylayeva-Gupta et al., 2011) (Figure 
3A).   
 
In many cancers, Ras has been irreversibly turned into an “ever-on” mode by mutations that 
severely dampen the intrinsic rate of GTP hydrolysis, making Ras insensitive to GAPs.  
Notably, oncogenic substitutions in residues G12 or G13 of Ras results in steric hindrance 
and prevents the formation of van der Waals bonds between Ras and the GAP.  This 
consequently perturbs the proper orientation of the catalytic glutamine (Q61) in Ras, 
blocking GTP hydrolysis (Scheffzek et al., 1997; reviewed by Pylayeva-Gupta et al., 2011).   
 
In humans, three Ras genes encode four highly homologous Ras proteins of about 21kDa: 
HRas, NRas, KRas4A and KRas4B (KRas4A and KRas4B are alternative splice variants of 
the Kras gene) (reviewed by Pylayeva-Gupta et al., 2011).  These proteins are 90% identical 
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Figure 3 (A) - An Illustration of the forward and reverse mechanism in which GTP is 
hydrolyzed to GDP by Ras. (B) - Statistics of the most frequently mutated 
(substituted) amino acids in Kras’s G12, G13 and Q61 residues (source: Pylayeva-
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in the first 168–169 amino acids (known as the G domain) but variable in the 20 amino acids 
at the carboxyl-terminus (Ahearn et al., 2012).  Ras proteins are also subjected to post-
translational modifications, particular in their carboxyl-terminus, and are subsequently 
directed to various subcellular compartments, including the Golgi apparatus and endosomes; 
hence they can signal from multiple membrane structures (reviewed by Ahearn et al., 2012).   
 
1.2.2 Activating mutations of Ras 
Mutations of Ras occur in a wide range of cancers in humans, in which the first known and 
most common are the point mutations at codon 12 (from GGT to GAT or GTT, and more 
rarely CGT) that results in substitution of glycine with aspartate, valine, or arginine (Figure 
3B, 4A).  These codon-12 mutations are present in 30% of early neoplasms and in most of 
the advanced pancreatic ductal adenocarcinoma in patients (Klimstra and Longnecker 1994; 
Rozenblum et al. 1997).  KRas mutations are also frequently detected in colorectal cancers 
and non-small-cell lung carcinomas (NSCLC) (reviewed by Pylayeva-Gupta et al., 2011).  
While HRas mutations are associated with skin, head and neck cancers, NRas mutations are 
common in haematopoietic malignancies (reviewed by Pylayeva-Gupta et al., 2011).   
 
KRas mutations are also found in pancreatic tissues of patients with chronic pancreatitis, of 
cigarrette-smokers, and of pancreatic neoplasias in patients without pancreatic cancer (Tada 
et al., 1993; Jimeno et al., 2006).  This is consistent with findings in several mouse models 
that KRas mutation is an early event to potentiate aggressive adenocarcinoma.  Yet different 
KRas mutations can cause distinct outcomes.  In colorectal and lung cancers, KRasG12V 
mutation has been associated with a worse prognosis than KRasG12D mutation, suggesting 
particular amino acid substitutions may dictate specific transforming characteristics of 
oncogenic Ras alleles (reviewed by Pylayeva-Gupta et al., 2011).   
 
Ras mutations at codons other than 12, 13 or 61 cause developmental disorders rather than 
cancer.  For example, KRas mutations are found in some Noonan syndrome patients (a kind 
of dwarfism),  and those mutations are restricted to targeting residues Val14, Thr58, Val152, 
Asp153 and Phe156, all of which are thought to cause moderate upregulation of Ras activity 




In mice, universal expression of KRasG12D is lethal to the developing embryo (Tuveson et al., 
2004), indicating such oncogenic activating mutation is not tolerated during embryogenesis.  
Tissue-specific expression of the mutant KRasG12D in transgenic mouse models initiates lung 
hyperplasia (Jackson et al., 2001; Johnson et al., 2001), accelerates intestinal tumorigenesis 
that also carried a mutant allele of the adenomatous polyposis coli (Apc) tumour-suppressor 
gene (Chan et al., 2004), and induces formation of PanINs in Pdx-Cre or Ptf1a-Cre mouse 
pancreatic cancer models (Hingorani et al., 2003).   
 
Among the three Ras isoforms, only KRas is essential for embryonic development.  KRas-
deficient mouse embryos died of anaemia, liver defects and cardiac abnormalities after two 
weeks of gestation (Johnson et al., 1997; Koera et al., 1997; Khalaf et al., 2005; reviewed by 
Schubbert et al., 2007).  Deletion of HRas or NRas, or both, does not cause any 
malformation or survival difference (Esteban et al., 2001, Umanoff et al., 1995; reviewed by 
Schubbert et al., 2007).  Mice are still viable when the Kras gene is replaced by the Hras 
gene (Potenza et al., 2005).  Thus, HRas and NRas are functionally redundant in 
development; and the Kras promoter plays an exclusive role to direct Ras function in the 
appropriate cell compartments. 
 
1.2.3 Downstream of KRas  
The mutant KRas engages in numerous downstream pathways in pancreatic cancer.  Among 
the most well studied are the Raf-mitogen-activated kinase (MAPK) pathway, and the 
phosphoinositide-3-kinase (PI3K) pathway (reviewed by Hezel et al., 2006) (Figure 4B).  I 
am going to briefly describe these two pathways, as they are not the main focus of my 
project.   
 
Along the MAPK pathway, the Raf family of serine/threonine kinases are immediately 
downstream of KRas.  One-third of pancreatic cancers with wild-type KRas have activating 
mutations in B-Raf, so the downstream signaling can still be constitutively active in the 
absence of mutant KRas (Calhoun et al., 2003; reviewed by Maitra & Hruban 2008).  The 
RAF kinases then phosphorylate Mitogen-Activated Protein Kinase (MEK) kinases, such as 
MEK1 and MEK1, resulting in their activation (reviewed Downward, 2003).  Activated 
MEK kinases then phosphorylate Extracellular Regulated MAP Kinase (ERK), which have 
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Figure 4 (A) - The crystal structure of a GTP-bound Ras, with arrows showing 
G12 and G13, two hotspot residues that are frequently mutated in cancer, 
(adapted from Schubbert et al., 2007).  (B) – An illustration of three of the 
many pathways downstream of Ras, respectively Ral, Mek and PI3K, which are 

























numerous pro-proliferative targets in both the cytoplasm and the nucleus (reviewed by 
Downward, 2003).   
 
The PI3K-AKT pathway is also constitutively activated in most pancreatic cancers (reviewed 
by Maitra & Hruban 2008).   Preventing Ras from binding to PI3K, but not pharmacological 
inhibition of PI3K, was found effective in preventing mutant KRas-induced lung tumour 
formation (Gupta et al., 2007), providing a potential strategy to be used in treating pancreatic 
cancer.  Although Ras certainly contributes to PI3K-AKT signaling in pancreatic cancer, the 
Akt2 gene on chromosome 19q is also found to be amplified in about 15% of the cases 
(Cheng et al., 1996; reviewed by Maitra & Hruban 2008).  Hence, targeting different 
downstream components of PI3K may be required in treating pancreatic cancer.   
 
1.3 p53 and its mutants 
The mutant p53R172H  acts as the accelerator for KRasG12D-induced pancreatic cancer in the 
Pdx1-Cre mouse model used in my study.  In this section, I am going to discuss the 
background of and recent findings about p53 in pancreatic cancer.   
 
1.3.1 Roles of p53 in normal cells 
P53 is the central mediator of cellular responses to acute stress and has a well established 
role in protecting cells against cancer (reviewed by Vousden & Lane 2007) (Figure 5A).  In 
doing so, p53 induces cell cycle arrest, senescence, or apoptotic activities upon DNA 
damage (Lassus et al., 1996; Gorgoulis et al., 2005) or oncogene expressions (Bartkova et 
al., 2005; Efeyan et al., 2006).  These selective mechanisms prevent errors during DNA 
duplication under stress, enhance the fidelity of cell division, and prevent cancers from 
arising (reviewed by Riley et al., 2008).   
 
For example, glucose starvation of normal cells causes phosphorylation at Ser15 on p53 by 
AMP kinase without activating additional p53-mediated transcriptions (reviewed by Riley et 
al., 2008).  Conversely, glucose starvation of transformed cells causes p53-mediated 
apoptosis (Feng et al., 2007).  Introduction of a mutant Ras oncogene into epithelial cells 
causes p53-mediated senescence (Yang et al., 2006), which in turn triggers production of 




Figure 5 (A) - Levels and functions of p53 in normal cells under non-stressed and 
stressed conditions (Source: Vousden & Lane 2007).  (B) - Frequency of different 
hotspot mutations on p53 found in human cancers (Source: Freed-Pastor & Prives 
2012).   
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cell from the organ (Yang et al., 2006).   
 
Hence, the “p53 network” is inter-regulated by numerous pathways, resulting in different 
programmes of transcription by p53 (reviewed by Riley et al., 2008).  Under normal 
conditions with minimal stress, p53 activity is held in check by multiple mechanisms in cells.  
For example, HDM2 (first discovered as MDM2 in mouse) is one of the key ubiquitin 
ligases that negatively regulates protein levels of p53.  Deletion of Mdm2 in mice results in 
pre-embryonic lethality due to failure to restrain p53-mediated apoptosis (reviewed by 
Vousden & Lane 2010).  
 
1.3.2 Mutant p53 and carcinogenesis  
Inactivation of Tp53 on chromosome 17p, the gene that encodes p53, is found in 50% of 
human cancers (reviewed by Toledo & Wahl 2006).  Inactivation is most commonly in the 
form of intragenic mutation, combined with loss of the second allele (Redston et al., 1994).  
While another 50% of human cancers show overexpression of its negative regulators, such as 
MDM2 and MDM4 (MDMX) (reviewed by Toledo & Wahl 2006).  Loss of p53 function 
allows cells to survive and divide even with faulty DNA, and this leads to accumulation of 
more and more genetic abnormalities (Vogelstein et al., 2004).   
 
Two of the most common and well studied hotspot mutants of p53 are R172H 
(corresponding to R175H in mouse) and R273H (corresponding to R270H in mouse) (Figure 
5B).  R175H disrupts p53’s DNA-binding domain and affects its overall structure (Sigal et 
al., 2000; Cho et al., 1994), whereas R273H still maintains a wild-type p53 conformation but 
is defective in DNA binding, since R273 directly binds DNA in the wild type p53 (Cho et al., 
1994).  Both mutants lose the ability to sensitize to cell-cycle arrest and to induce senescence, 
despite this there is no intrinsic survival difference between Tp53 mutant or Tp53 null mice 
(Lang et al., 2004; Olive et al., 2004).   
 
However, mutant p53 has acquired additional or even malignant functions.  Notably,  p53 
mutants enhance metastatic potential in multiple knock-in mouse models (Liu et al., 2000; 
Lang et al., 2004; Olive et al., 2004; reviewed by Donehower & Lozano, 2010), and this is 
not observed in the p53-null mice.  Such acquired pro-metastatic function of p53 mutants 
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also depends on additional genetic modifiers that vary among different mouse strains 
(Donehower & Lozano, 2010, as unpublished data).   
 
Mutation to different amino acids at the same site of p53 can end up with different outcomes.  
For example, if R175 is mutated to P instead of H, the p53 mutant still retains some tumour 
suppressor capacity and is rarely selected for during tumour evolution in both mouse and 
human (Liu et al., 2004).  Furthermore, these R to H p53 mutants can induce genomic 
instability by inactivating Mre11/ATM-dependent DNA damage responses, causing 
chromosomal translocation and defects in the G2/M checkpoint (Liu et al., 2010).  In 
addition, both wild type and mutant p53 can be extensively modified by phosphorylation, 
acetylation, methylation, ubiquitination, sumoylation, neddylation and even addition of N-
acetyl glucosamine (reviewed by Levine & Oran 2009), each of which influences the 
stability and activity of p53. 
 
1.3.3 Stability of p53 and mutant p53 
Since mutant p53 is stabilised by evading MDM2-mediated degradation, it is often easily 
detected by immunohistochemistry; this is in contrast to wild-type p53, which is present at 
very low levels in unstressed normal cells (Donehower & Lozano, 2010).  However, in 
homozygous Tp53 mutant mice, mutant-p53 is not necessarily stable in all cell types, 
irrespective of the particular Tp53 mutation they inherited (Lang et al., 2004; Olive et al., 
2004; reviewed by Donehower & Lozano, 2010).  This suggests that signals (such as MDM2) 
that keep wild-type p53 at low levels may also maintain low levels of mutant p53.  Hence, 
additional factors are needed to stabilize mutant p53 during cancer progression (Donehower 
& Lozano, 2010).   
 
One of these factors is loss of the INK4A cell cycle inhibitor (reviewed by Kim & Sharpless 
2006), which occurs in 80% of human pancreatic cancer (reviewed by Tuveson 2012).  
Malfunctioning INK4A leads to increased Cyclin-D and CDK complexes, which in turn 
phosphorylate retinoblastoma protein (Rb).  Phosphorylated Rb releases the transcription 
factor E2F1, which activates a tumour suppressor ARF (one of the gene products the Cdkn2a 
gene);  ARF sequesters MDM2 and eventually stabilizes p53 (reviewed by Polager & 
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Figure 6 – An illustration of how p53 and its “network partners” regulate the activity of 
one another.  When DNA damage is detected, the cells will undergo a transient arrest; If 
DNA damage exceeds certain threshold levels, cells will undergo either apoptosis or 
senescence.  Although p21CIP and p15INK4B are now known to mark senescence, it is 
still not clear how cells determine which way to go; the cell type and the nature of the 
damage are believed to be important factors (reviewed by D’Adda di Fagagna 2008).  
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cell-type dependent manner, as only a subset of cell types showed stabilized mutant p53 in 
Tp53R172H/R172H/ Cdkn2aINK4A-/- mice (Terzian et al., 2008). 
 
1.4 The canonical Wnt pathway 
The canonical Wnt pathway has been well known to be deregulated in colorectal cancer.  
Since the pancreas is also a part of the gastroenterological system, as a secondary project, I 
investigated whether or not the canonical Wnt pathway is upregulated in only a subset of the 
KRas-induced mouse cancer cells, despite there is little evidence for the Wnt pathway to 
play an important role in pancreatic cancer.  In this section, I am going to present the 
background of the canonical Wnt pathway and the tankyrase inhibitors used in my study.   
 
1.4.1 The central role of β-catenin  
β-catenin is the central messenger of the canonical Wnt pathway; it shuttles from the 
cytoplasm to the nucleus to induce Wnt specific transcriptional responses.  When the 
pathway is inactive, cytoplasmic β-catenin levels are kept low by continuous proteasome-
mediated degradation, which is mediated by the β-catenin destruction complex involving 
GSK-3β, APC and Axin (reviewed by Logan & Nusse, 2004) (Figure 7A).  GSK-3β is a 
serine/threonine kinase that phosphorylates β-catenin as a label for its degradation (Yost et 
al. 1996), whereas both Axin and APC are scaffolding proteins (Hart et al. 1998, Kishida et 
al. 1998) that enhance interaction between GSK-3β and β-catenin.  This complex is 
subjected to negative regulation by tankyrase, which directs Axin to degrade through 
ubiquitination of Axin (Huang et al., 2009).  In addition to GSK-3β, casein kinase Iα can also 
phosphorylate β-catenin to mediate its degradation (Amit et al. 2002, Liu et al. 2002, 
Yanagawa et al. 2002).  Phosphorylated β-catenin is recognized by β-TrCP, targeted for 
ubiquitination, and eventually degraded by the proteosome (Aberle et al. 1997, Latres et al. 
1999, C. Liu et al. 1999; reviewed by Logan & Nusse, 2004).   
 
Activation of the canonical Wnt pathway is normally initiated at the cell surface upon 
binding of Wnt-ligands to Frizzled receptors and co-receptor (LRP5 or LRP6) complexes.  
Upon activation, the Frizzled receptor complexes transduce signals to stabilise β-catenin by 
dissociating the destruction complex, thereby allowing sufficient β-catenin to translocate into 
the nucleus (Figure 7A).  Nuclear β-catenin interacts with transcription factors such as 
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Figure 7 (A) – An illustration of the canonical Wnt pathway, featuring how β-
catenin is set free or being targeted to degradation, when the pathway is active 
(ligand binding to receptors) and inactive (no ligand binding to receptors).  (B) The 
chemical structure of two tankyrase inhibitors used in this study. Axin is stabilized 
as tankyrase’s Axin binding site is blocked by the inhibitors, and this eventually 
enhances the formation of the β-catenin destruction complex, thereby suppressing 
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lymphoid enhancer-binding factor 1/T cell-specific transcription factor (LEF/TCF) to 
regulate Wnt-specific transcription. Numerous Wnt target genes have been identified, and 
these include components of the Wnt pathway itself, indicating that the canonical Wnt 
pathway is also regulated by feedback mechanisms (reviewed by Logan & Nusse, 2004). 
 
1.4.2 Studying Wnt in the mouse pancreas 
Mutations in β-catenin regulatory proteins are rare in pancreatic cancer (reviewed by Morris 
et al., 2010), hence the role of β-catenin in pancreatic cancer has been controversial.  
Moreover, deletion of APC in the mouse pancreas (Pdx1-Cre/ Apcflox/flox), which resulted in 
constitutively activated canonical Wnt pathway, was insufficient to initiate PanIN lesions or 
pancreatic cancer (Strom et al., 2007).  Yet, these mice showed increased post-natal 
pancreatic mass that correlates with enhanced proliferation of acinar cells, accumulation of 
nuclear β-catenin in older mice, and increased expression of β-catenin target genes (Strom et 
al., 2007).  This suggests that the canonical Wnt pathway may contribute to proliferation of 
acinar cells during aging. 
 
Furthermore, both Pdx1-Cre/ LSL-Wnt1 and Pdx1-Cre/ LSL-Wnt5a mice had severe 
hypoplasia, suggesting these ligands of the canonical and non-canonical Wnt pathway 
suppress pancreas development or cell differentiation.  In contrast, transgenic expression of 
other ligands of Wnts2, 4, 6, or 7a, caused no phenotype (reviewed by Gittes, 2008).  
Consistent with these findings, targeted expression of a constitutively active β-catenin 
(having negative regulatory phosphorylation sites removed) under the control of the Pdx1 
promoter resulted in severe hypoplasia (Heiser et al., 2006).  Taken together, it appears that 
hyperactivation of certain aspects of the Wnt pathway potentiates proliferation and 
suppresses differentiation of pancreatic cells.   
 
1.4.3 Activated Wnt pathway in colorectal cancers 
Since constitutive activation of the Wnt pathway is prevalent in colorectal cancer, a large 
part of our understandings of the pathway has come from studying colorectal cancer.  
Sporadic colorectal cancer accounts for about 85% of all colorectal cancers cases, while 
some other colorectal cancers evolve from a genetic disease known as familial adenomatous 
polyposis (FAP) (Ashton-Rickardt et al., 1989; Groden et al., 1991; reviewed by Klaus & 
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Birchmeier 2008).  Patients with FAP develop hundreds to thousands of adenomatous polyps 
in the colon; if the polyps are not removed, some of these polyps can progress to malignant 
carcinomas (reviewed by Klaus & Birchmeier 2008).   
 
Abnormal activation of the Wnt pathway in both familial and sporadic colorectal cancers is 
most often attributed to truncations of APC, a key component of the β-catenin destruction 
complex described in the preceding section. APC mutations are commonly found to be 
frameshift, nonsense or splice-site mutations, which result in truncations of about 50% of the 
APC protein (reviewed by Polakis 2000).  As an early event in colorectal cancer progression, 
mutation in a single APC allele is insufficient to induce adenomatous polyposis; alterations 
in the remaining APC allele or additional oncogenic mutations, commonly in Kras, Smad2, 
Dpc4 or Tp53, are required (reviewed by Klaus & Birchmeier 2008).  
 
1.4.4 Tankyrase mediates Axin to degrade and stabilize β-catenin 
Tankyrase was first identified as a Poly (ADP-Ribose) Polymerase localized to human 
telomeres (Smith et al., 1998), and later found to have a central role in regulating the 
canonical Wnt pathway (Huang et al., 2009).  It is expressed in adipose tissue, brain, and 
endocrine pancreas but scarcely in the exocrine pancreas and skeletal muscle in mouse (Yeh 
et al., 2009).  Tankyrase-deficient mice are viable but show an increase in both fatty acid 
oxidation and insulin-stimulated glucose utilization, resulting in increased food intake and 
higher core body temperatures as compared with normal mice (Yeh et al., 2009).   
 
Tankyrase’s role in the canonical Wnt pathway is to bind Axin and to catalyze poly-ADP-
ribosylation of Axin, thereby promoting Axin degradation, which results in stabilization of 
β-catenin (Huang et al., 2009).  The co-crystal structure of  
‘tankyrase-binding-to-Axin’ reveals two well conserved tankyrase-binding segments of Axin 
(amino acid 18-30 and 60-80).  These two segments are each marked by a glycine residue 
that interacts with two parallel tyrosine side-chains on tankyrase’s surface (Morrone et al., 
2012).  Mutation of either glycine residue abolishes bivalent binding of the corresponding 





Two of the earliest compounds that disrupt the interaction between tankyrase and Axin are 
XAV939 (Huang et al., 2009) and IWR-1 (Chen et al., 2009; Huang et al., 2009) (Figure 
7B).  IWR1 was found effective in a well documented, canonical Wnt-active human colon 
cancer cell line, DLD1.  Stabilization of Axin by IWR1 in DLD1 cells did not reduce total β-
catenin levels, but promoted phosphorylation of β -catenin (Chen et al., 2009).  XAV939 
decreases β -catenin levels, and increases β -catenin phosphorylation (S33/S37/T41) by 
GSK3β in SW480 cells (Huang et al., 2009).  In addition, XAV939 also appears to be a more 
potent tankyrase inhibitor, with an IC50 of 0.004 - 0.011µM, compared with that of IWR1 
between 0.78 – 1.897µM (Huang et al., 2009).  Nevertheless, such high-affinity inhibition of 
tankyrase in vitro is not reflected in vivo in zebrafish, as both compounds are required at 
higher dose (between 5 – 10 µM) in order to be effective (Chen et al., 2009; Huang et al., 
2009).  This suggests that both XAV939 and IWR1 are inefficient to be used in vivo.   
 
1.4.5 Axin2 and Lgr5 – two most commonly used in vivo Wnt reporter genes 
Axin2 and Lgr5 are only two of the many Wnt target genes, but they are commonly found to 
be more specific than many other target genes to be used as readouts of the canonical Wnt 
pathway in vivo.  The Jackson Laboratory, one of the dominant suppliers of transgenic mice, 
is producing robust mouse strains bearing intrinsic reporter for the activity of Axin2 and Lgr5 
to visualise Wnt activity in mouse tissues.  Indeed their transcriptional levels have been a 
useful measurement of canonical Wnt activity in my study of anchorage independent 
proliferation of murine pancreatic cancer cells, but not other Wnt-target genes tested, such as 
Myc and Tcf7, which appeared to be less reflective of Wnt activity.   
 
Axin2 expression is directly induced by canonical Wnt signalling.  As a negative-feedback 
protein, its expression pattern marks the cells exposed to Wnt signals (Jho et al., 2002; 
Lustig et al., 2002).  Similar to Axin1, which instead is ubiquitously expressed, Axin2 can 
inhibit and stabilize β -catenin when overexpressed in cells (Behrens et al., 1998).  Despite 
their differences in expression pattern, Axin2 can fully replace the function of Axin1 during 
mouse development, when it is homozygously knocked into the Axin1 locus (Chia & 
Costantini 2005).  However, deletion of Axin2 in mice resulted in defects in skull and tooth 
development (Yu et al., 2005), suggesting it has unique roles in development and cell 




Lgr5 (leucine-rich-repeat-containing G-protein-coupled receptor 5, also known as Gpr49) is 
a Wnt target gene of the TCF4 family of transcription factors (Barker et al., 2007).  This G 
protein coupled receptor interacts with the Frizzled/lrp Wnt receptor complex upon binding 
of the ligand, R-spondin (de Lau et al., 2011).  It was originally identified in colon cancer, 
and has also been shown to be overexpressed in ovarian and hepatic cancers (reviewed by 
Haegebarth & Clevers 2009).  It is a useful marker of adult stem cells in the colon and skin 
(Barker et al., 2007; reviewed by Haegebarth & Clevers 2009).  Lgr5 is expressed 
exclusively in cycling columnar cells in the crypt base; whereas in the stem cell niche of the 
murine hair follicle, Lgr5 is expressed in actively cycling follicle cells (reviewed by 
Haegebarth & Clevers 2009).  Mice deficient for Lgr5 exhibit a malformation of the tongue 
and the lower jaw, causing newborns to swallow air, leading to early neonatal death (Morita 
et al., 2004). 
 
1.5 The Transforming Growth Factor-β (TGFβ) superfamily 
The TGFβ/BMP pathway is one of the implicated pathways in pancreatic cancer, in which 
SMAD4, the central mediator of the pathway’s many upstream signals, is known to be 
deleted in 50% of pancreatic cancer cases.  As the main focus,  as well as the key discovery 
of my project, I am going to present the backgrounds and chemical inhibitors of the 
TGFβ/BMP pathway.   
 
1.5.1 Overview of the TGFβ superfamily  
The human TGFβ super family comprises more than 30 cytokines or cytokine-like ligands 
that can be divided into two distinct branches (Massague 2008).  Activin, Nodal, Lefty, 
Myostatin, and TGFβ are clustered in one family branch, and bone morphogenetic proteins 
(BMPs), anti-muellerian hormone (AMH, also known as MIS), and various growth and 
differentiation factors (GDFs) are grouped into the other branch (Derynck and Akhurst, 
2007; Roberts and Wakefield, 2003; Shi and Massagué, 2003; Massagué 2008).  Among 
these branches, the TGFβ and the BMP sub-branches have been more extensively studied.  
Their ligands exist in multiple forms, for example, TGFβ family has TGFβ1, β2, and β3 




The BMP/TGFβ ligands are synthesized within the cell as dimeric pro-hormones (Gray et al., 
1990).  These dimeric precursors are then secreted into the extracellular matrix, where they 
are cleaved by furins and other convertases to become active ligands (Dubois et al., 1995; 
Constam et al., 1999).  Active ligands bind their specific type-2 receptors, such as BMPR2 
and TGFβR2.  Binding of the mature ligand causes phosphorylation of the type-1 receptors 
(also known as Activin-receptor-link kinase, ALK) by the type-2 receptor, and the two 
receptors consequently form a heterotetrameric receptor complex (reviewed by Massague 
2008).  Both type 1 and type 2 receptors contain serine or threonine kinase domains in their 
intracellular portions (Heldin et al., 1993).  These heterotetrameric receptor-complexes 
activate both SMAD-dependent and non-SMAD-dependent pathways (reviewed by Derynck 
& Zhang 2003).  Non-SMAD-dependent pathways overlap with many other pathways, such 
as the PI3-kinase, p38-MAP kinase, Ras homolog gene family - member A (RhoA), and 
Rho-associated protein kinase (ROCK) (reviewed by Derynck & Zhang 2003).   
 
1.5.2 Signal transduction by SMAD proteins 
The SMAD proteins are mammalian homologs of the Drosophila melanogaster protein, 
Mothers Against Decapentaplegic (MAD), and the Caenorhabditis elegans protein SMA 
(from gene sma for small body size).  Hence, SMAD is a portmanteau of the two.  Of the 
five Receptor-associated SMADs (R-SMADs) in mammals, type-1 receptors of the TGFβ 
branch (ALKs 4, 5 and 7) phosphorylate SMADs 2 and 3, whereas those of the BMP branch 
(ALKs 1, 2, 3 and 6) phosphorylate SMADs 1, 5, and 8, (Piek et al., 1999; Jornvall et al., 
2001) (Figure 8A).  However, it is now known that TGFβ ligands can also phosphorylate 
SMAD1 and SMAD5 in certain cell types via TGFβR2-ALK1/5 complexes (Irwin et al., 
2008; Wrighton et al., 2009).  Upon phosphorylation, the R-SMADs lose affinity to their 
cytoplasmic retention proteins, such as SARA (SMAD anchor for receptor activation), and in 
turn exposing their nuclear localization signal sequences (Tsukazaki et al., 1998).  These 
activated R-SMADs may then form heteromeric complexes with SMAD4 (also known as co-
SMAD) and accumulate in the nucleus (Shi & Massague 2003).   
 
In the nucleus, the SMADs complexes associate with additional DNA-binding co-factors to 
specifically regulate target gene expressions.  These SMAD partners are members of various 
families of transcription factors, such as the forkhead, homeobox, zinc-finger, basic helix-
loop-helix (bHLH), and Activator Protein-1 (AP1) families (Feng and Derynck, 2005; 
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Figure 8 (A) – An illustration of the TGFβ/BMP pathway, starting from 
activation of receptors by ligands, to signaling through their respective R-
SMADS and SMAD4, and accumulation of these complexes in the nucleus and to 
bind DNA to initiate transcription programs (B) – The chemical structure of two 
BMP type-I receptor inhibitors (left) and a TGFβ type-I receptor inhibitor (right) 
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Massagué et al., 2005; reviewed by Massague et al., 2005).  However, SMAD4 is not always 
required for the RSMADs to go into the nucleus.  For example, Transcriptional intermediary 
factor 1γ (TIF1γ) competes with SMAD4 to interact with phosphorylated SMAD2/3 and 
mediate TGFβ-induced erythroid differentiation (He et al., 2006).  Independent of SMAD4, 
phospho-SMAD2/3 can also bind IκB kinase α (IKKα), which negatively regulates 
keratinocyte proliferation by upregulating the Myc antagonists, Mads, during mouse 
epidermal differentiation (Descargues et al., 2007).   
 
1.5.3 SMAD4, the co-SMAD 
Dpc4 (Deleted in Pancreatic Cancer locus 4), which codes for the SMAD4 protein, is a 
tumour suppressor gene on chromosome 18q21.  As its name implies, homozygous deletion 
is found in about 30% of pancreatic cancer cases, and loss of one allele coupled with an 
intragenic mutation in the second allele is found in another 25% of the cases (Hahn SA et al., 
1996; Wilentz et al., 2000).  Deletion of Dpc4 is frequent in ductal pancreatic cancer 
(Hruban et al., 2006), and with a relatively low incidence in non-ductal pancreatic cancer and 
in other cancers, including colon, breast, and ovarian or biliary tract carcinomas (Schutte et 
al., 1996; Hahn et al., 1998).  On immunohistochemistry, SMAD4 protein expression reflects 
the Dpc4 gene status in pancreatic cancers with rare exceptions (Wilentz et al., 2000).  In 
addition, absence of SMAD4 often correlates with higher metastatic potential in patients of 
pancreatic cancer (Wilentz et al., 2002).  Somatic mutation of SMAD4 in pancreatic cancer 
usually emerges during the transition from adenoma to carcinoma (Jaffee et al., 2002; Jones 
et al., 2008; reviewed by Massague 2008).  Hence, loss of SMAD4 in tumours is generally a 
late event (reviewed by Massague 2008).  
 
Despite the fact that TGFβ receptor or SMAD4 mutations are often found in cancer, tissue-
specific ablation of the gene encoding TGFβR2 alone in mouse cancer models is rarely 
sufficient to induce tumourigenesis (reviewed by Massague 2008).  For example, no 
developmental or pathological changes are observed upon deletion of TGFβR2 in the 
epithelia of the murine oral cavity, esophagus, forestomach (Lu et al., 2006), pancreas (Ijichi 
et al., 2006), intestine (Muñoz et al., 2006), or skin (Guasch et al., 2007).  In the mouse 
mammary gland, although deletion of TGFβR2 results in excessive lobular-alveolar cell 




Similarly, deletion of SMAD4 does not affect normal development or cause spontaneous 
tumour formation in the mouse liver (Wang et al., 2005b) or mouse pancreas (Bardeesy et 
al., 2006, Kojima et al., 2007; Xu et al., 2010).  However, it does cause spontaneous 
squamous cell carcinomas in the mammary gland, which shows trans-differentiation of 
mammary epithelium to squamous epithelium (Li et al., 2003).  Overall, mouse models 
reveal that TGFβ is not a universal proliferation suppressor; it suppresses proliferation only 
under some conditions, for example, when there is tissue injury or oncogenic stress.   This is 
demonstrated by increased rate of keratinocyte proliferation, migration, and would healing in 
injured mouse skin that lacks SMAD3 or TGFβR2 expression.   
 
Both TGFβR2 and SMAD4 have been shown to accelerate cancer progression in mouse 
models.  Deletion of TGFβR2 promotes carcinoma conversion of intestinal polyps initiated 
after deletion of the Apc gene or by chemically-induced mutagenesis (Biswas et al., 2004 and 
Muñoz et al., 2006).  Similarly, heterozygous deletion of a single Dpc4 allele potentiates the 
progression of intestinal polyps to carcinoma in APC-deficient mice with loss of the 
remaining wild-type Dpc4 allele (Takaku et al., 1998).  In a mouse model of pancreatic 
cancer, KRasG12D-induced PanIN lesions progress to IPMN-type lesions when combined with 
deletion of SMAD4 (Bardeesy et al., 2006).  Somatic mutation of SMAD4 in pancreatic 
cancer, and of TGFβR2 or SMAD4 in colorectal cancer, are selected during the adenoma to 
carcinoma transition (Jaffee et al., 2002 and Jones et al., 2008).  Furthermore, loss of 
SMAD4 promotes metastasis in mouse pancreatic cancer models (reviewed in Mazur and 
Siveke, 2011), and loss of SMAD4 also correlates with increased metastasis in patients 
(Iacobuzio-Donahue et al., 2009). 
 
1.5.4 The TGFβ-responsive R-SMADS 
Despite their crucial function in connecting signalling pathways, R-SMAD mutations are 
infrequent in cancer (Massague 2008).  Intragenic mutations in SMAD2 occur in only a 
small proportion (5%) of colorectal cancers (Sjoblom et al., 2006); loss of SMAD3 
expression occurs in some gastric cancers and T cell lymphoblastic leukemias (Levy and 
Hill, 2006). However, SMAD2 may occasionally mark metastasis, as histological analysis 
demonstrates that 75% of human breast cancer bone metastasis biopsies show nuclear 
phosphorylated-SMAD2 in metastatic cancer cells (Kang et al., 2005).  Mice deficient in 
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SMAD3 develop colon cancer after Helicobacter infection due to increased inflammation 
(Maggio-Price et al., 2006).   
 
Although both SMAD2 and SMAD3 are downstream of the TGFβ branch of the pathway, 
they have distinct target genes (Brown et al., 2007).  One important difference between 
SMAD2 and SMAD3 is their ability to bind DNA.  The SMAD3 homodimer can form 
DNA-binding complexes with its MAD homology1 domain (MAD1) in the absence of 
SMAD4 (reviewed by Brown et al., 2007).  In contrast, the SMAD2 homodimer cannot bind 
DNA without SMAD4, because the MH1 domain of SMAD2 has a small insert encoded by 
an extra exon of about 30 amino acids that blocks its way to directly bind DNA (Yagi et al., 
1999).  In some human pancreatic cancer cell lines that lack SMAD4, TGFβ signalling 
through SMAD2 and SMAD3 seem to remain intact, as both proteins are serine 
phosphorylated and localized to the nucleus (Fink et al., 2003; Subramanian et al., 2004).  In 
addition, nuclear SMAD2/3 is also detected in mouse PanIN lesions by 
immunofluoresccence (Bardeesy et al., 2006).   
 
1.5.5 The BMP responsive R-SMADs 
Multiple mouse models indicate that the BMP-SMADs pathway acts to suppress 
tumourigenesis in most situations.  BMPR1A-null mice died at embryonic day 8.0 (E8.0), 
due to lack of mesoderm formation (Mishina et al., 1995a).  Similarly, heterozygous or 
homozygous deletion of SMAD1 or SMAD5 is embryonic lethal; in contrast, SMAD8-null 
mice are viable and fertile (Arnold et al., 2006; Pangas et al., 2008).  If both SMAD1 and 
SMAD5 are homozygously deleted in ovarian granulosa cells or in testicular cells, tumours 
would arise and cause infertility.  These mice develop peritoneal and lymphatic metastases 
regardless of gender, indicating that SMAD1 and SMAD5 are essential to development of 
germ cells, and are critical tumour suppressors with redundant functions (Pangasa et al., 
2008).  
 
Another example showing the tumour suppressor role of the BMP-SMAD pathway is 
Juvenile Polyposis Syndrome.  It is a rare autosomal dominant disorder characterized by a 
predisposition to hamartomatous polyps and cancers of the gastrointestinal and colorectal 
tract.  This syndrome is caused by germline mutation of either SMAD4 (15%–20% of the 
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patients) or BMPR1A (in 20%–25% of the patients) (Calva-Cerqueira et al., 2009; Friedl et 
al., 2002; Howe et al., 2002; van Hattem et al., 2008; reviewed by Yang & Yang 2010).   
 
Consistent with the human disease, heterozygous deletion of SMAD4 in mice causes polyps 
along the gastrointestinal tract.  These polyps morphologically resemble those of Juvenile 
Polypsosis Syndrome, and loss of heterozygosity (LOH) are frequently observed in advanced 
tumours of the Dpc4+/- mice (reviewed by Yang & Yang 2010).  In addition, both Bmpr1a, 
and Dpc4 are among the cancer driver genes identified in a mouse model using transposons 
to insert mutations in the gastrointestinal epithelium, along with Pten and Apc (Starr et al., 
2009).  Deletion of Bmpr1a under the control of a gastric epithelium promoter, Mx1-Cre, 
caused polyps in the intestinal epithelium and carcinomas in the gastrointestinal transitional 
zone (Bleuming et al., 2007). 
 
1.5.6 SB-431542, a potent TGFβ receptor inhibitor used in this study 
SB-431542 is a potent inhibitor against the TGFβ type-I receptors (ALK4, ALK5 and 
ALK7) (Inman et al., 2002) (Figure 8B).  2μM SB-431542 can completely inhibit the 
activity of endogenous ALK5 receptors with little apparent non-specific effects.  For 
example, it does not affect growth factors’ mediated pathways, such as EGFR induced 
ERK/MAP kinases or stress induced JNK or p38 MAP kinases (Inman et al., 2002).  
Importantly, it does not cross-inhibit the BMP type-I receptors (ALK1, ALK2, ALK3 and 
ALK6), except at very high concentration of 10μM, it starts to exert relatively weak activity 
against ALK3 (Inman et al., 2002).   
 
1.5.7 Dorsomorphin and LDN1931890, the two potent BMP receptors inhibitors used in 
this study 
Dorsomorphin selectively inhibits the BMP type-I receptors ALK2, ALK3 and ALK6 and 
thus blocks BMP-mediated SMAD1/5/8 phosphorylation and their respectively downstream 
signals (Yu et al., 2008) (Figure 8B).  It does not inhibit TGFβ type-I receptors (ALK4, 
ALK5 and ALK7).  Dorsomorphin’s action is mediated by blocking the constitutively active 
form of the BMP type-I receptor kinases (Yu et al., 2008).  Conversely, it is unable to block 
SMAD-independent pathways (Yu et al., 2008).  Dorsomorphin is structurally identical to 
compound C, a molecule previously shown to antagonize AMP-activated kinase (AMPK) 
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activity in vitro (Zhou et al., 2001; Yu et al., 2008).  LDN-193189 is an optimized derivative 
of Dorsomorphin (Cuny et al., 2008; Yu et al., 2008b).  It inhibits BMP-mediated 
phosphorylation of SMAD1/5/8 with an IC50 value that is much lower than that for 
Dorsomorphin (5nM versus 470nM) (Yu et al., 2008b).  It also shows enhanced specificity 
for the BMP type-I receptors over TGF-β type I receptors and AMPK (Yu et al., 2008b). 
 
1.6 Hepatocyte Nuclear Factor 4 – Alpha (HNF4α) 
With an inspiration from the paper by Sirard et al., Genes Dev. 1998 “The tumour suppressor 
gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the 
mouse embryo.”, I directly established for the first time that the nuclear receptor HNF4α is 
downstream of the BMP-SMAD pathway, and that such pathway is selectively activated in a 
subset of pancreatic cancer cells.  In this section, I am going to introduce what is known in 
the literature about this important nuclear receptor. 
 
1.6.1 An overview of HNF4α 
HNF4α is a highly conserved nuclear receptor that is expressed in almost all levels of 
animals, from sponge to humans (reviewed by Sladek 2011) (Figure 9A).  It is classified as 
an ‘orphan’ receptor within the nuclear receptor superfamily and functions as a homodimer 
(Jiang et al., 1995).  Like many other nuclear receptors, HNF4α is activated through a 
conformational change, which allows the release of co-repressors and binding of co-
activators (reviewed by Gonzalez 2008).  HNF4α activates the expression of a wide range of 
genes for metabolism, including those for glucose, fatty acid, cholesterol and xenobiotic and 
drug metabolism (Odom et al., 2004; Waxman et al., 2009).  Expression of HNF4α can be 
driven by two promoters, and there are at least six splice variants, which are present in 
different cell types (reviewed by Sladek 2011).   
 
1.6.2 HNF4α and SMAD4 during early embryogenesis 
HNF4α is expressed during gastrulation of the mouse embryo.  It is essential for the 
formation of visceral endoderm; as deletion of the Dpc4 gene, which codes for SMAD4, 
causes growth retardation and absence of HNF4α in the mouse embryo (Sirard et al., 1998) 
(Figure 9B).  Deletion of the Alk2 gene, which codes for a BMP Type-I Receptor, causes 





Figure 9(A) – The amino acid sequence of Hepatocyte Nuclear Factor 4-α (HNF4α) is highly 
conserved across species.  (B) – Left, deletion of SMAD4 in the the mouse embryo disrupts 
gastrulation and results in absence of the endoderm marker HNF4α (Source: Sirard et al., 
1998).  Right, deletion of ALK2, a BMP Type-I receptor, also disrupts gastrulation of the 
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other hand, data suggests that TGFβ down-regulates the expression of HNF4α, reportedly by 
inducing proteasome-dependent degradation; however, it is not clear whether or not SMAD4 
is involved (Lucas et al., 2004). 
 
1.6.3 Inactivation of HNF4α causes diabetes 
In humans, HNF4α is mainly expressed in organs along the gastrointestinal tract, including 
liver, pancreas, small intestine, where they are all endoderm-derived tissue (with reference to 
mouse development); however, there is one exception – the kidneys, which are derived from 
the mesoderm (Sladek et al. 1990; Si-Tayeb 2010).  In human hepatocytes and pancreatic 
islet cells, HNF4α regulates a large fraction of their transcriptomes by binding directly to as 
many as half of the actively transcribed genes, as shown by Chromatin Immunoprecipitation 
(CHIP) assays; this may well explain why HNF4α is essential to both development and 
proper function of the liver and pancreas (Odom et al., 2004).  
 
Indeed, heterozygous mutations of HNF4α cause type-1 maturity-onset diabetes of the young 
(MODY1), a genetic disorder of the insulin-secreting pancreatic beta cells characterized by 
diabetes mellitus before 25 years of age with an autosomal dominant pattern of inheritance 
(Fajans et al., 2001).  These MODY1 patients show normal insulin sensitivity, and both liver 
and kidney function, but have a defect in glucose-stimulated insulin secretion from the 
pancreatic β-cells (Gupta et al., 2005).  Of interest, no homozygous mutations of the HNF4α 
gene have been found in humans.  This is in agreement with the neonatal lethality found in 
mice with ubiquitous deletion of HNF4α (Chen et al., 1994), in which the mouse embryos 
failed to go through normal gastrulation; in which HNF4α is normally expressed specifically 
in the visceral endoderm (Duncan et al., 1994, 1997). 
 
1.6.4 Ablation of HNF4α in mice 
Mice with homozygous deletion of HNF4α in pancreatic β-cells (Ins-Cre; Hnf4αflox/flox) show 
impaired insulin secretion, resembling maturity-onset diabetes of the young (MODY).  
Unlike in humans, heterozygous deletion of HNF4α in mice does not result in diabetes 




In the embryonic mouse liver, HNF4α is essential for the differentiation of hepatocytes and 
is engaged in hepatocyte-specific gene regulation related to the synthesis of apolipoproteins, 
acute phase reactive proteins, and many other secreted proteins (Mizutani et al., 2011).  In 
the adult mouse liver, deletion of HNF4α causes severe deregulation of fatty acid 
metabolism, resulting in higher mortality (Hayhurst et al., 2001; Inoue et al., 2002, 2004, 
2006).  Furthermore, HNF4α is required for development of the mouse colon, as HNF4α 
deficiency in the developing colon results in absence of crypt formation (Garrison et al., 
2006).  
  
1.6.5 HNF4α in drug metabolism 
HNF4α is also an important player in cellular response to xenobiotics.  It directly participates 
in xenobiotics induced expression of Cytochrome P450 3A4 (CYP3A4), a well documented 
enzyme responsible for the biotransformation of many structurally divergent drugs in clinical 
use (Tirona et al., 2003).  Conditional heterozygous deletion of HNF4α in the fetal mouse 
liver showed little expression of CYP3A, and reduced basal and inducible expression of 
CYP3A in the adult mouse liver (Tirona et al., 2003).  
 
1.6.6 HNF4α and reactive oxygen species in cancer 
Conflicting reports have put HNF4α in both tumour-promoting and tumour suppressing roles 
depending on the cellular context.  Transient inhibition of HNF4α initiates hepatocellular 
transformation through a microRNA inflammatory feedback loop circuit in mouse 
(Hatziapostolou et al., 2011).  However, HNF4α acts to protect intestinal cancer cells from 
the generation of reactive oxygen species (ROS) (Darsigny et al., 2010).  Microarray 
analysis of gene expression profiles from mice lacking HNF4α in the intestinal epithelium 
identified novel functions of HNF4α in targeting oxidoreductase-related genes involved in 
the regulation of ROS levels.   
 
1.7 The pancreas and mouse models of pancreatic cancer 
 
1.7.1 Overview of the pancreas 
The pancreas has both exocrine (regulation of protein and carbohydrate digestion) and  
endocrine (glucose homeostasis) compartments (Figure 10A, B).  The exocrine pancreas, 
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Figure 10 (A) - Distribution of the exocrine and endocrine glands in the pancreas - 
taken from the website of Johns Hopkins University Pancreatic Cancer Center: 
www.path.jhu.edu/pancreas/professionals/DuctLesions.php. (B) – An illustration of 
the known cell types present in the normal adult pancreas (a mouse pancreas in the 
H&E stained photograph). In the endocrine pancreas, alpha cells produce glucagon 
(15–20% of total islet cells), Beta cells produce insulin (65–80%), Delta cells produce 
somatostatin (3–10%), PP cells (gamma cells) produce pancreatic polypeptide (3–
5%), and Epsilon cells produce ghrelin (<1%).  In the exocrine pancreas, acinar cells 
produce digestive enzymes such as amylase, secret and deliver enzymes via the duct 






which makes up over 95% of the pancreatic mass, is composed of a branching network of 
acinar and duct cells (reviewed by Murtaugh & Melton 2003 and Hezel et al., 2006).  The 
acinar cells, which are organized in functional units along the duct network, synthesize and 
secrete zymogens, such as trypsin and amylase, into the ductal lumen in response to cues 
from the stomach and duodenum (reviewed by Hezel et al., 2006).  These pancreatic ducts 
merge and feed into progressively larger structures, finally connecting to the common bile 
duct (reviewed by Murtaugh & Melton 2003).  Within the acinar units, near the ducts, are 
centroacinar cells.   
 
Endocrine cells are organized into globular clusters of Islets of Langerhan and are dispersed 
throughout the exocrine tissue.  The islets make up only a small fraction of the total organ 
mass, about 1–2% (reviewed by Murtaugh & Melton 2003).  Within the islets, the endocrine 
cell types are present in varying proportions: β-cells make up the majority (60–80%) and 
form a core around which the others are arranged. α-cells comprise 15–20% of the islet 
mass, and the remaining cells are of δ and Pancreatic Polypeptide (PP) type (reviewed by 
Murtaugh & Melton 2003).  Rare cells expressing endocrine markers, such as insulin, can 
also be found associated with the acini and the ductal epithelium (Mills, 2007).   
 
1.7.2 Lineage-specific promoters used in mouse models  
Pancreas and liver progenitors develop from endoderm cells in the embryonic foregut (Zaret 
et al., 2008).  Specifically, the pancreas derives from two patches of epithelial outgrowth that 
bud dorsally and ventrally from the gut epithelium, between the stomach and duodenum.  
This starts in the mouse at about embryonic day 9 (E9).  Prior to and during budding of the 
pancreatic primordium, all progenitor cells express the homeodomain protein Pdx1, and 
these cells later give rise to all pancreatic cell types (Figure 11A), (Ohlsson et al. 1993, Gu et 
al. 2002), including pancreatic duct cells (Gu et al. 2002).   
 
During the course of budding, Pdx1 expression was at high levels in developing β-cells and 
at lower levels in undifferentiated precursors (Guz et al. 1995, Jensen et al. 2000a).  
Inactivation of the Pdx1 gene in the pancreata results in growth arrest just after budding 
(Ahlgren et al. 1996, Offield et al. 1996), indicating that although Pdx1 expression has been 
initiated before budding, its functions are mainly in post-budding differentiation of the 
endocrine cells (Burlison et al., 2008).  Thus, some other developmental transcription 
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Figure 11 
Figure 11 (A) - Lineage specification during pancreas development, showing Ptf1a and 
Pdx1 are among the earliest genes expressed in the developing pancreatic duct, and 
Pdx1 is eventually also expressed in β-cells. (Hruban et al., 2006).  (B) - Cross of strains 
to generate Pdx1-Cre; LSL-KrasG12D+/-; LSL-Tp53R172H+/-, with options to include a 













































factors, but not Pdx1, are required for budding of the pancreatic epithelium (reviewed by 
Murtaugh & Melton 2003).  Furthermore, Pdx1 is required for proliferation in the post-
budding pancreatic epithelium; conditional suppression of the Pdx1 gene, using tetracycline 
transactivator protein (tTA), perturbs islet and acinar differentiation (Holland et al. 2002).  
However, at later stages of development beyond E9.5, Pdx1 is also expressed in the 
epithelium of the duodenum, the bile duct, and the posterior part of the stomach (Li et al., 
1999, Offield et al. 1996, Miller et al., 1994, Guz et al., 1995; Jørgensen et al., 2007).   
 
In the adult pancreas, Pdx1 was originally found to be a critical transcriptional inducer of 
insulin and somatostatin in adult islet cells (Ohlsson et al., 1991, 1993; Miller et al., 1994; 
Leonard et al., 1993; Peshavaria et al., 1994; reviewed by Jørgensen et al., 2007).  Pdx1 
expression is limited to β-cells in the Islet of Langerhans; β-cell-specific deletion of the Pdx1 
gene results in loss of insulin production and diabetes (Ahlgren et al. 1998).  Heterozygous 
ablation of Pdx1 in mice results in a MODY-like diabetic phenotype (Dutta et al. 1998). 
 
Another pancreatic lineage promoter that has been widely used for pancreatic specific 
transgenic expression is Ptf1a.  It is coexpressed with Pdx1 in both dorsal and ventral pre-
budding pancreatic epithelia from E9.0 to E9.5 (Jørgensen et al., 2007).  At E10.5, Ptf1a is 
restricted to the epithelium of the pancreatic primordia with sharp boundary with the 
duodenum (Jørgensen et al., 2007).  Later at E12.5, Ptf1a expression segregates to the 
growing tips of the branching epithelium to eventually end up in the acinar cells (Jørgensen 
et al., 2007), in contrast, Pdx1 is also expressed in some extra-pancreatic tissues and 
eventually in mature β-cells.  Like Pdx1, Ptf1a is dispensable for budding of the early 
pancreatic epithelium, but indispensable for post-budding differentiation of the exocrine-
acinar lineage (Krapp et al. 1998; Kawaguchi et al., 2002; Burlison et al., 2008).  Co-
expression of Ptf1a and Pdx1 is required for pancreas development, as pancreas formation is 
restored in the offspring from crossing Pdx1-null mice with Ptf1a-Pdx1 mice (expressing 
Pdx1 under the control of the Ptf1a promoter) (Kawaguchi et al. 2002).   
 
In the developing pancreatic primordium, Ptf1a-expressing cells contribute to almost all cell 
types of the dorsal and ventral pancreas (Kawaguchi et al. 2002).  This has been shown by 
lineage tracing in mice using the Ptf1aCre/+ genotype coupled to a Cre-catalyzed activation of 
a LacZ reporter gene (Kawaguchi et al. 2002).  Furthermore, Ptf1a-null mice fail to develop 
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the ventral pancreatic bud, and cells are instead integrated into the duodenum, resulting in 
absence of acinar cells (Krapp et al. 1998; Kawaguchi et al., 2002).  While in the dorsal 
pancreas, outgrowth and branching are decreased comparing with the wild-type pancreatic 
buds (Kawaguchi et al., 2002).  These lines of evidence suggest that Ptf1a is essential for 
specification and terminal differentiation of acinar cells and for suppression of an intestinal 
fate.   
 
1.7.3 Lineage specificity of Pdx1 and Ptf1a  
In terms of specificity to the pancreas, both Pdx1 and Ptf1a genes are not exclusive.  Pdx1 is 
also expressed in cells that give rise to stomach and duodenum during embryogenesis 
(Gannon et al., 2000), while Ptf1a is also expressed in the cerebellum (Hoshino et al., 2005).  
In transgenic models, the Pdx1-Cre system occasionally develops extra-pancreas tumours 
(Aguirre et al. 2003; Hingorani et al. 2005), in contrast to Ptf1a-Cre which was reported to 
be free of extra-pancreas tumours, even in the cerebellum (Ijichi et al., 2006).  Moreover, 
Cre-mediated recombination appears to be more homogeneous in the Ptf1a-Cre system than 
in the Pdx1-Cre system (Ijichi et al., 2006; Hingorani et al. 2003).  Hence the Ptf1a-Cre 
system may have a small advantage in specificity over the Pdx1-Cre system.  While the 
mouse model used for my experiment in this thesis were driven by Pdx1-Cre, with reference 
to Hingorani et al., 2003; 2005.   
 
1.7.4 The Pdx1-Cre/ LSL-KrasG12D/+/ LSL-Tp53R172H/+ (KPC) mouse model 
The so called KPC mouse model was originally developed by Tyler Jacks and David 
Tuveson’s group, in which mouse pancreatic malignant neoplasia and cancer are efficiently 
generated by conditional expression of KRasG12D and p53R172H, driven by Cre-recombinase 
under control of the Pdx1 promoter that covers all pancreatic lineage (Figure 11B).  Once the 
LoxP-Stop-LoxP (LSL) sequence upstream of the knock-in mutant allele is removed by Cre-
mediated recombination, KRasG12D and p53R17H2  mutant proteins can continue to be 
expressed in all surviving progeny, even while Pdx1 has ceased expression in the mature 
acinar cells in the postnatal pancreas (reviewed Hruban et al., 2006) (Figure 12A).  
Importantly, expression of KRasG12D and p53R17H2 do not visibly affect normal development 
of the pancreas.  As shown by very young KPC mice of about 4 to 6 weeks old, most of the 
pancreatic parenchyma appears histologically normal, suggesting tumorigenesis is unlikely 


















Figure 12 (A) - Mechanism of CRE-recombinase to target conditional expression of 
KRasG12D and p53R172H in all pancreatic lineage under the control of a pancreas-specific 
transcription factor, PDX1.  (B) - An example of the appearance of mouse pancreatic cancer 
and liver metastasis (left) and the microscopic view of tumour sections by H&E staining 
(right); photographs from Hingorani et al., 2005.   
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Expression of KRasG12D alone is sufficient to induce PanIN lesions in about 12 months time, 
with only occasional incidences of tumour development (Hingorani et al., 2003); but when 
the mutant p53 is also expressed together with KRasG12D in the pancreas, these premalignant 
lesions are rapidly transformed into pancreatic ductal adenocarcinoma and metastasized to 
the liver and lung, at around 10-week old, and their median survival length is only 20 weeks 
(Hingorani et al., 2005) (Figure 12B).  The mutant p53R172H (or loss of p53) acts to retain 
KRasG12D-expressing cells in the pancreas by overcoming growth arrest or senescence 
(Morton et al., 2009), while the remaining wild-type Tp53 allele is uniformly lost and 
genomic instability is acquired.  Moreover, the mutant p53R172H can simultaneously inhibit 
the wild type counterpart (Kern et al., 1992).  Since PanIN lesions are observed in a similar 
stage and degree in both the KrasG12D/+/ Tp53R172H/+ and KrasG12D/+-alone mice, additional 
genetic alterations must have been acquired to promote neoplasia development.   
 
The KPC mouse model closely recapitulates the human pancreatic cancer in many respects.  
The mice display symptoms that are highly reminiscent of clinical symptoms, including 
cachexia, abdominal distension, and obstruction of the biliary and small bowel (Hingorani et 
al., 2005).  The pattern of Erbb2/Her2 in mouse pancreatic tumour is variable even within a 
given animal, consistent with the heterogeneous nature of Erbb2/Her2 expression observed 
in human pancreatic cancer (Day et al., 1996).  Phospho-ERK/MAP kinase level is variable 
and appears to correlate with the pattern of Erbb2/Her2 expression (Hingorani et al., 2005).  
Furthermore, mutant p53R172H is stabilized while the wild-type Tp53 allele is lost in all 
primary and metastatic pancreatic tumour cell lines (Hingorani et al., 2005).  This is in 
agreement with observations in human (Rozenblum et al., 1997; Scarpa et al., 1993), 
suggesting LOH is a requisite step in tumour progression (Hingorani et al., 2005).  
Furthermore, the distribution of metastases also resembles that of human pancreatic cancer, 
mostly encountered in the liver (80%), lung (50% to 60%), adrenal glands (20%), and 
peritoneum (20% to 30%) (reviewed by Lillemoe et al., 2000; Hingorani et al., 2005). 
 
1.7.5 Roles of SMAD4 (Dpc4) and TGFβR2 during pancreatic carcinogenesis 
The combination of KRasG12D and SMAD4 deficiency causes rapid development of tumours 
resembling IPMN lesions, and consequently a dramatic reduction in survival compared with 
KRasG12D alone (Bardeesy et al., 2006).  All these mice, regardless of whether Pdx1 or Ptf1a 
was used, presented with a palpable abdominal mass between ages 7 and 12 weeks, and 
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reached terminal morbidity between ages 8 and 24 weeks of age.  Comparing age-matched 
Cre LSL-KrasG12D/+ and Cre LSL-KrasG12D/+/ Dpc4lox/lox pancreas at 2 weeks, there was no 
significant differences in tumour morphology, but the 4-week time point shows a SMAD4 
deficiency that correlated with a significant increase in both the number and size of the 
lesions.  These early lesions progress to extensive IPMN and advanced PanIN lesions by 8 
weeks, while the age-matched Ptf1a-Cre/ LSL-KrasG12D/+ counterparts had only focal low-
grade PanINs.  BrdU staining also revealed that PanINs and metaplastic ductal lesions in Cre 
LSL-KrasG12D/+/ Dpc4lox/lox mice demonstrated increased proliferation relative to lesions in 
Cre LSL-KrasG12/+/ Dpc4+/+ mice and to controls, for both epithelial and stromal tissues.     
 
The Tgfbr2 gene is inactivated in less than 5% of human pancreatic cancers, and mostly in 
medullary carcinoma types, a rare variant of pancreatic cancer (Goggins et al. 1998).  Similar 
to deletion of SMAD4, deletion of Tgfbr2 in the context of KRasG12D develop well-
differentiated mouse pancreatic cancer with 100% penetrance and a median survival of about 
15 weeks (Ijichi et al., 2006).  In the absence of KRasG12D, deficiency in TGFβR2 alone in 
the Ptf1a-expressing lineage did not affect pancreas development or cause tumour 
development (Ijichi et al., 2006), but ubiquitous deficiency of TGFβR2 is embryonic lethal 
(Oshima et al., 1996).  Unlike Pdx1- or Ptf1a-Cre/ LSL-KrasG12D/+/ Dpc4lox/lox mice, which 
develop locally advanced disease, the Ptf1a-Cre/ LSL-KrasG12D/+/ Tgfbr2flox/flox tumours also 
displayed distant metastasis, local invasion, and peritoneal dissemination; the mice survived 
to a similar age to the Pdx1-Cre/ LSL-KrasG12D/+/ LSL-Tp53R172H/+ mice, which produces 
highly metastatic tumours (Ijichi et al., 2006).  
 
The SMAD4-deficient mice show different histological phenotypes from that in human 
pancreatic cancer.  Loss-of-SMAD4 has had a well-documented correlation with metastasis 
in human (discussed in the previous paragraph), but no metastases are found in aged Pdx1-
Cre/ KrasG12D/+/ Dpc4lox/lox mice up to 33 weeks.  Furthermore, loss-of-SMAD4 is not 
typically found in association with IPMN in human pancreatic cancer (Furukawa et al., 2005; 
Iacobuzio-Donahue et al., 2000).  However, mice bearing Ptf1a-Cre/ LSL-KrasG12D/+, 
ablation of SMAD4, but not TGFβR2, develop IPMN (Ijichi et al., 2006).  This suggests that 
mutations in just KRas and SMAD4 in mice are unable to resemble the human cancer, which 
is likely to involve additional genetic aberrations.  For example, p16Ink4A and p53 are known 
to be frequently mutated in human pancreatic cancer; while in the mouse models, both may 
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have remained wild-type (Kojima et al., 2007), let alone other potential non-conserved 
underlying pathways between human and mouse.   
 
In addition, discrepancies in the phenotype between SMAD4-null and TGFβR2-null mice 
suggest a potential involvement of the BMP-SMAD1/5/8 route, which surprisingly, has not 
been studied much in pancreatic cancer to date – only a few in vitro reports using established 
cell lines can be found in the literature.  This may have been due to lacking robust antibodies 
to distinguish different SMADs on immunohistochemistry.  Nevertheless, BMPR1 and 
SMAD3 (of the TGFβ route) mutations have already been identified by high throughput 
sequencing in human pancreatic cancer samples (Jones et al., 2008).  Hence, it would be of 
immediate interest for the research community to investigate the roles of the BMP-SMAD4 
pathway during pancreatic carcinogenesis, such as via the use of the Pdx-Cre/Ptf1a-Cre 
system in mice, along with some improved SMAD antibodies that may now be available.  
 
1.8 Thesis Aims 
It is not clear whether human cancers originated from a single cell or from multiple cells, or 
from particular lineages of cells in an organ.  However, in the mouse model used in this 
project, all pancreatic cells could express the mutant KRasG12D and mutant p53R172H under the 
control of Pdx1-Cre-mediated recombination.  Considering the pancreas parenchyma already 
comprises different cells types, along with genomic instability acquired during cancer 
progression, heterogeneous tumour cells were likely to evolve simultaneously from different 
cell compartments in the pancreas.  Moreover, histology of both human and mouse 
pancreatic cancer already demonstrate extensive heterogeneity of cells.  Hence, I wished to 
identify some important differences in the properties between individual tumour cell types, 
and to find out what pathways and transcription factors were activated in the background of 
KrasG12D and p53R172H.   
 
In order to first find out if heterogeneous cell types exist in the primary culture of mouse 
pancreatic cancer cells, I conducted single-cell cloning, which has never been done with this 
mouse model in the literature.  I identified at least seven cell sub-clones were present, in 
which they showed different morphologies under the light microscope, and each having a 
gene expression profile indicated by screenings with PCR and immunoblots.  Among the 
pathways examined, I found that the canonical Wnt pathway and ERK phosphorylation were 
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more active in some of the cell-sub-clones that proliferated under anchorage independent 
conditions.  As a minor project, I examined which pathway was playing a stronger role in 
supporting proliferation under anchorage independent conditions.   
 
As my main project and of particular interest, the mouse pancreatic cancer cell sub-clones 
demonstrated differential phospho-SMADs downstream of the TGFβ/BMP receptors, which 
appeared to correlate with HNF4α expression in some of the cell sub-clones.  Since SMAD4 
is lost in 50% of the pancreatic cancer cases, such differential SMAD phosphorylation would 
be of high relevance to human pancreatic cancer.  Moreover, HNF4α is well documented in 
the control of glucose metabolism, I therefore investigated a potential relationship between 
the TGFβ/BMP pathway, HNF4α expression, and influence of glucose concentration on the 




MATERIALS & METHODS 




2.1.1 Subcutaneous injection in mice 
 
Supplier: Charles River, UK 
CD1 nude mice  
 
Supplier: Invitrogen, Paisley, UK 
Hank's Buffered Salt Solution (HBSS) 
 
Supplier: Beckman Coulter UK Ltd, Buckinghamshire, UK 
21G needle and 1ml syringe  
 
2.1.2 Cell culture medium & routine buffers 
 
Supplier: Invitrogen, Paisley, UK 
Foetal Bovine Serum 
Dulbecco's Modified Eagle Medium (DMEM - high glucose) 
Dulbecco's Modified Eagle Medium (DMEM - no glucose) 
Minimum Essential Medium (MEM) 
L-Glutamine 
Non Essential Amino Acids 
200mM L-Glutamine 
MEM Vitamins (100x) 
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MEM Non-Essential Amino Acids (NEAA) (100x) 
2.5% Trypsin solution 
 
Supplier: Edinburgh Cancer Research Centre 
Sterile PBS 
Sterile PBS/1mM EDTA 
 
2.1.3 Cell culture plastic ware 
 
Supplier: TPP Helena Biosciences, Tyne & Wear, UK 
FACS polypropylene tubes 
Falcon tissue culture dishes (60mm, 90mm and 120mm) 




2.1.4 Cell culture chemicals 
 
Supplier: Sigma Chemical Co, Poole, UK 
Dimethyl Sulphoxide (DMSO) 
Sodium Pyruvate 
Calcium Chloride 
Propidium Iodide (PI) 
Bovine Serum Albumin (BSA) solution 
 
Supplier: Qiagen, Crawley, UK 
RNase A 
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Supplier: R&D systems, Abingdon, UK 
Recombinant mouse BMP9 
 
Supplier: Cell Signaling Technologies, Hertfordshire, UK 
Recombinant mouse TGFβ1  
 
Supplier: Millipore, Hampshire, UK 




Supplier: Thermo Fisher Scientific, Loughborough, UK 
37% Formaldehyde Solution 
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Supplier: Invitrogen, Paisley, UK 
Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) 
Alexa Fluor® 488 Goat Anti-Rabbit IgG (H+L) 
Alexa Fluor® 594 Goat Anti-Mouse IgG (H+L) 
Alexa Fluor® 594 Goat Anti-Rabbit IgG (H+L) 
 
Supplier: Thermo Fisher Scientific, Loughborough, UK 
Microscope glass slides 
Coverslips (19mm) 
 
Supplier: Vector Laboratories Ltd, Peterborough, UK 
Vectashield mounting medium 
Vectashield mounting medium with DAPI 
 
Supplier: Olympus UK Ltd, Hertfordshire, UK 
Olympus FV1000 Confocal microscope 
 
(Primary antibodies) 
Supplier: Cell Signaling Technologies, Hertfordshire, UK 
Anti phospho-Histone H3 rabbit Ab 
 
Supplier: R&D systems, Abingdon, UK 
Anti HNF4α mouse monoclonal Ab 
 
Supplier: Transduction Laboratories, BD Biosciences, Oxford, UK 
Anti E-cadherin monoclonal mouse Ab 
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Supplier: Abcam plc, Cambridge, UK 




Supplier: Dako UK Ltd, Ely, UK 
DAKO Envision kit ™ (mouse and rabbit) 
 
Supplier: Olympus UK Ltd, Hertfordshire, UK 
Olympus BX51 microscope 
 






Supplier: Vector Labs, UK 
Immedge pen 
 
Supplier: Thermo Fisher Scientific, Loughborough, UK 
DPX mounting reagent 
 
Supplier: Leica Microsystems, Milton Keynes, UK 
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(Primary antibodies) 
Supplier: R&D systems, Abingdon, UK 
Anti-HNF4α mouse monoclonal Ab (used 1 in 500) 
 
Supplier: Santa Cruz Biotechnology Inc, USA 
Anti-SMAD4 mouse monoclonal Ab clone B8 (used 1 in 100) 
 
2.1.7 Protein extraction & western blotting  
 
Supplier: PERBIO, Glasgow, UK 
Micro BCA ™ protein assay kit 
 
Supplier: Beckman Coulter UK Ltd, Buckinghamshire, UK 
Beckman DU® 650 spectrophotometer 
 
Supplier: GE Healthcare, Little Chalfont, UK 
Full range molecular weight rainbow ™ marker 
 
Supplier: Genetic Research Instrumentation, Dunmow, UK 
Atto protein electrophoresis apparatus 
 
Supplier: Jencons, Leighton Buzzard, UK 
Wet blotting apparatus 
 
Supplier: Severn Biotech Ltd, Kidderminster, UK 
Design-a-gel 30% acrylamide, Bis-Tris (37: 5: 1) 
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Supplier: Schleicher and Schuell, London, UK 
Nitrocellulose membrane 
 
Supplier: Whatman, Maidstone, UK 
3mm filter paper 
 
Supplier: Cell Signaling Technologies, Hertfordshire, UK 
Anti-mouse/horseradish peroxidase conjugate 
Anti-rabbit/horseradish peroxidase conjugate 
 
Supplier: Millipore, UK 
Re-blot Plus Strong antibody stripping solution 
 
Supplier: Sigma Chemical Co, Poole, UK 
Ammonium persulphate (APS) 
Bovine serum albumin (BSA) 
TEMED 
Tween 20 
0.1% (v/v) aprotinin 
Bovine serum albumin (BSA) 
2mM phenylmethylsulphonyl fluoride (PMSF) TEMED 
Sodium fluoride (NF) 
Sodium orthovanadate (Na3VO4)  
Sodium chloride (NaCl) 
Sodium pyrophosphate (Na4P2O7)  
Sodium dodecyl sulphate (SDS)  
Magnesium chloride (MgCl2) EGTA 
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Supplier: Tesco, UK 
Marvel skimmed milk powder 
 
Supplier: Sigma Chemical Co, Poole, UK 




Supplier: Santa Cruz Biotechnology Inc, USA 
Anti-SMAD4 mouse monoclonal Ab clone B8 
 
Supplier: Cell signalling Technologies, Hertfordshire, UK 
Anti-FAK rabbit Ab 
 
Supplier: R&D systems, Abingdon, UK 
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Anti-HNF4α mouse Ab 
 
Supplier: Merck, UK 
Anti-p53 (PA240) mouse monoclonal Ab 
Anti-p53 (PA421) mouse monoclonal Ab (a gift from Ted Hupp lab) 
 
Supplier: Cell signalling Technologies, Hertfordshire, UK 
Anti Axin1 rabbit Ab 
Anti ERK rabbit Ab 
Anti MEK mouse Ab 
Anti FAK rabbit Ab 
Anti Src rabbit Ab 
Anti phospho-MEK1/2 (Ser217/221) rabbit Ab 
Anti phospho-ERK-S42/S44 rabbit Ab 
Anti phospho-FAK-Y397 rabbit Ab 
Anti SMAD1 rabbit Ab 
Anti phospho-SMAD1/5/8 rabbit Ab 
Anti phospho-SMAD2 rabbit Ab 
Anti phospho-Src-Y416 rabbit Ab 
Anti γ-tubulin mouse Ab 
Anti Wnt5A rabbit Ab 
Anti ZO2 rabbit Ab 
Anti Phospho β-catenin (Ser33/37/Thr41) Ab 
 
Supplier: Sigma Chemical Co, Poole, UK 
Anti β-actin mouse Ab 
Anti Vimentin mouse Ab 
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Anti Actin mouse Ab 
 
Supplier: Transduction Laboratories, BD Biosciences, Oxford, UK 
Anti E-cadherin mouse Ab 
Anti N-cadherin mouse Ab 
Anti β-catenin muose Ab 
Anti ILK mouse Ab 
Anti p27KIP1 mouse Ab 
 
Supplier: Darling lab, University of Louisville, USA 
Anti ZEB1 goat Ab 
 
Supplier: Epitomics Inc, USA 
Anti phosphoSMAD3 (SMAD1/2/3) rabbit Ab  
 
Supplier: Fujifilm, Bedford, UK 
X-ray films 
 
Supplier: Agfa, UK 
X-ray film developer 
 
2.1.8 DNA/RNA preparations 
 
Supplier: Sigma Chemical Co, Poole, UK 
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Supplier: Bioline, UK 
DNA Hyperladder  
 
Supplier: Sigma Chemical Co, Poole, UK 
Mission PLKO non-targeting shRNA control plasmid 
 
Supplier: Open Biosystems, Thermo Scientific, Abgene Ltd., Epsom, UK 
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Supplier: Ambion, UK 
DNase turbo kit 
 
Supplier: Qiagen, Crawley, UK 
miRNeasy mini RNA extraction 
QIAquick Gel purification Kit 
QIAprep Spin Miniprep Kit 
QIAprep Plasmid Maxi Kit 
 
Supplier: Invitrogen, Paisley, UK 
Superscript First-Strand cDNA synthesis kit 
 
2.1.9 Polymerase chain reactions 
 
Supplier: Bio-Rad, Hertfordshire, UK 
DNA Engine ® thermal cycler 
DNA Engine ® thermal gradient cycler 
 
Supplier: Qiagen, Crawley, UK 
TopTaq Master Mix Kit 
 
 
Supplier: Bioline, UK 
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Quantitative PCR sensimix Kit (one step) 
 
Supplier: Qiagen, Crawley, UK 
Corbett Robocycler 
Rotorgene tubes and caps 
 
Supplier: Agilent, Berkshire, UK 
PFU Ultra Mastermix 
 
Supplier: Invitrogen, Paisley, UK 
(Mouse genes, designed by MIT Primer3, http://bioinfo.ut.ee/primer3-0.4.0/) 
Axin2 
5’ GCTCCAGAAGATCACAAAGAGC 3’ 
3’ AGCTTTGAGCCTTCAGCATC 5’  
 
Lgr5  
5’ GAGTCAACCCAAGCCTTAGTATCC 3’ 
3’ CATGGGACAAATGCAACTGAAG 5’ 
  
cMyc 
5’ TGAAGAAGAGCAAGAAGATGAG 3’ 
3’ CTGGATAGTCCTTCCTTGTG 5’  
 
Cxcr4 
5’ CGGCTGCACCTGTCAGTGGCTGACCTCCTCTTT 3’ 
3’ CATAGACTGCCTTTTCAGCCAGCAGTTTCCTTGGC 5’  
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Cdh1 (E-cadherin) 
5’ GCACTGGCCGGCCAAGGACAGCCTTCTTTTCG 3’ 
3’ GGTGGTGCCCCATGGACTTCAGCGTCACTTTG 5’  
 
Hnf4α 
5’ CCTCACCTGATGCAAGAACA 3’  
3’ TGGCAGGAGCTTGTAGGATT 5’  
 
Gata6 
5’ ATGCTTGCGGGCTCTATATGAA 3’ 
3’ AGGTGGTCGCTTGTGTAGAAGG 5’ 
 
Pdx1 
5’ GAAATCCACCAAAGCTCACG 3’ 
3’ TTCAACATCACTGCCAGCTC 5’  
 
2.1.10 SRB cell proliferation assay 
 




Supplier: Thermo Fisher Scientific, Loughborough, UK 
Glacial acetic acid  
 
Supplier: TPP Helena Biosciences, Tyne & Wear, UK 
96-well plates 
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Supplier: Biohit, UK 
BP800 microplate photometer 
 
Supplier: Gilson, Bedfordshire, UK 
Multichannel Pipette P200 
 
2.1.11 Soft agar assay 
 
Supplier: R&D systems, Abingdon, UK 
2.8% Methylcellulose in MEM 
 
Supplier: Invitrogen, Paisley, UK 
Minimal Essential Medium (MEM) power 
 
Supplier: Sigma Chemical Co, Poole, UK 
Ultrapure agarose (low melting point - 65.5°C) 
 
2.1.12 Stock solutions and buffers 
 
RIPA buffer for protein lysis 
50mM Tris/HCl, pH 7.4 
150mM Sodium Chloride  
Triton X-100 
1% Sodium Deoxycholate 
1% NP40 
5mM EGTA 
100μM Sodium Orthovanadate 
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1mM PMSF 
10μg/ml Aprotinin 
100mM Sodium Fluoride 
10μg/ml Leupeptin Hemisulfate 
10mM Tetra-Sodium Pyrophosphate  
 
DNA electrophoresis running buffer (TBE) 10X 
890mM Tris-borate 
890mM boric acid 
20mM EDTA 
 
Acrylamide gel (8.5%) 
11.3ml 30% Acrylamide Bis-Tris (37: 5: 1) 
15ml Tris pH 8.8 
13.7ml H2O 
400μl 10% SDS 
375μl 10% APS 
20μl TEMED 
 
Acrylamide gel (15%) 
20ml 30% Acrylamide Bis-Tris (37: 5: 1) 
15ml Tris pH 8.8 
10ml H2O 
400μl 10% SDS 
375μl 10% APS 
20μl TEMED 
Stacker Acrylamide gel 
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3.2ml 30% Acrylamide, Bis-Tris (37: 5: 1) 
2.5ml Tris pH 6.8 
14ml H2O 
200μl 10% SDS 
200μl 10% APS 
20μl TEMED 
 
Protein sample buffer – 5x 
800μl 2-mercaptoethanol 
1.3ml Tris pH 6.8 
2ml glycerol 
5ml 10% SDS 
1.3ml H2O 
Bromophenol blue  
 









20% methanol  
 
Membrane Wash buffer 
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0.2% Tween 20 in Phosphate Base Solution 
 
Electrochemiluminescence (ECL) solution A (500 ml) 
20ml 1M Tris pH 8.5 
1 vial of Luminol 
1 vial of pCoumaric Acid 
 
Electrochemiluminescence (ECL) solution B (500 ml) 
20ml 1M Tris pH 8.5 
128µl of 30% NaOH 
 
Fix solution (SRB assay) 
25% trichloroacetic acid (TCA) solution in distilled water. 
 
Wash solution (SRB assay) 
1% glacial acetic acid in distilled water. 
 
SRB staining solution 
0.4% Sulforohodamine B (SRB) solution in 1% acetic acid. 
 
SRB solubilising solution 
10mM Tris base pH 10.5 in distilled water with pH adjusted using 1M sodium Hydroxide. 
 
Fix and permeabilisation buffer (Immunofluorescence) 
1ml formaldehyde 1ml  
100mM EGTA 4ml  
250mM Pipes 10ml  
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1M MgCl2 20l  
Triton X-100 3.7ml H2O 
 
Wash buffer (Immunofluorescence) 
100ml PBS 
 100μl Triton X-100 
 
 Block buffer (Immunofluorescence) 
100ml PBS 
100μl Triton X-100  
2g BSA 
Antibodies Supplier  Clone/Catalog Westen  IF IHC 
Anti-SMAD4 mouse monoclonal Ab  Santa Cruz B8 1 in 2000 1 in 500 1 in 100 
Anti phospho(S10)-Histone H3 rabbit 
Ab Cell Signaling  3377 n/a 1 in 500 n/a 
Anti HNF4α mouse monoclonal Ab R&D systems H1415 1 in 1000 1 in 1000 1 in 500 
Anti SMAD1 rabbit Ab Cell Signaling  9743 1 in 1000 n/a n/a 
Anti phospho-SMAD2 rabbit Ab Cell Signaling  (138D4) 3108  1 in 500 n/a n/a 
Anti phospho-SMAD1/5/8 rabbit Ab Cell Signaling  9511 1 in 1000 n/a n/a 
Anti phospho-SMAD3 (SMAD1/2/3) 
rabbit Ab  Epitomics EP823Y 1 in 1000 n/a n/a 
Anti p27KIP1 mouse Ab BD G173-524 1 in 500 n/a n/a 
Anti Pdx1 mouse Ab Abcam ab47267 n/a 1 in 500 n/a 
Anti-p53 (PA240) mouse monoclonal 
Ab Abcam ab26 1 in 1000 n/a n/a 
Anti-p53 (PA421) mouse monoclonal 
Ab  
EMD 
Millipore MABE283 1 in 1000 n/a n/a 
Anti ERK rabbit Ab Cell Signaling  4370 1 in 1000 n/a n/a 
Anti MEK mouse Ab Cell Signaling  L38C12/4694 1 in 1000 n/a n/a 
Anti phospho-MEK1/2 (Ser217/221) 
rabbit Ab Cell Signaling  9121 1 in 1000 n/a n/a 
Anti phospho-ERK-S42/S44 rabbit 
Ab Cell Signaling  9101 1 in 1000 n/a n/a 
Anti Src rabbit Ab Cell Signaling  2109 1 in 1000 n/a n/a 
Anti phospho-Src-Y416 rabbit Ab Cell Signaling  2101 1 in 1000 n/a n/a 
Anti FAK rabbit Ab Cell Signaling  3285 1 in 1000 n/a n/a 
Anti phospho-FAK-Y397 rabbit Ab Cell Signaling  3283 1 in 1000 n/a n/a 
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2.2.1 Cell culture  
Human Primary mouse pancreatic cancer cells were originally derived by Jennifer Morton at 
the Beatson Institute for Cancer Research (Glasgow, Scotland), from tumour pieces of 
mouse number 83320, with genotype Pdx1-Cre/ KrasG12D/+/ Tp53R172H/+.  Mouse pancreatic 
cancer cells were maintained in Dulbecco's Modified Eagle Medium (Gibco, Invitrogen) 
supplemented with 10% Fetal Bovine Serum (Invitrogen) and 2mM L-Glutamine (Gibco, 
Invitrogen).  Single cell clones were isolated by distributing 30 cells in a 96-well plate and 
resulting colonies were transferred to T25 flasks until 80% confluent.  Cells were detached 
by 0.25% Trypsin, 1.3mM EDTA, PBS, and re-suspend in DMEM/ 10%FBS/ 2mM L-
Glutamine.  Cells were then split to a T75 flask at 1 in 15 dilution.  The remaining cells were 
centrifuged at 1500rpm for 4 min, resuspended in ice cold FBS with 10% DMSO and stored 
as backup stocks in the liquid nitrogen tank.  Cells were regularly maintained by splitting 1 
in 15 for every 3 days.  Cells were not kept for more than 15 passages; then a new vial cells 
at their earliest passage was taken out from the liquid nitrogen and recovered in the tissue 
culture.  As for established human cancer cell lines, A549, HepG2, Caco, HT29 and SW480 
Anti E-cadherin mouse Ab BD 610182 1 in 1000 1 in 200 n/a 
Anti N-cadherin mouse Ab BD 610921 1 in 1000 n/a n/a 
Anti β-catenin muose Ab BD 610154 1 in 1000 n/a n/a 
Anti ILK mouse Ab BD 611803 1 in 1000 n/a n/a 
Anti ZO2 rabbit Ab Cell Signaling  2847 1 in 1000 n/a n/a 
Anti Vimentin mouse Ab Sigma Aldrich VIM13.2 1 in 5000 n/a n/a 
Anti ZEB1 goat Ab DS Darling, Louisville KY  n/a 1 in 5000 n/a n/a 
Anti Wnt5A rabbit Ab Cell Signaling  2392 1 in 1000 n/a n/a 
Anti Phospho β-catenin 
(Ser33/37/Thr41) Ab Cell Signaling  9561 1 in 500 n/a n/a 
Anti Axin1 rabbit Ab Cell Signaling  C76H11/2087 1 in 1000 n/a n/a 
Anti γ-tubulin mouse Ab Cell Signaling  2144 1 in 2000 n/aå n/a 
Anti Actin mouse Ab Sigma Aldrich A4700 1 in 2000 n/a n/a 
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were originally from American Type Culture Collection (ATCC); they were cultured in the 
medium as described above.      
 
2.2.2 Immunoblotting 
Cells were washed twice in ice cold PBS and then lysed in ice cold RIPA buffer (50mM 
Tris, pH7.4, 150mM NaCl, 5mM EGTA, 0.1% SDS, 1% NP40, 1% sodium deoxycholate) 
with inhibitors: 1mM phenylmethylsulfonyl fluoride (PMSF), 10µg/ml aprotinin, 10µg/ml 
leupeptin, 100µM sodium vanadate, 500µM sodium fluoride, and 10mM Tetra-sodium 
pyrophosphate.  Cells were washed twice in ice-cold PBS and scraped from the plate on ice 
by a sterile plastic cell scraper.  Crude lysate was clarified by spinning at maximum speed 
for 15 min at 4°C in bench top Eppendorf centrifuge.  Protein concentration was measured 
by Micro BCA protein assay kit (Thermo Scientific), light absorbance of protein-BCA 
complexes (purple) was then measured with a cuvette-based spectrophotometer (Biorad) at a 
wavelength of 562nm.  Protein samples at a final concentration of 1μg/μl were denatured 
with addition of 5x sample buffer by heating at 95°C for 5 min.  Samples were kept on ice in 
all steps before heat-denaturation.   
 
Denatured samples were run on SDS acrylamide gels, transferred to nitrocellulose membrane 
in transfer buffer, and blocked with 5% Bovine Serum Albumin (BSA) or skimmed milk, in 
either PBS or TBS containing 0.1% Tween.  Primary antibodies used have been listed in the 
‘Materials’ section.  Secondary antibodies anti-rabbit HRP and anti-mouse HRP were 
purchased from Cell Signaling Technologies.  Membranes were stripped by incubating on 
the shaker for 10 min at room temperature, in 1X Re-blot Plus Strong solution (Millipore), 
then re-blocked for 45 min in 5% BSA (or milk) in PBS (or TBS) with 0.1% Tween.  HRP-
bounded protein-bands on membranes were amplified by Enhanced chemiluminescence 
(ECL), followed by exposure on x-ray films (Fujifilm) in the dark room and visualised 
through a film developer (Agfa AC002).   Quantification of intensity of protein bands were 
done by using ImageJ software (National Institute of Health, Bethesda, USA), relative to the 
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2.2.3 Immunofluorescence 
Glass coverslips had been auto-claved before seeding cells.  Each coverslip was seeded with 
0.5 x 105 cells, in a 12-well plate.  After 2 days in the incubator, cells were washed once with 
TBS and immediately fixed for 10 min in 3.7% Formaldehyde, 10mM EGTA pH8, 25mM 
Pipes pH6.8, 0.1mM MgCl2, 0.002% Triton X100.  Fixation buffer was removed and 
coverslips were washed twice with wash buffer (TBS, 0.1% Triton X100), followed by 1 hr 
in blocking buffer (TBS, 2% Bovine Serum Albumin, 0.1% Triton X100).  Fixed cells were 
then incubated overnight with primary antibody diluted in blocking buffer.  The next day, 
coverslips were washed three times in wash buffer and incubated with secondary fluorescent 
antibodies (Invitrogen) and/or Rhodamine-Phalloidin (Sigma Aldrich) for 45 min at room 
temperature.  Coverslips were washed three times with wash buffer, drained excess buffer, 
and mounted onto glass slides (Fisher Scientific) with Vectrashield mounting reagent with 
DAPI (Vector Labs).  Photographs of ‘stained cells’ in the glass slides were taken via a 
Olympus Confocal Microscope FV1000.  Images were processed by FV1000 Viewer 
(complementary software provided by Olympus) and Photoshop CS3 (Adobe).  
 
2.2.4 RNA extraction and RT-PCR 
On Day0, 0.5 x 106 cells were plated on 10cm dish.  Cells at growth phase (50-70% 
confluence) on Day 2 were lysed to extract total RNA by RNeasy Mini Kit (Qiagen) 
according to manufacturer’s protocol.  Genomic DNA was removed by using DNase turbo 
kit (Ambion) according to manufacturer’s protocol.  RNA concentration was measured using 
Nanodrop (Thermo Scientific).  For Reverse Transcriptase reaction (non quantitative), 1μg 
of RNA of each sample was converted to cDNA by SuperScript First Strand Reverse 
Transcriptase kit (Invitrogen) according to manufacturer’s protocol.  PCR was conducted by 
using Abgene PCR Ready Mix (Thermo scientific) with 20ng cDNA running on Biorad PCR 
machine; product was analyzed by 1.5% agarose gel electrophoresis in TBE.  All primers 
were designed using PRIMER-3 website (MIT, MA, USA) and purchased from Invitrogen.  
Sequencing was conducted by the MRC Human Genetics Unit, University of Edinburgh.  
 
2.2.5 Quantitative RT-PCR 
0.5 x 106 cells were plated on 10cm dish on Day 0.  Cells at growth phase (50-70% 
confluence) on Day 2 were lysed to extract total RNA by RNeasy Mini Kit (Qiagen) 
according to manufacturer’s protocol.  Genomic DNA was removed by using DNase turbo 
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kit (Ambion) according to manufacturer’s protocol.  RNA concentration was measured using 
Nanodrop (Thermo Scientific).  For quantitative RT-PCR, a reaction standard curve was 
generated by using 50ng, 5ng, 0.5ng and 0.05ng total RNA of the cell line that most robustly 
expresses the gene of interest.  The control (also known as the housekeeping gene) used for 
all reactions was 18s rRNA.  RNA samples to be measured were loaded at 20ng per reaction.  
Standard curve reactions were done in duplicates, and sample reactions were done in 
triplicates, running in a Rotorgene Robocycler (Corbett Research, Qiagen).   Quantification 
of transcript abundance of samples was done by using Rotorgene 6000 software (Qiagen).   
 
2.2.6 Soft agar assay 
In a six-well plate for each well, a base agarose layer (0.9% agarose by weight) was prepared 
by mixing 1ml of 2x concentration of MEM (with 20% FBS, 2x concentration for each of 
non essential amino acid, vitamins, sodium pyruvate, and L-glutamine, diluted from 100x 
Invitrogen stock) and 1ml 1.8% low melting-point agarose that had been dissolved in dH2O 
(autoclaveed).  Such 2x concentration of MEM was prepared by dissolving twice the amount 
of MEM powder (Invitrogen) needed for 1x MEM.  The base layer was left to set at room 
temperature.  The top layer was 1.4% methylcellulose in MEM (with 10% FBS, 1x 
concentration of each of non essential amino acid, vitamins, sodium pyruvate, and L-
glutamine, diluted from 100x Invitrogen stock), which was made up from a stock of 2.8% 
methyl cellulose in MEM.   
 
Cells were added to the 1.4% methylcellulose MEM to a density of 10,000 cells per ml; 2ml 
of such cell-methylcellulose suspension was placed on top of the base agarose layer in each 
well.  Cells were then left overnight in the incubator to allow suspended cells to settle on top 
of the agarose layer (Day0).  On Day1 and Day7, photographs of suspended cells were 
captured by Qimaging Retiga Exi CCD camera attached to Leica Dmil LED inverted routine 
microscope.  Photographs were processed by ImageJ (National Institute of Health, Bethesda, 
MD, USA), by measuring arbitrary particle area of single cells or colonies.  Quantification of 
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2.2.7 Treatment with inhibitors 
In soft agar assay, tankyrase inhibitors (XAV939 and IWR1) and MEK inhibitors (UO126 
and PD184352) were used.  Each inhibitor was dissolved in DMSO as stock (10mM), and 
diluted into both the bottom agar layer and the top methylcellulose layer, before mixing the 
suspended cells into the methylcellulose layer.  Both XAV939 and IWR was added (and well 
mixed by pipetting up and down) to a final concentration of 5μM in the medium of both the 
agar and the methylcellulose layers, while PD184352 was used at final a concentration of 
0.25μM.  UO126 was used at a final concentration of 1µM.  In immunoblot analysis, cells 
were seeded on 6cm plates at 2.5 x 106 cells with DMEM/ 10% FBS/ 2mM L-Glutamine.  On 
Day1, respective inhibitors or DMSO (as the vehicle) was added to the medium and well-
mixed, to a final concentration as the same as in soft agar assay.  Cells were then left in the 
incubator overnight.  On Day2, protein of cells was harvested and analysed by immunoblots 
as described in 2.2.2.   
 
2.2.8 Sulforhodamine B (SRB) colorimetric assay 
Cells were plated on wells of a 96-well plate on Day0; they were then fixed and SRB-stained 
on required dates to measure any changes in total protein content.  Fixation was done by 
adding 50µl of 25% Trichloracetic acid solution (ice cold) into each well, originally 
containing 200µl culture medium.  Plates were chilled in the cold room for 1 hour.  Wells 
were then washed 10 times with dH2O, and dried in an 50°C oven.  Staining of protein 
content in the well was by adding 50µl 0.4% SRB solution in 1% acetic acid into each well, 
incubated at room temperature for 30 min.  Wells were then washed four times with 1% 
glacial acetic acid in dH2O, and dried in a 50°C incubator.  SRB-stained protein was 
resuspended in 150µl 10 mM Tris solution (pH 10.5) by leaving on shaker for 1 hr at room 
temperature.  Protein content was measured by absorbance at 540nM, using BP800 
microplate photometer (Biohit).  Data analysis was done using Microsoft Excel.  
 
2.2.9 Immunohistochemistry 
Fresh mouse tissues were fixed by formalin overnight, which were then processed 
(dehydration, clearing and embedding in paraffin block) by the histology service department 
of the Breakthrough Research Centre (Western General Hospital, Edinburgh).  Paraffin 
blocks of human pancreatic cancer tissues were obtained from Experimental Cancer 
Medicine Centre (ECMC, reference code TR163).  Paraffin blocks of tissue were sectioned 
68
MATERIALS & METHODS 
to 5-micron thick and mounted on slides (positively charged on the surface) by the 
Breakthrough Research Centre.  Slides containing tissue section were dewaxed by 
immersing in xylene for 5min, twice, and rehydrated for 5min in 99%, 99%, 80% and 50% 
ethanol, chronologically.  Slides were then boiled in a pressure cooker containing antigen 
retrieval buffer (10mM Sodium Citrate pH6.0) for 10 min, and left to cool down at room 
temperature for 20min.  After washing with dH2O, slides were washed twice with TBS-
0.025% Triton x100, followed by drawing around the tissue with Immedge pen (Vector 
Science) to form a water repellent barrier.  Tissues were then blocked with DAKO total 
protein block for 2hr.  Upon draining away the block solution, tissues were immersed in 
primary antibody of the appropriate concentration (listed in the Materials section) in DAKO 
antibody diluent, overnight.   
 
The next morning, tissues were washed twice with TBS-0.025% Triton x100 for 5min, 
followed by adding DAKO peroxidase block for 15min, and then wash once with TBS for 
another 5min.  Tissues were then immersed in DAKO Envision labelled Polymer (secondary 
antibody and HRP conjugated to a Dextran molecule) for 1hr, plus two washes with TBS for 
5min each, then added DAB chromogen for peroxidise reaction for 10min.  After a quick 
rinse in water, tissues were counter-stained with Haematoxylin for 5 min to stain nuclei blue, 
and then washed in water for another 5min.  Upon dehydration with ascending % of ethanol 
(50%, 80%, 99%, 99%), and eventually xylene, tissues were mounted to coverslips with Di-
n-butyl Phthalate in Xylene (DPX) and air-dried.   Slides were processed using an Olympus 
BX51 microscope system and its adjunct software.  
 
2.2.10 DNA preparation  
Each glycerol stock of bacteria (E-coli) carrying individual PLKO-shRNA plasmids 
(Thermo Scientific) was gently streaked on ampicillin (50mg/ml) selection plates and 
incubated at 37°C.  The next day, a single colony was picked by an autoclaved pipette tip, 
inoculated into 250ml of L-broth medium containing ampicillin (50mg/ml), and incubated 
overnight at 37°C on a rotating shaker. The next day, cells were spun down by centrifugation 
at 500g, supernatant was discarded and the pellet was lysed to extract DNA plasmid using 
Qiagen’s Plasmid Maxi Kit.  DNA was eventually dissolved in dH2O, and the concentration 
was measured by Nanodrop (Thermo Scientific).  In addition, both plasmids of 
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pcDNA3.HIV1 and pcDNA3.VSV-G were prepared from glycerol using the same Maxi Kit 
of Qiagen, according to the protocol recommended by the manufacturer.   
 
2.2.11 Transfection of HEK293FT cells and lentiviral infection of shRNA  
HEK293FT cells were used as host cells to produce virus.  They were maintained in DMEM 
with 10% FBS and G418 at 100mg/ml.  On Day0, 1 x 106 HEK293FT cells were plated on 
10cm culture plate.  The next day, HEK293FT cells were transfected with 10μg PLKO 
shRNA plasmid, 6.5μg pcDNA3.HIV1, and 3.0μg pcDNA3.VSV-G, using calcium chloride 
dissolved in Hepes Buffered Saline at pH6.9, at a final volume of 1ml, in the category-2 
tissue culture facility.  On Day-2, transfection medium on HEK293FT was replaced by fresh 
DMEM with 20% FBS, as higher serum level enhances production of virus by the 
transfected HEK293FT cells.  Concurrently, at 0.25 x 106 murine pancreatic cancer cells (the 
target cells) were plated on 10cm plates.   
 
Conditioned medium was prepared on Day 3, by passing the HEK293FT medium through a 
0.45μm filter, supplemented with the same volume of fresh DMEM-10% FBS and 5μg/ml 
polybrene.  Mouse pancreatic cancer cells were incubated in this conditioned medium 
overnight, and this step of conditioned medium was repeated on Day-4.  On Day-5, the 
conditioned medium on mouse pancreatic cancer cells was replaced by fresh DMEM with 
10% FBS, followed by antibiotics selection using 5μg/ml puromycin in DMEM with 
10%FBS on Day-6.  Infected mouse pancreatic tumour cells were passaged at 1 in 5 and 
further selected for 6 days with 5μg/ml puromycin.  Before moving the infected mouse 
pancreatic cancer cells out of the category-2 tissue culture, infected mouse pancreatic cells 
were ensured not themselves producing lentivirus, by treating a dish of uninfected cells with 
conditioned medium of the infected cells, followed by addition of 5μg/ml puromycin which 
was supposed to kill all the uninfected cells.   
 
2.2.12 Cell cycle blockage with thymidine or with Gemcitabine  
On Day0, cells were seeded on 6cm plates at 2.5 x 106 cells with DMEM/ 10% FBS/ 2mM 
L-Glutamine.  On Day1, cells were washed once with sterile PBS, and then replaced with 
1mM glucose DMEM/ 10% FBS, with the addition of thymidine (2μM), or Gemcitabine 
70
MATERIALS & METHODS 
(100nM or 500nM), or just PBS (the vehicle).  On Day2, protein of cells was harvested and 
analysed by immunoblots as described in 2.2.2.  
 
2.2.13 Treatment with recombinant mouse TGFβ1 and BMP9 
On Day0, Cells were seeded on a 6-well plate at 0.1 x 106 cells with DMEM/ 10% FBS/ 
2mM L-Glutamine.  On Day1, photographs of cells were taken using a phase contrast 
microscope (Leica) connected to a Qimaging Retiga EXi camera.  Cells were then washed 
twice with PBS, and replaced with serum free DMEM at 1mM or 25mM glucose, plus 
recombinant mouse BMP9 or recombinant mouse TGFβ1 to a final concentration of 
2.5ng/ml; whereas BSA was added to the well of carrier control.  Photographs of cells were 
then taken on Day2.  Both recombinant mouse BMP9 and recombinant mouse TGFβ1 were 
reconstituted in a stock solution of 10 μg/mL in sterile 4mM HCl containing 0.1% BSA.  
 
2.2.14 Immunoprecipitation  
Cells at 80% confluence were lysed in ice cold RIPA buffer with protease and phosphatase 
inhibitors as described previously in western blot.  Lysate was cleared by spinning at full 
speed by a bench top eppendorf centrifuge.  Protein concentration was measured by 
MicroBCA assay (Thermo Scientific).  20µg of each sample protein lysates was retained to 
load to reflect the total protein input.  1µg of β-catenin antibody was added to 1000µg 
protein for immunoprecipitation; after overnight incubation with antibody in the cold room, 
25µl of 50% slurry of protein-G conjugated agarose was added to each sample, and further 
incubated in the cold room for 45 min.  The control sample was added with IgG-conjugated 
agarose.  Agarose was then spun down and washed for three times with ice cold RIPA buffer 
with inhibitors.  20µl of 5x sample buffer was added to the Pelleted agarose and boiled at 
98°C, followed by SDS-PAGE and western blot for phospho-β-catenin and total β-catenin. 
 
2.2.15 Subcutaneous injection 
Cells at about 60-70% confluence were trypsinized, spun down at 1400rpm in a universal 
tube and washed once with PBS.  Cell number was counted by a haemocytometer.  5 x 104 
cells in 100µl HBSS were injected into both sides of a nude mouse in a sterile hood; three 
mice (6 injections) were used for each cell sub-clone, in the animal facility, by Ms 
Morwenna Muir, in the Western General Hospital.  Two perpendicular diameters of each 
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tumour were measured by a caliper twice a week for 28 days.  Measurements were recorded, 







3.1 Characterization of heterogeneity of mouse pancreatic cancer cells  
 
3.1.1 Isolation of heterogeneous cell types from primary culture 
I started my project with a flask of primary culture of mouse pancreatic cancer cells, which 
had been derived from an excised portion of a primary pancreatic tumour of a Pdx1-Cre/ 
LSL-KrasG12D/+/ LSL-Tp53R172H/+ mouse (number 83320), by Dr Jennifer Morton at the 
Beatson Institute, Glasgow.  Such mouse lived for around 11 weeks,  with locally advanced 
pancreatic cancer and ascites, but with no metastasis at that time.  The mouse’s genotype had 
been confirmed by routine PCR at the Beatson Institute, before the derived-cells were 
brought over to the Edinburgh Cancer Research Centre.  
 
Under the light microscope, these primary mouse pancreatic cells exhibited mixed 
morphologies; some cells appeared epithelial and grew in flat clusters, while some others 
appeared spindly and grew on top of each other (data not shown).  In order to examine 
whether these primary cells comprised heterogeneous cell populations, I conducted 
‘separation’ of distinct cell morphologies, using a method of single-cell cloning, by dilution 
and distribution of 30 single cells into a 96-well plate.  Upon picking and expanding colonies 
in larger culture flasks, in around 3 weeks, I identified at least 7 types of cells which differed 
in morphology and growth properties on tissue culture dishes.  In total, 14 colonies had been 
picked, and based on morphological characteristics, those 14 were eventually narrowed 
down to 7 distinct clones for further characterization (Figure 13).  I named each of them with 
a single letter.  Cell sub-clone E had an epithelial morphology with well defined cell-cell 
junctions.  Cell sub-clones V and H were of another morphological type, as both appeared to 
be elongated, but sub-clone H was more spindle-like with sharper ends, whereas sub-clone V 
was relatively flatter with rounder edges.  Cell sub-clones N and T were close in appearance 
and look mesenchymal with less well-defined cell junctions, but sub-clone T had more 
filopodia-like protrusions than sub-clone N.  Cell sub-clone K was even flatter and spread-
out, with low contrast under the light microscope, while sub-clone M was cobble-stone-like, 
with clear cell-cell junctions, and it grew in clusters.  These seven cell sub-clones were stable 
in culture, as their morphology had not changed for at least 15 passages, the time point at 
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Figure 13 - Morphology of the seven mouse pancreatic cancer cell sub-clones 
derived from primary culture of pancreatic cancer from mouse 83320. Condition: 
50 x 104 cells were seeded onto a 6 cm dish on Day0 in normal DMEM, 10% serum; 
on Day1, photographs were taken under the light microscope using the standard 40x 
objective (scale bar = 50µm). 
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which I replaced the flask with an early passage from the liquid nitrogen.  Moreover, 
immunoblots generally appeared consistent between early and later passages.  Yet I could 
not eliminate the possibility that when these sub-clones were growing in the original mixture 
of primary cells, some or all of them would induce plasticity through interactions between 
multiple cell types.   However, they were stable upon isolation, which provided a basis for 
studying heterogeneity of tumour cells within a pancreatic cancer.   
 
3.1.2 Confirmation of pancreatic cell identity 
I first ensured that the seven cell sub-clones were of the Pdx1-expressing pancreatic lineage, 
but not of some other cell types, such as fibroblast, that might have come along with tumour 
cells into culture.  I conducted reverse transcriptase-PCR and amplified the Pdx1 gene 
transcript (mRNA) (Figure 14B), confirming the transcription activity of Pdx1.  I also used 
confocal microscopy to detect immunofluorescence-labelled PDX1 protein, along with a 
negative control, M15 mouse kidney fibroblasts, which showed minimal staining (Figure 
14A).  In addition, the PDX1 protein was detected by immunofluorescence in Panc1 cells, 
but not Miapaca2 cells, both of which are established human pancreatic cancer cell lines 
(Figure 14C).  This was in agreement with a recent report showing by 
immunohistochemistry that PDX1 was expressed in some but not all human pancreatic 
cancer sections (Park et al., 2010).  Sequencing of PCR-amplified cDNA confirmed that all 7 
mouse pancreatic cancer cell sub-clones expressed mutant KrasG12D and p53R172H, indicating 
successful recombination by CRE-recombinase (one example is shown in Figure 15A, which 
was of cell sub-clone E).  Both mutants appeared to be dominantly expressed in these cells, 
as no fluorescence signal of the wild-type nucleotide had been detected in the sequencing 
chromatograms.  Possibly, the remaining wild type allele had been eliminated due to 
selective pressure to lose heterozygosity during cancer progression.   
 
3.1.3 Evidence for heterogeneity among the sub-clones 
Since these 7 mouse pancreatic cancer sub-clones showed distinctive morphology, I 
hypothesised that they had different genetic profiles and protein expressions.  To address this, 






Figure 14 (A) - Immunofluorescence staining of Pdx1 protein in the nucleus of all seven sub-
clones, compared with the the negative control, M15 mouse embryonic kidney fibroblast.  (B) - 
Reverse Transcriptase PCR confirms that Pdx1 gene is expressed in all seven cell sub-clones; 
PCR of the actin cDNA was used as a arbitrary loading control; and the empty lanes labeled with 
a lower case letter are the corresponding RNA-only negative controls, to show that the genes 
amplified were essentially from cDNA, and not from contaminated genomic DNA (C) - Pdx1 is 
expressed in human pancreatic cell line, Panc1, but not in Miapaca2.     
scale bar =25µm 
Miapaca2  Panc-1 (C) 
PDX1 
scale = 25 µm 
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Figure 15 (A) – Showing sub-clone E as an example, sequencing of the 
amplified cDNA confirmed that all seven sub-clones express KRasG12D and 
mutant p53R172H.  (B) – Western blot shows activated MEK-ERK pathway, 
suggesting upstream activity of the constitutively activated KRasG12D; mutant p53 
levels varied among the cell sub-clones.  Condition: 50 x 104 cells were seeded 
onto a 6 cm dish on Day0 in normal DMEM, 10% serum; cells were harvested 
for protein on Day2; 20μg protein was loaded into each lane.  




I first examined the ERK pathway, which is downstream of mutant KRasG12D, and levels of 
mutant p53R172H (Figure 15B), as both mutants were the basis of the mouse model.  Western 
blot revealed that both MEK1/2 and ERK1/2 were phosphorylated and thus activated in all 7 
cell sub-clones, indicating the activity of the upstream mutant KRasG12D.  As for p53 levels, I 
used two antibodies, PAb240 (epitope at a.a. 207-212) and PAb421 (epitope at a.a. 363-372),  
so as to minimize the risk of one epitope being shielded by post-translational modifications, 
of which p53 is well-known to have numerous types (reviewed by Bode & Dong 2004).  
Among the 7 cell sub-clones, only E and K did not show stabilized p53 on western blot, 
suggesting that they might have lower transcription levels or faster turnover rates of mutant 
p53 than the other cell sub-clones.  In the Pdx1-Cre/ LSL-KrasG12D+/- mice (without mutant 
p53), it has been known that most of the KRasG12D-expressing cells would be lost over time 
due to growth arrest and senescence; only a minority of them could overcome this 
senescence barrier to form premalignant lesions (Morton et al., 2009).  Therefore, cell sub-
clones E and K might be two examples of such cell types that were not so reliant on mutant 
p53R172H to survive.   
 
In addition, I also examined the possibility that these cells were different with respect to 
epithelial-to-mesenchymal states, because they showed distinctive morphology under the 
phase contrast microscope.  I performed western blotting to examine some common 
junctional proteins, namely E-cadherin, β-catenin and N-cadherin for adheren junctions, as 
well as a major tight-junction protein, ZO2 (Figure 16A).  E-cadherin levels varied among 
the seven sub-clones, while β-catenin levels were relatively similar, and N-cadherin level 
was the highest in cell sub-clone K, which along with M, expressed little E-cadherin.  ZO2-
levels did not vary much among the sub-clones, indicating that these cells probably had 
similar levels of ZO-2-dependent tight junctional complexes.  Under the confocal 
microscope, immunofluorescence staining of E-cadherin showed that only cell sub-clones E 
and V still possessed some E-cadherin visibly localized to cell-cell junctions, while the other 
five sub-clones showed mostly cytoplasmic E-cadherin (Figure 17).   
 
I then asked whether such difference in E-cadherin levels was attributed to different levels of 
transcriptional repression by classical ‘Epithelial-Mesenchymal Transition’ (EMT) mediators 
that had been reported in human pancreatic cancer (Hotz et al., 2007).  In particular, I looked 
at protein levels of ZEB1, which is a transcriptional repressor of the E-cadherin promoter, 
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Figure 16 (A, upper panel) – Immunoblot analysis of some classical pro-epithelial 
cell-cell junction proteins in the seven cell sub-clones; 20μg protein was loaded into 
each lane.  (A, lower panel) – Quantification of band intensities of the epithelial 
markers relative to Actin, using ImageJ.  (B) - Immunoblot analysis of some 
classical “mesenchymal markers”, along with Capan1 cell-lysate as the negative 
control, and Panc1 cell-lysate as the positive control. Condition: 50 x 104 cells were 
seeded onto a 6cm dish on Day0 in normal DMEM, 10% serum; cells were 


























Scale bar = 25 µm 
Figure 17 - Immunofluorescent staining of E-cadherin in the seven sub-clones; 
please note that it was only based on one focal plane, a better indication of E-
cadherin localization should have been a photo of stacked focal layers taken from 
top to bottom of the cells on the coverslip.  Condition: on Day0, 1 x 104 cells 
were seeded on each coverslip in a 12-well plate, in 10% serum DMEM; cells 
were fixed on Day2, at about 50% confluency.   
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(Aigner et al., 2007; Spaderna et al., 2008; Wellner et al., 2009).  However, all seven cell 
sub-clones expressed similar amounts of ZEB1 (Figure 16B), implying that ZEB1 was 
unlikely repressing E-cadherin in these mouse pancreatic cancer cells.  
 
I also examined whether or not these cell sub-clones differed in expressions of proteins 
associated with focal adhesions and ‘mesenchymalness’, as activation of these proteins is 
often believed to be implicated in acquired invasive capacity, for example, after EMT.  
Vimentin, which is often used as a marker of mesenchymal cells or cells that have undergone 
EMT in developmental biology and in some putative “cancer stem cell” studies, was 
expressed by all seven cell sub-clones (Figure 16B).  This suggests that either the sub-clones 
were all putative mesenchymal cells, or Vimentin has not been a universal mesenchymal-
marker as previously thought, at least for this mouse model of pancreatic cancer.  As for 
focal adhesion proteins, phospho-Focal Adhesion Kinase (FAK) levels appeared to be the 
lowest in sub-clones E and V, which had the highest E-cadherin levels, whereas sub-clones 
K and M showed the highest levels of phospho-FAK (Figure 18).  This roughly paralleled 
decrease of E-cadherin levels among the seven sub-clones, suggesting an overall correlation 
between increase in FAK activity and decrease in E-cadherin levels.  In addition, sub-clones 
V and H showed higher phospho-Src family kinase levels.  This was consistent with the 
observation that they were morphologically closer, compared with the other cell sub-clones.  
More similarities and differences between sub-clones V and H will be discussed in following 
paragraphs.  
  
I also investigated whether the cell sub-clones differed in certain signalling pathways or key 
transcription factors that had been implicated in pancreatic cancer or in pancreas 
development.  Of interest, the TGFβ/BMP pathway and the canonical Wnt pathway were 
active only in some of the cell sub-clones, and they respectively became the major and the 
minor studies in my project.  Other lines of evidence for heterogeneity among the sub-clones 
included detection of the mRNA transcript of CXCR4 (a chemokine receptor), GATA6 (a 
developmental transcription factor), WNT5A (a well established ligand of non-canonical 
Wnt pathway) and HNF4α (an orphan nuclear receptor, discussed in Introduction), in distinct 
subsets of cells (Figure 19).  CXCR4 was exclusively expressed in sub-clone V, while the 
ligand CXCL12/SDF1 was also expressed in sub-clones V, T, K and M (Figure 19A).   
CXCR4-mediated signalling has been reported to play a central role during metastasis, 
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Figure 18 (upper panel) – Immunoblot analysis of proteins involved in focal 
adhesion.  (lower panel) – Quantification of the respective band intensities of 
the focal adhesion proteins, relative to actin levels, using ImageJ.  Condition: 
50 x 104 cells were seeded onto a 6 cm dish on Day0 in normal DMEM, 10% 
serum; cells were harvested for protein on Day2.  
Figure 18 
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Figure 19 (A) – Representative results from RTPCR screens for marker gene 
expressions in the seven cell sub-clones of mouse pancreatic cancer.  (B) – 
Quantitative PCR analysis of Gata6 and Hnf4α; error bar = standard deviation of 
the mean. (C) – Representative results from immunoblot screens for 
heterogeneous protein expressions in the seven cell sub-clones.  Condition: 50 x 
104 cells were seeded onto a 6cm dish on Day0 in normal DMEM, 10% serum; 




autoloop in sub-clone V, while sub-clones T, K and M could present the ligand to sub-clone 
V, as these cell types co-existed in the original tumour.  However, I was unable to detect the 
CXCR4 protein, no matter by flow cytometry or by western blotting; verification of this 
result requires the future use of a positive control.  
 
Multiple studies have shown that the Gata6 gene is amplified in a subset of pancreatic cancer 
cells in human (discussed in Introduction), and among the seven cell sub-clones, Gata6 was 
transcribed only in V and H (Figure 19B), the two sub-clones that shared a spindly 
morphology.  Of interest, Wnt5a was also expressed exclusively in sub-clones V and H, with 
H having proportionally lower levels of Gata6 transcription and WNT5A protein than V, 
indicating a potential correlation between GATA6, Wnt5a and higher levels of phospho-Src 
family kinases in these two cell sub-clones.   
 
In addition, HNF4α, a nuclear receptor that is crucial to gene regulation of glucose 
metabolism in hepatic and pancreatic cells, was expressed only in sub-clones E, N and T 
(Figure 19B, C).  In Chapter 3.4, I am going to establish a novel connection between HNF4α 
and the BMP-SMADs pathway.  To sum up, screenings by immunoblots and by qRTPCR 
confirmed that the seven mouse pancreatic cancer sub-clones were heterogeneous not only in 
their morphology, but also in their respective signalling drivers.   
 
3.1.4 Differential rates of 2D- and anchorage independent proliferation 
On polystyrene culture dish in DMEM with 10% FBS, the fastest-proliferating sub-clone (T) 
was about 2 times the rate of the slowest proliferating sub-clone (V), and the other sub-
clones lay in between.  This was measured by SRB assay, which was based on measuring 
protein content per well in a 96-well plate over 5 days (Figure 20A).  When serum was 
reduced to only 0.5% in DMEM, all seven cell sub-clones proliferated very slowly (SRB-
stained protein content merely doubled over 5 days), with negligible differences between 
each sub-clone (data not shown).  However, when they were subjected to anchorage-
independent conditions in DMEM-methylcellulose suspension with 10% FBS, some of their 
intrinsic difference in “strength” of transformation was unveiled.  In this soft-
agar/methylcellulose assay, the average area of cell spheres on Day1 was used as the 
baseline (denominator) to that measured on Day7, using the ‘arbitrary particle area 


































Figure 20 (A) - SRB proliferation assay shows the differences in proliferation speed 
among the sub-clones, in which the fastest (T) and slowest (K) proliferating cells 
does not exceed one fold.  Condition: 500 cells were seeded on each well of 96-
well plates on Day0, identical plates were then fixed with Trichloroacetic acid on 
Day2, Day4 and Day5.  (B) In soft agar assay, sub-clones V, N and H stand out of 
the other sub-clones in their strength of colony formation.  Condition: On Day0, 
single cell suspensions each containing 2 x 104 cells of respective sub-clone were 
respectively mixed with methylcellulose on top of a soft agar layer, both layers 
contain nutrients equivalent to 10% serum, normal DMEM; photographs were taken 
on Day1 and Day7; the photographs shown above are of Day7.   





N and H stood out of the others with around 3 to 4 times increase in average particle area 
over 7 days; while the other sub-clones had only around 1 to 2 times increase in average 
particle area (Figure 21B, 22).  
 
However, it is important to understand the limitations in this assay.  In particular, analysis of 
photographs by ImageJ software reflected only the area of one side facing the camera, but 
not the back-side of the spheres.  Hence if cells proliferate toward the “unexposed side”, it 
was impossible to measure using 2D photographs.  In addition, not all single cells on Day0 
could start to divide and eventually proliferate into larger spheres till Day7.  Hence the 
analysis had a number of assumptions, including survival of the suspending cells; changes in 
sphere size were based on proliferation, and that individual cell size did not change 
throughout the incubation period.   
 
3.1.5 Growth of subcutaneous xenograft tumour in CD1 nude mice 
Anchorage independent proliferation in vitro is often believed to reflect a cancer cell line’s 
potential to form tumours in vivo (Cifone & Fidler 1980; Mani et al., 2008).  Since sub-
clones V, N and H showed stronger anchorage independent proliferation than the others, it 
would be important to examine if they actually bear any advantage during in vivo growth.  In 
order to compare the sub-clones in vivo, all seven of them, along with the original primary 
mixture (designated as X), were injected into the subcutaneous layer of nude mice.  Tumour 
growth (in terms of increase in two perpendicular diameters of the tumour) was measured by 
a caliper twice a week (Figure 22A).  In the growth curve of tumours over 28 days, growth 
rates of sub-clones V and H were always ahead of the rest after Day10, whereas sub-clones E, 
N, T and the original primary mixture (X) grew at similar rate with about a 5-day lag behind 
V and H to reach the same tumour size.  Sub-clone K displayed about another 5-day lag 
behind E, N, T and X, and sub-clone M was the slowest with around a 18-day lag behind 
sub-clones V and H to reach the same tumour size.  Hence, no direct relationship was 
observed between anchorage independent proliferation and subcutaneous tumour growth 
among these mouse pancreatic cancer cells.  Despite that, sub-clones V, N and H did grow 
relatively well in the subcutaneous layer of immunocompromised mice. 
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(A) 
Percentage of cells that has grown into colonies on Day7 
(B) 
Figure 21 A representative set of data of anchorage independent proliferation of the 
seven sub-clones. (A) – Ratio of average 2D-size of cell spheres (measured by ImageJ  
arbitrary particle area) on Day7 versus that on Day1; error bars represent standard 
error with sample size (colony counts) > 150 (B) - Percentage of cells that had grown 
into colonies on Day7; a colony was defined by the size being equal to or more than 
double over 7 days, i.e. proliferated. Condition: On Day0, single cell suspensions 
containing 2 x 104 cells of each sub-clone were mixed with methylcellulose on top of a 
soft agar layer, both layers contain nutrients equivalent to 10% serum, normal DMEM; 
photographs were taken on Day1 and Day7, and analyzed by ImageJ using “arbitrary 
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Growth of subcutaneous tumours formed by injecting the sub-clones  
Figure 22 
(A) 
Figure 22 (A) – Subcutaneous growth rate of tumours formed with each pancreatic cancer 
cell sub-clone, alongside the original primary cells (PDX-X, mixed population) in nude 
mice over a 28 day period.  Condition: Three mice were injected with one kind of the sub-
clones (5 x 104 cells), both sides, 6 injections in total; a pair of perpendicular diameters 
were measured by a caliper twice a week.  Growth rate was calculated by dividing average 
diameters of the six tumours at a time point, by the average diameters on Day1 as the 
basis.  (B) – Three seemingly heterogeneous human pancreatic cancer cell sub-clones (in 
terms of morphology) isolated from primary cell culture, which was originally derived by 
Mark Duxbury (currently a consultant surgeon at Glasgow Royal Infirmary) with an 
excised piece of cancer tissue from a patient; photographs were taken using a 4x objective.   
(B) 
scale bar = 50 µm 



































3.1.6 Isolation of heterogeneous sub-clones from another mouse and from patient 
tumour tissues 
If heterogeneous cell types were isolated from only one mouse pancreatic tumour, it would 
have been questionable of being an exception in the transgenic strain.  Nevertheless, I did 
identify four heterogeneous cell types with primary culture derived from another mouse 
pancreatic tumour (mouse number 82739, data not shown).  Since the seven sub-clones from 
mouse 83320 offered higher potential of genetic variations, I did not further characterize that 
series of four sub-clones from mouse 82739.  Moreover, multiple genomics studies with 
patient samples have supported the existence of heterogeneous clonal populations in the 
human cancer (discussed in Introduction).  Therefore, the next essential task would be to see 
if I could isolate, in tissue culture, heterogeneous pancreatic cancer cells from patients. 
 
As a complementary investigation, I obtained primary human pancreatic cancer cells of two 
patients, which were originally derived by Mr Mark Duxbury, a Hepatobiliary consultant 
surgeon in the Royal Infirmary of Edinburgh.  By the same 96-well method to separate and 
to sub-clone mouse pancreatic cancer cells, at least 3 human pancreatic cancer cell types 
have been isolated (Figure 22B).  Due to time-limit, I only conducted one preliminary 
western blot analysis on these human cancer cell sub-clones.  In brief, they proliferated at 
different rates, particularly, one of them grew at a rate of three times faster than the others, 
and they expressed different levels of E-cadherin (data not shown), but without showing 
heterogeneity in phospho-SMADs status, p53 levels, and they did not express HNF4α.  I 
conclude that heterogeneous pancreatic cancer cells can also be found in some human 
tumours.  However, this would require much more work to characterize them and establish 
how similar or different they are to the mouse tumour heterogeneity I have identified in my 
work.   
 
3.1.7 Summary 
I identified heterogeneous cell sub-clones from primary cell culture of a mouse pancreatic 
tumour, in the sense that each of them has a unique genetic profile.  No two of them were the 
same, albeit with the limited analysis I performed.  Their cell junctional protein levels did 
not agree with the classical hypothesis of epithelial-mesenchymal transition, as they all 
expressed similar levels of ‘mesenchymal markers’, such as Vimentin, and ZEB1, while at 
the same time, they also expressed different levels of E-cadherin.  Hence they could not 
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simply be classified into either epithelial or mesenchymal cell types.  Conversely, these sub-
clones seem to agree with the hypothesis of clonal evolution in human pancreatic cancer 
cells (Yachida et al., 2010), as already discussed in the Introduction.  Notably, they showed 
differing phospho-SMAD status (which are downstream of the BMP/TGFβ receptor), and 
distinct upregulation of canonical Wnt target genes.  Hence I focused on investigating the 
BMP/TGFβ pathway, the canonical Wnt pathway, and their possible biological relevance to 
pancreatic caner progression.  
 
If resources were available during the course of my project, more efficient methods of 
characterization of the cell sub-clones could have been used, such as DNA microarray and 
proteomics. DNA microarray can simultaneously screen thousands of gene expressions with 
the cDNA library of the sub-clones, down to pico mole scale; while proteomics systems 
provide simplified and automated solutions to simultaneously detect multiple proteins by 
pre-defined antibodies.  Both methods could offer informative preliminary screenings for 
activities of any “signature pathways” in the sub-clones. 
 
A summary table of for Chapter 3.1: 
Proliferation 
Sub-clones Morphology on agar on plastic in nude mice (subcutaneous) 
E compact modereate fast 2 
V spiky/ ellipse  best slow 1 (fastest) 
N spiky best fast 2 
H spiky, overlapping best slow 1 (fastest) 
T spiky moderate fastest 2 
K flat weak slowest 3 
M cubical  weak slow 4 
 
Molecular Markers 
Sub-clones p53 HNF4α Gata6  Wnt5a CXCR4/SDF1 pSrc pFAK 
E lower higher nil nil nil lower lower 
V higher nil highest highest Both higher lower 
N higher higher nil nil nil lower lower 
H higher nil high high nil higher lower 
T higher higher nil nil SDF1 lower higher 
K lower lower nil nil SDF1 lower higher 




3.2 The MEK-ERK pathway correlated with anchorage independent proliferation, but 
not 2-dimensional proliferation on plastic culture plates.  
 
3.2.1 Phospho-ERK1/2 levels correlated with anchorage independent proliferation  
The ERK pathway correlated with stronger anchorage independent proliferation of cell sub-
clones V, N and H, as they have higher phosphorylation levels of ERK1 and ERK2 (Figure 
16B).  Although sub-clone T also showed comparable phospho-ERK levels, T is not as 
competent as V, N and H to grow in soft agar, which may be attributed to other factors that 
affect functions of phosphorylated ERK in cells, such as localization of ERK in different 
cellular compartments.  Moreover, there have been reports linking the ERK pathway to 
anchorage independent proliferation, including in some breast cancer cell lines bearing 
mutant KRas (Fukazawa & Uehara et al., 2000).   
 
To examine this hypothesis in the mouse pancreatic cancer sub-clones described here, I used 
two potent MEK inhibitors, U0126 and PD184352 (a more specific, second generation MEK 
inhibitor), which prevents MEK1/2 from phosphorylating ERK1/2.  For PD184352, 0.25µM 
was sufficient to decrease phospho-ERK levels by more than 50%, and at 1µM, virtually all 
detectable phospho-ERK levels are lost on western blot (Figure 23).  Accordingly, when 
0.25µM of PD184352 was added to V, N and H growing in soft agar assay, the average 
colony size of all three sub-clones decreased, particularly in sub-clones V and H, which were 
most sensitive to PD184352 with about 67% decrease, whereas N is less sensitive to MEK 
inhibition, showing a decrease in average colony size of about 35% (Figure 24).  U0126, a 
less specific inhibitor for MEK, also resulted in the same degree of inhibition on anchorage 
independent proliferation of sub-clones V, N, and H, but required a higher concentration 






























V N H 
   Ctrl       0.25      1     Ctrl      0.25     1      Ctrl     0.25      1 PD184352 (µM) 
Cell sub-clones 
Figure 23 (A) – Immunoblot analysis of the effect by the MEK inhibitor 
PD184352 on ERK1/2 phosphorylation in the three “anchorage 
independent sub-clones”, V, N and H.  Condition: Cells were seeded on 
Day0 in DMEM with 10% serum, then on Day1, replaced with fresh 10%-
serum medium, plus PD184352 or DMSO as shown above, and incubated 
for 16 hr before harvesting protein.  (B) - Quantification of band intensity 
of phospho-ERK2 and phospho-ERK1, relative to tubulin, as shown in (A) 
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     VDMSO      VPD          NDMSO           NPD               HDMSO      HPD                
Figure 24 (A) – Anchorage Independent proliferation of sub-clones V, N and 
H, in the presence of a relatively new and specific MEK inhibitor, PD184352, 
or with DMSO as the control.  Condition: On Day0, single cell suspensions 
each containing 2 x 104 cells of respective sub-clone were respectively mixed 
with methylcellulose on top of a soft agar layer, both layers contain nutrients 
equivalent to 10% serum, normal DMEM, plus 0.25μM PD184352 or DMSO; 
photographs were taken on Day1 and Day7; the photographs shown above are 
of Day7.  (B) Quantification of average 2D-size of colonies in ratio of Day7: 
Day1 (by ImageJ); slashed bars represent samples treated with PD184352.  
(error bar = standard error with cell spheres counted (n) > 150) 
66% 67% 
34% 
scale bar = 50µm 
Arbitrary particle area of cell spheres (measured by Image J) 







3.3 The canonical Wnt pathway  
3.3.1 Axin2 and Lgr5 as two readouts of the canonical Wnt pathway 
Since sub-clones V and H were more dependent on the ERK pathway than sub-clone N in 
anchorage independent proliferation, it implied that additional drivers were used by sub-
clone N to proliferate under anchorage independent conditions.  One of the pathways I 
examined was the canonical Wnt pathway.  First, quantitative PCRs screens of Wnt target 
genes revealed that sub-clone N had the highest transcription levels of Axin2 and Lgr5, 
followed by sub-clone V, which had around half the level, while other sub-clones show 
comparatively low transcription levels of Axin2 and Lgr5 (Figure 25).  For example, cell 
sub-clone H expressed more or less the same levels of Axin2 and Lgr5 as sub-clone T, which 
did not grow as well as sub-clone H on soft agar, suggesting that sub-clone H was unlikely to 
rely on the canonical Wnt pathway to form colonies in soft agar.   
 
There was no correlation between cells’ 2D proliferation rate on plastic culture plates and 
transcription levels of Axin2 and Lgr5.  Furthermore, comparisons of transcription levels of 
Axin2 between the sub-clones were in agreement with that of Lgr5, implying that both genes 
were effective readouts of the canonical Wnt pathway in these mouse pancreatic cancer cells.  
In contrast, other Wnt target genes that had been tested, such as Tcf7 and cMyc, did not show 
a consistent trend of transcription levels across the seven cell sub-clones.  Moreover, Myc is 
overexpressed in many cancer cells bearing KRasG12D, because Myc is a also a downstream 
transcription target of ERK (Sears et al., 2000), hence it was not a specific Wnt taget.  While 
Sox9 showed a relatively better-matched trend of transcription levels with Axin2 and Lgr5, 
its levels were higher in K and M  In addition, both Axin2 and Lgr5 reporter mice, but not 
that of Myc or Sox9, are available from the Jackson laboratory and well documented for use 
in specifically visualising canonical Wnt activity in vivo (commented by Roel Nusse, the 
Wnt homepage, Stanford University).  Therefore, transcription levels of Axin2 and Lgr5 
were adopted as the Wnt-readouts in this study.   
 
LGR5 is a G-protein coupled receptor that is present in adult stem cells in the colon and the 
skin (reviewed by Haegebarth & Clevers 2009), as well as in a subset of colorectal cancer 
cells.  It has been used as a crypt stem cell marker. It has recently been identified as a 
















































Sox9:18s  qPCR 
cMyc:18s  qPCR 
Figure 25 
Figure 25 - Quantitative PCR of analysis of some well documented Wnt 
target genes, (relative to the 18s gene),  showing that Axin2, Lgr5 and Sox9 
are expressed in a similar trend among the seven cell sub-clones, but not c-
Myc.  Notably, V and N show elevated levels of Wnt target-gene 
transcriptions (error bar = standard deviation of the mean of 3 samples).  
Condition: 50 x 104 cells were seeded onto a 6 cm dish on Day0 in normal 
DMEM, 10% serum; cells were harvested for RNA on Day2. 
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experiments, it would be of interest to find out by knockdown experiments if the canonical 
Wnt pathway promotes growth via activation of Lgr5-mediated signals in cancer cells.  
 
3.3.2 Tankyrase inhibitors suppress anchorage independent growth  
In order to examine that transcription levels of Axin2 and Lgr5 are genuinely reflecting the 
activity of the canonical Wnt pathway in promoting anchorage independent proliferation in 
these mouse pancreatic cancer cells, I used two chemically unrelated tankyrase inhibitors, 
XAV939 and IWR (their background information has been discussed in Introduction), I 
found that both drugs have consistent effects on all three sub-clones V, N and H.  Tankyrase 
binds and promotes Axin ubiquitination (Huang et al., 2009), hence inhibiting tankyrase is 
expected to stabilize Axin and in turn promote degradation of free β-catenin by the Axin1-
GSK3β-APC complex, thus suppressing  the canonical Wnt transcription programmes (Chen 
et al., 2009; Huang et al., 2009).   
 
Incubation with 5µM of XAV939 for 16 hours resulted in substantial increase in Axin1 
protein levels in all three sub-clones of V, N and H (Figure 26), in which two of them had 
high Wnt pathway activity.  At the same time, quantitative PCR indicated a decrease in 
transcription levels of Axin2 and Lgr5, without affecting transcription levels of Axin1 
(Figure 27).  This implies that transcription of Axin2 and Lgr5 are indeed responsive to 
stabilization of the Axin1 protein and decreased in activity of canonical Wnt signalling.  In 
soft agar assays, 5µM of XAV939 decreased average colony size of both N and V down to 
50% of the corresponding DMSO control, whereas H only showed a more modest decrease 
(around 11%) (Figure 28).  Consistently, use of 5µM IWR1 also resulted in the same degree 
of inhibition (data not shown).  
 
3.3.3 knockdown of β -catenin suppressed anchorage independent proliferation in cell 
sub-clone N.   
Since β -catenin acts as the “central messenger” in the canonical Wnt pathway, I examined 
whether depletion of β-catenin would affect anchorage independent proliferation of the three 
cell sub-clones V, N and H.  Knockdown of β-catenin by viral shRNA (Figure 29B) resulted 
in decrease in anchorage independent proliferation of sub-clone N, but not sub-clones V and 
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Figure 26 (A) – Immunoblot analysis of the effect by the tankyrase  
inhibitor XAV939 on Axin1 levels in the three “anchorage independent 
sub-clones”, V, N and H.  (B) - Quantification of band intensity of Axin1 
and β-catenin, relative to tubulin, as shown in (A) using ImageJ. 
Condition: Cells were seeded on Day0 in DMEM with 10% serum, then 
on Day1, replaced with fresh 10%-serum medium, plus XAV939 or 
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Axin1:18s  qPCR 
Figure 27 - Quantitative PCR analysis of Axin1, Axin2 and Lgr5 
transcriptions in response to XAV939 treatment in the anchorage 
independent sub-clones V, N and H, (relative to 18s transcription). 
Condition: 50 x 104 cells were seeded onto a 6cm dish on Day0 in 




















V                                      N                                    H 
VDMSO        VXAV         NDMSO         NXAV         HDMSO       HXAV 
Arbitrary particle area of cell spheres (measured by Image J) 
Day 
Cell sub-clones 
Figure 28 (A) Tankyrase inhibitor suppresses anchorage independent 
proliferation on soft-agar of sub-clones V and N (about 50% down), but only 
11% down in sub-clone H, suggesting V and N are relatively (to sub-clone H) 
more sensitive to down-regulation of the canonical Wnt activity.   Condition: 
On Day0, single cell suspensions each containing 2 x 104 cells of respective sub-
clone were respectively mixed with methylcellulose on top of a soft agar layer, 
both layers contain nutrients equivalent to 10% serum, normal DMEM, plus 
5μM XAV939 or DMSO; photographs were taken on Day1 and on Day7; the 
photographs shown above are of Day7.  (B) Quantification of colony size by 
Image J, using ratio of arbitrary particle area of Day7: Day1 (Error bar = 














were downregulated in all V, N and H (Figure 30B, C).  This indicates that N was more 
dependent on the canonical Wnt pathway in anchorage independent proliferation than the 
other sub-clones.   
 
Furthermore, immunoprecipitation and immunoblots revealed that sub-clone V had less β -
catenin phosphorylation by Glycogen Synthase Kinase 3 beta (GSK3β) than sub-clones N 
and H.  These phospho-β-catenin were known to be targeted for ubiquitination and 
proteasomal degradation (Liu et al., 2002).  This implies that sub-clone V might have a 
higher amount of active β-catenin than sub-clones N and H, perhaps due to lower rate of β-
catenin degradation (Figure  29A).  Hence, if only a small amount of β-catenin was needed 
to transduce sufficient Wnt signals to the nucleus, sub-clone V might still retain sufficient 
active β -catenin to support anchorage independent proliferation.  Nevertheless, I could not 
rule out another possibility that suppression of anchorage independent proliferation was 
attributed to depletion of cell-cell adhesion required during colony formation, rather than the 
canonical Wnt pathway itself.   
 
3.3.4 Summary 
Three out of the seven murine pancreatic cancer cell sub-clones, V, N and H, demonstrated 
stronger anchorage independent proliferation than the others.  Their extra-strength in 
anchorage independent proliferation was driven by both the MEK-ERK pathway and the 
canonical Wnt pathway, in which activation of the canonical Wnt pathway could be 
measured by transcription levels of two downstream target genes, Axin2 and Lgr5.  In 
addition, MEK inhibitors suppressed anchorage independent proliferation more effectively in 
cell sub-clones V and H than sub-clone N.  Conversely, Wnt inhibition by tankyrase 
inhibitors, suppressed anchorage independent proliferation in sub-clones V and N more 
effectively than in H.  However, both the MEK-ERK pathway and the canonical Wnt 
pathway were dispensable for 2-dimensional proliferation of tumour cells on plastic culture 
dishes.   
 
Thus, analysing anchorage independent proliferation revealed heterogeneous dependency on 
the MEK-ERK and the canonical Wnt pathway in a subset of cell types from a genetically-
induced mouse pancreatic tumour.  Due to limited time of my studentship, and the fact that 
the BMP-SMAD4 pathway was highly relevant to human pancreatic cancer, I chose to 
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concentrate on this, and I did not further study anchorage independent proliferation of sub-
clone N.     
 
A summary table for Chapter 3.2 and 3.3, regarding anchorage independent proliferation: 
Sub-clones dependency on the canonical Wnt dependency on MEK/ERK 
V high high 
N highest lower 
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Figure 29 (A) - Left, immunoprecipitation of β-catenin from 1mg protein 
lysate of each of sub-clones V, N and H; right - quantification of phospho-β-
catenin relative to total β-catenin levels, using ImageJ.  (B) Immunoblot of 
β-catenin knockdown (kd b-cat) in sub-clones V, N and H, compared with 
the non-targeting controls (nt).  (C) – Quantification of immunoblot of the β-
catenin knockdown and the non-targeting control of sub-clones V, N and H, 
relative to Actin, using Image J.  Condition: 50 x 104 cells were seeded onto 
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Sub-clones V, N and H (nt – non targeting; kd b-cat – knockdown) 
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Figure 30 (A) - Quantification of colony size by Image J; Vn refers to sub-
clone V infected with non-targeting shRNA, “Vcat” refers to cells infected 
with shRNA targeting β-catenin, and vice versa for sub-clones N, and H 
(Error bar = standard error with counts > 150). (B) and (C) – qRTPCR 
analysis of transcription levels of two Wnt target genes, Axin2 and Lgr5, in 
sub-clones V, N and H, upon knocking down β-catenin.  Condition: 50 x 104 
cells were seeded onto a 6cm dish on Day0 in normal DMEM, 10% serum; 
cells were harvested for RNA on Day2.
V n          V cat           N n           N cat         H n          H cat 
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3.4 The-SMAD4-HNF4α pathway and metabolic stress in pancreatic cancer cells 
 
3.4.1 Heterogeneous R-SMADS phosphorylation and HNF4α expression 
SMAD4 is one of the most common aberrations in pancreatic cancer; the Dpc4 gene, which 
encodes SMAD4, is lost in ductal tumours of around 50% of patients (Hruban et al., 2006).  
Western blot analysis showed that all seven cell sub-clones expressed SMAD4 at similar 
levels, suggesting that KrasG12D and p53R172H did not necessarily cause loss of the Dpc4 gene 
during tumorigenesis of Pdx1 positive cells (Figure 31).  Furthermore, immunofluorescence 
showed that SMAD4 accumulates in the nucleus of all seven sub-clones with seemingly 
uniform intensity of staining (Figure 31C).  However, it is well documented that SMAD4 
mediates at least two closely related pathways initiated by the BMP/TGFβ superfamily of 
ligands.   
 
To examine whether or not the seven murine pancreatic cancer cells possessed 
heterogeneous signalling in the BMP/TGFβ-SMADs pathway upstream of SMAD4, I used 
antibodies against phospho-SMAD1/2/3, phospho-SMAD1/5/8 and phospho-SMAD2 for 
western blotting (Figure 31B).  I temporarily assumed a classical definition that BMP 
triggers SMAD1/5/8 phosphorylation, while TGFβ triggers SMAD2/3 phosphorylation, 
although cross BMP/TGFβ phosphorylation of SMADs had also been reported (Irwin et al., 
2008; Wrighton et al., 2009).  Of interest, the BMP-responsive phospho-SMAD1/5/8 was 
detected only in cell sub-clones E, N, T, K and M, whereas the TGFβ-responsive phospho-
SMAD2 was detected only in sub-clones V, H and K, and phosho-SMAD3 in only sub-
clones V and H.  Hence, these mouse pancreatic cancer cells demonstrated heterogeneity in 
having either phospho-SMAD1/5/8 or phospho-SMAD2/3, except for sub-clone K, which 
had both BMP- and TGFβ-mediated SMAD phosphorylation.  
 
As discussed in an earlier ‘Result’ section (3.1), screening for heterogeneous gene 
expressions revealed that only cell sub-clones E, N and T, and very weakly for sub-clone K, 
expressed HNF4α, an orphan nuclear receptor (and also a transcription factor) that is critical 
in embryonic development and glucose metabolism in the adults pancreatic cells.  A 
correlation has thus emerged between HNF4α expression and SMAD1/5/8 phosphorylation, 
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Figure 31 
Figure 31 – (A) A list of SMAD antibodies used in the immunoblot in (B), and their 
respective specificity to different SMADs.  (B) Immunoblot analysis of phospho-SMAD status 
and expression of HNF4α, in the seven mouse pancreatic cancer cell sub-clones. Condition: 
50 x 104 cells were seeded onto a 6cm dish on Day0 in normal DMEM, 10% serum; cells were 
harvested for protein on Day2.  (C) Immunofluorescent staining of SMAD4 and DAPI in the 
nuclei of the seven cell sub-clones. Condition: cells were seeded on coverslips on Day0 in 









Phospho-SMAD antibodies Specificity 
Cell Signaling 9511 SMAD1 (60kDa), SMAD5 (60kDa), SMAD8 (52kDa) 
Cell Signaling 3108 (138D4) SMAD2 (60kDa) 
Epitomics EP823Y SMAD1 (60kDa), SMAD2 (60kDa), SMAD3 (52kDa) 









not express HNF4α.  While cell sub-clone K, which showed both phospho-SMAD1/5/8 and 
phospho-SMAD2/3, expressed little HNF4α.  Such a low level of HNF4α in sub-clone K 
might have been an outcome of counteractions between the BMP-SMADs and the TGFβ-
SMADs pathways (this will be further discussed in a later section).   Furthermore, sub-clone 
M did not express HNF4α despite having phospho-SMAD1/5/8. This indicates that phospho-
SMAD1/5/8 might be required but not sufficient to induce HNF4α expression.   
 
To sum up with these observations, I made a hypothesis that HNF4α was downstream of the 
BMP-SMADs pathway in some of these heterogeneous mouse pancreatic cancer cell sub-
clones.  Importantly, my hypothesis was also supported by two reports in the literature that 
ablation of SMAD4 or the BMP type-1 Receptor 1A (BMPR1A) in the mouse embryo 
caused absence of HNF4α expression in the primitive endoderm and failed gastrulation 
(Sirard et al., 1998; Gu et al., 1999, discussed in Introduction 1.6.2).  In view of this, it 
would be of interest to investigate why (biological meaning) and how (signalling) such 
mouse embryonic pathway was reactivated in this mouse model of pancreatic cancer, and 
whether HNF4α was similarly expressed in a subset of cells in human pancreatic cancer 
samples.   
 
3.4.2 HNF4α was directly downstream of SMAD1/SMAD4 
In cell sub-clones E, N and T, knockdown of SMAD4 simultaneously suppressed HNF4α 
expression by a close percentage, but not in the controls which had been infected by a non-
targeting viral shRNA instead (Figure 32).  Quantitative RT-PCR showed that transcription 
of the Hnf4α gene decreased upon knocking down SMAD4 in cell sub-clone N, compared 
with the “control-N” which had been infected with non-targeting shRNA.  Hence both 
transcription and expression of HNF4α required SMAD4.  This was in agreement with a 
previous observation in the Dpc4-/- mouse embryo, in which SMAD4-deficiency caused 
absence of HNF4α expression in the primitive endoderm (Sirard et al., 1998).   
 
SMAD4 is so-called a co-SMAD that binds different TGFβ/BMP responsive R-SMADs and 
mediates their nuclear translocation.  Two of the HNF4α-negative cell sub-clones (V and H) 
showed phosphorylation of SMAD2 and SMAD3 instead of SMAD1.  Moreover, a previous 
study has shown that ubiquitous genetic deletion of BMPR1A in the mouse embryo results in 
absence of HNF4α expression and failed gastrulation, therefore, it is likely that the BMP 
106





   E                       N                    T  
Cell sub-clones 
Hnf4α:18s  qPCR 




SMAD4 knockdown - N 















Figure 32 (A) –Top: Immunoblot analysis of HNF4α-expressing sub-clones 
E, N and T, infected with non-targeting shRNA (N nt, the control) and with 
SMAD4 knockdown shRNA (Nkd41, Nkd42).  Bottom: qRTPCR analysis of 
Hnf4α transcription upon knocking down SMAD4 in sub-clone N.  (B) – 
Quantification of the immunoblot in (A), relative to Tubulin levels, using 
ImageJ.  Condition: 50 x 104 cells were seeded onto a 6cm dish on Day0 in 
normal DMEM, 10% serum; cells were harvested for protein on Day2.
Band-intensity relative to Tubulin (by ImageJ)  





receptors, SMAD1, SMAD4 and HNF4α are linked in the same pathway.  To test this 
hypothesis, I knocked down SMAD1 in cell sub-clone N using viral shRNAs.  Consistent 
with knocking down SMAD4, knocking down SMAD1 compromised HNF4α expression, 
suggesting that HNF4α was downstream of the classical SMAD1/SMAD4 pathway in these 
mouse pancreatic cancer cells (Figure 33).   
 
From here, I postulate with findings in the literature that either the TGFβ family receptors or 
the BMP family receptors were upstream of SMAD1 phosphorylation.  As a quick test for 
this postulation, I used two specific chemical inhibitors, Dorsomophin (Yu et al., 2008) and 
SB431542 (Inman et al., 2002), respectively against the BMP- and TGFβ- type-1 receptors. 
Dorsomophin suppressed phosphorylation of SMAD1 and inhibited HNF4α expression 
without affecting total SMAD4 levels (Figure 34A), whereas SB431542 did not affect 
SMAD1 phosphorylation and HNF4α expression.  SB431542 is potent inhibitor of the TGFβ 
type-1 receptors (ALK4, 5 and 7) and it potently suppressed phosphorylation of SMAD2 and 
SMAD3 in these mouse pancreatic cancer cells (Figure, 34B).  Hence treatment with 
Dorsomophin provided the first line of evidence showing that HNF4α expression was 
upregulated by SMAD1/SMAD4 downstream of the BMP receptors.   
 
3.4.3 Glucose was required for the BMP-HNF4α pathway 
The next questions were how these different mouse pancreatic cancer cells activated the 
BMPR-SMAD1-SMAD4-HNF4α pathway, i.e., was it autocrine or paracrine, and how to 
silence such pathway for further analysis.  In addition, since HNF4α is known to regulate a 
broad range of genes related to glucose metabolism in human pancreatic cells (Odom et al., 
2004), I also asked whether or not extracellular glucose concentration could affect the 
activity of the SMAD1/SMAD4-HNF4α pathway.  Both questions could be simultaneously 
answered by removing serum from the medium, while at the same time lowering glucose 
concentration from the 25mM present in standard growth medium (DMEM) to 
concentrations that are more physiologically relevant.  In human blood, 1mM glucose is 
regarded as hypoglycaemia while 4-5mM is the minimum of the normal concentration range 
(Cryer 2001, in Goodman et al., section 7 of Handbook of Physiology).   
 
Using cell sub-clone N as the paradigm, immunoblots showed that serum was dispensable 
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Figure 33 (A) – Immunoblot analysis of sub-clone N infected with non-
targeting shRNA (nt, the control) and five individual SMAD1 knockdown 
shRNAs (11, 12, 13, and 14).  (B) – Quantification of the immunoblot in (A), 
relative to Tubulin levels, using ImageJ.  Condition: 50 x 104 cells were 
seeded onto a 6cm dish on Day0 in normal DMEM, 10% serum; cells were 
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(A) Cell sub-clones 
(B) Cell sub-clones 
Figure 34 (A) - Immunoblot analysis of changes in HNF4α levels, in 
response to 5μM Dorsomorphin (DO), the BMPR1 inhibitor, and 
SB431542 (SB), the TGFβR1 inhibitor, of sub-clones E, N and T.  
Condition: Cells were seeded on Day0 in normal DMEM with 10% serum, 
then on Day1, replaced with fresh serum medium, plus respective inhibitors 
or DMSO as shown above, and incubated for 16 hr before harvesting 
protein.  
 
(B) - Immunoblot analysis of the changes in phospho-SMADs status of 
sub-clones V and N, in response to 10ng/ml TGFβ and in the presence or 
absence of the TGFβR1 inhibitor, SB431542 (SB).  Condition: Cells were 
seeded on Day0 in DMEM with 10% serum, then on Day1, washed twice 
with PBS and replaced with fresh 1mM glucose DMEM, without serum, 
plus SB, and control treatments as shown above, and incubated for 16 hr 









phospho-SMAD1 and HNF4α diminished in the absence of glucose (Figure 35).  Although 
10% serum stimulated rapid phosphorylation of SMAD1 in the absence of glucose 
(neglecting the trace amount of diluted glucose from the 10% serum), HNF4α expression 
was not upregulated.  Hence, SMAD1 phosphorylation was required but not sufficient to 
induce HNF4α expression.   
 
Next, increasing glucose concentration to 0.1mM simultaneously increased phospho-
SMAD1 and HNF4α levels.  At 1mM glucose, levels of both phospho-SMAD1 and HNF4α 
appeared to have reached their maximum, as an increase in glucose concentration up to 
25mM even decreased HNF4α and phospho-SMAD1 levels.  Therefore, 1mM glucose in the 
medium was the minimum or the threshold concentration for sub-clone N to maintain a 
“maximal intrinsic activity” of the SMAD1/SMAD4-HNF4α pathway, under serum 
starvation.   In contrast, pyruvate, another source of energy commonly used in culture 
medium, was unable to induce phosphorylation of SMAD1 or HNF4α expression.   
 
Since HNF4α levels appeared to be higher when cells were serum starved than with serum 
(comparing with the standard DMEM at 25mM glucose), I asked whether or not the pathway 
correlated with synchronization of cells at the G0 phase of the cell cycle.  I therefore probed 
for a G0 phase (quiescence) marker, p27KIP1 (Georgia et al., 2006; Besson et al., 2006; 
Oesterle et al., 2011), which also marks metabolic stress (Liang et al., 2007; Björklund et al., 
2010), and found that it was indeed upregulated upon serum starvation in a manner 
proportional to that of HNF4α levels.  More interestingly, p27KIP1 levels also correlated with 
both glucose concentration and HNF4α levels, in which p27KIP1 reached the highest level at a 
minimum of 1mM glucose.  
 
To sum up with the new information discussed above, intrinsic SMAD1 phosphorylation and 
HNF4α expression of the cells under serum starvation required at least 1mM glucose.  Also, 
HNF4α was more abundant when cells were blocked at the G0 phase by metabolic stress 
under serum starvation, which was marked by expression of p27KIP1.  In the presence of 
serum, SMAD1 phosphorylation was required but not sufficient to induce downstream 
expression of HNF4α. Glucose was essential to activate the pathway in both serum starved 
cells and proliferating cells.  
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Band-intensity relative to Tubulin (by ImageJ)
Figure 35 (A) – Immunoblot analysis of changes in HNF4α levels in cell 
sub-clone N, under different concentrations of glucose and serum. 
Condition: Cells were seeded on Day0 in normal DMEM with 10% serum 
(50 x 104 cells onto a 6 cm plate), then on Day1, washed twice with PBS 
and replaced with the medium as shown above, and incubated for 16 hr 
before harvesting for protein. (B) – Quantification of the immunoblot in (A) 
relative to Tubulin levels, using ImageJ.   
1        2       3      4      5       6       7        8      9     10 Lane 
(B) 




3.4.4 Recombinant BMP9 induced HNF4α expression  
In order to confirm that the SMAD1/SMAD4-HNF4α pathway could be activated by the 
BMP-family ligands, I treated the mouse pancreatic cell sub-clones with recombinant mouse 
BMP9 (Figure 36).  The basis for picking BMP9 among about ten other variants of BMP 
family ligands was its involvement in glucose metabolism (Chen et al., 2003; Caperuto et al., 
2008), and in phosphorylation of SMAD1/5/8 via BMP type-I receptors (David et al., 2007; 
Herrera et al., 2009). 
 
Using cell sub-clone N as the paradigm, 16 hour treatment with excess (10ng/ml) BMP9 in 
0.1mM glucose of serum-free medium increased phospho-SMAD1 and HNF4α expression 
up to a level similar to that when the cells were in 1mM glucose and treated only with BSA 
(the carrier protein of BMP9 in the stock solution).  This suggests that excess exogenous 
BMP9 and probably also some other BMP ligands could induce SMAD1 phosphorylation 
and HNF4α expression, even when glucose concentration was lower than the 1mM required 
by the cells to intrinsically activate the pathway.  Such requirement of 1mM glucose was 
likely to be upstream of the production and secretion of BMP ligands by the cells, if this was 
the true mechanism used by the cells to self-initiate the pathway in the presence of sufficient 
glucose.  Alternatively, glucose could have been upstream of some other parallel pathways 
which by-passed the normal ligand-receptor interaction to induce SMAD1 phosphorylation 
and HNF4α expression.   
 
Furthermore, in serum-medium at 0.1mM glucose, recombinant BMP9 induced only a 
modest increase in HNF4α expression.  This consistently showed that the overall HNF4α 
levels were suppressed when cells were progressing through the cell cycle (in the presence of 
serum), comparing with that when cells were under metabolic stress in the absence of serum.  
To sum up, BMP9 was identified to be an upstream ligand of the SMAD1/SMAD4-HNF4α 
pathway.  HNF4α expression was more effectively induced by recombinant BMP9 in the 
absence of serum than in the presence of serum.  In the next section, I am going to discuss 
the differences in the efficacy of HNF4α expression between serum starved cells and 
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(B) Band-intensity relative to Tubulin (by ImageJ) 
Figure 36 (A) – Immunoblot analysis of changes in HNF4α levels in cell 
sub-clone N, under different concentrations of glucose and serum. 
Condition: Cells were seeded on Day0 in normal DMEM with 10% serum 
(50 x 104 cells onto a 6 cm plate), then on Day1, washed twice with PBS and 
replaced with the medium with treatments as shown above, and incubated for 
16 hr before harvest.  (B) – Quantification of the immunoblot in (A) relative 
to Tubulin levels, using ImageJ.   




3.4.5 Recombinant TGFβ suppressed HNF4α expression  
Like cell sub-clone N, treatment with recombinant BMP9 also caused SMAD1 
phosphorylation and upregulated HNF4α expression in sub-clones E and T.  In contrast, 
recombinant TGFβ1 induced SMAD3 phosphorylation, but not SMAD1 or SMAD2, and 
diminished HNF4α levels in all three sub-clones E, N and T (Figure 37A).  This suggests 
that BMP and TGFβ pathways were counteracting each other in these mouse pancreatic 
cancer cells (Figure 37).  This was also consistent with the observation that cell sub-clones V 
and H, which did not express HNF4α, had intrinsic SMAD3 phosphorylation (Figure 37B).   
 
To check whether phospho-SMAD3 was preventing expression of HNF4α in cell sub-clones 
V and H, they were treated with recombinant mouse BMP9.  BMP9 effectively stimulated 
SMAD1/2 phosphorylation in sub-clones V and H, but no induction of HNF4α was detected.  
This suggests that additional factors were preventing or required for HNF4α expression in 
these two cell sub-clones (Figure 37C).  
  
One of the potential antagonistic factors against HNF4α expression in sub-clones V and H 
might be phospho-SMAD2, which appeared to have an inverse correlation with HNF4α 
expression among the seven cell sub-clones (Figure 31).  As mentioned in the previous 
paragraph, in sub-clones V and H, BMP9 induced SMAD1/2 phosphorylation, and 
recombinant mouse TGFβ1 induced SMAD3 phosphorylation, but not SMAD2 (Figure 
37C); while in the presence of serum in normal DMEM, both SMAD2 and SMAD3 were 
phosphorylated (Figure 31).  This suggests that ligands other than TGFβ1 in the serum could 
have induced SMAD2 phosphorylation.  Moreover, the cell sub-clone K, which weakly 
expressed HNF4α, had both intrinsic phospho-SMAD1/5/8 and phospho-SMAD2, but not 
SMAD3.  If sub-clone K’s weak HNF4α expression was attributed to a net balance of BMP- 
and TGFβ-mediated phospho-SMADs activity, then SMAD2, as a well document TGFβ-
SMAD, could have been a counteracting factor against BMP-mediated HNF4α expression.   
 
Nevertheless, since SMAD1 and SMAD2 are of the same molecular weight, they are 
indistinguishable on the immunoblots when using the phospho-SMAD1/2/3 antibody.  The 
anti-phospho-SMAD2 initially used in Figure 32 should have been able to address whether 
SMAD2 was phosphorylated in response to BMP9 in sub-clones V and H. However, it was 






Figure 37 (A) – Immunoblot analysis; treatment with 10ng/ml recombinant 
mouse BMP9 or TGFβ, sub-clones E, N and T, under 0.1mM glucose, which 
kept intrinsic phosphorylation of SMADs minimal.  (B) – Immunoblot 
analysis of  serum starved sub-clones V, H, K and N, showing intrinsic 
phospho-SMADs as compared with that in the presence of serum, at 1mM 
glucose.  (C) – Immunoblot analysis; treatment of recombinant BMP9 on 
sub-clones V and H, and side by side, treatment with recombinant TGFβ on 
sub-clones E, N and T.  Condition: Cells were seeded on Day0 in normal 
DMEM with 10% serum, then on Day1, washed twice with PBS, and 
replaced with 1mM glucose DMEM serum free medium, plus the treatments 
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clone M possessed intrinsic phosphorylation of SMAD1, it did not express HNF4α.  This 
strengthens the idea that additional factors were required for HNF4α expression. 
 
3.4.6 HNF4α was transiently expressed and stabilized at its peak level during cell cycle 
progression 
In order to examine the intrinsic phospho-SMADs status of all seven heterogeneous mouse 
pancreatic cancer cell sub-clones, I put them under 1mM glucose and compared by 
immunoblotting with protein samples of cells in the presence and absence of 10% serum.  
Consistent with cell sub-clone N, the other two HNF4α-expressing sub-clones E and T, also 
had constitutive pathway activity in 1mM glucose of serum-free medium.  However, in the 
presence of serum (which means the cells were proliferating), HNF4α expression was 
suppressed (Figure 38).   
 
This implies at least two non-mutually-exclusive possibilities that may explain the 
relationship between the presence of serum and HNF4α expression.  First, the 
SMAD1/SMAD4-HNF4α pathway may be active only in certain phases of the cell cycle, 
such as at the G0 phase.  In this case, when cells were proliferating and transitioning in cell 
cycle, the time opportunity for the SMAD1/SMAD4-HNF4α pathway throughput would be 
smaller than when cells were serum starved, leading to lower HNF4α levels on immunoblots, 
which represented an average level of all phases in the cell cycle.  Second, the 
SMAD1/SMAD4-HNF4α pathway may have been upregulated by metabolic stress during 
serum starvation; when cell are proliferating in the serum, stress was relatively minimal, and 
therefore lowering HNF4α levels.  Alternatively, serum may contain factors that suppress 
HNF4α expression, despite promoting SMAD1 phosphorylation.   
 
I first examined the possibility that HNF4α expression was upregulated only in a limited 
period in the cell cycle, as this had been suggested by several studies in the literature 
(Verdeguer et al., 2010; Takagi et al., 2010; Bonzo et al., 2012).  Notably, Verdeguer et al., 
2010 demonstrated by a time lapse video that ectopic HNF4α-GFP was expressed in the 
nucleus before and just after mitosis, using an immortalized mouse kidney cell line.  I 
therefore conducted immunofluorescence to co-stain HNF4α and phospho-histoneH3, a 
marker for mitotic nuclei (Figure 39), so as to examine whether or not these mouse 
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Band-intensity relative to Tubulin (by ImageJ) 
Figure 38 (A) – Immunoblot analysis of HNF4α expressions in sub-clones E, N and 
T, in DMEM containing 0.1mM glucose, 1mM glucose, and 1mM glucose plus 10% 
serum. Condition: Cells were seeded on Day0 in normal DMEM with 10% serum, 
then on Day1, washed twice with PBS, and replaced with modified DMEM with 
different glucose concentrations as shown above, and incubated for 16 hr before 
harvest.  (B) – Quantification of HNF4α and phospho-SMAD1 levels in the 
immunoblot in (A), relative to Tubulin levels, using ImageJ. 




pancreatic cancer cells expressed endogenous HNF4α in the same manner as in Verdeguer et 
al., 2008.   
 
Using cell sub-clone N as the paradigm, in serum-medium at 1mM glucose (i.e. proliferating 
cells), HNF4α was strongly stained in 9.5% of the nuclei, while another 11.3% showed a 
moderate-to-weak HNF4α staining, and the rest were essentially negative.  Importantly, 
HNF4α staining did not co-localize with that of phospho-histoneH3, indicating that HNF4α 
was not expressed during mitosis.  Moreover, among the HNF4α-positive nuclei, almost half 
of them (0.095/0.113 = 0.4) showed distinctively strong HNF4α staining.  This suggests that 
HNF4α expression may have started going up when the cells enter a particular stage in the 
cell cycle.  Upon reaching a maximum level, HNF4α expression started to decrease as the 
cells transit to another phase of the cell cycle.  
 
I then looked at staining of serum starved cells in 1mM glucose.  Consistent with 
immunoblot analysis described in previous sections, an overall increase in HNF4α staining 
relative to that of proliferating cells was observed, with 17% of the nuclei showing intense 
HNF4α staining, 40% showing moderate-to-weak staining, and the rest were essentially 
negative.  Nevertheless, in the absence of both glucose and serum, with camera exposure 
settings unchanged, there were still 12% of the nuclei showing intense HNF4α staining, 
while only 8% of the nuclei remained to show moderate-or-weak HNF4α staining.  This 
suggests that the glucose-dependent SMAD4-HNF4α pathway promoted an overall increase 
in HNF4α-positive nuclei, however, such pathway did not have a strong correlation with the 
nuclei showing high-HNF4α staining.  Rather, those high-HNF4α nuclei were most likely 
attributed to a glucose-independent pathway that induced transient and rapid HNF4α 
expression or stabilization, or both.  In addition, the intensity of nuclear SMAD4 staining did 
not have a correlation with the “high-and-low” levels of nuclear HNF4α staining, as SMAD4 
was uniformly stained in all nuclei when cells were in 1mM glucose, the same as shown in 
Figure 31C.  This suggests that as long as SMAD4 is present at a basal level, HNF4α can be 
expressed and additional pathways must have stepped in to regulate the turnover of HNF4α 
across different stages of cell cycle progression.  
 
To sum up, HNF4α expression appeared to start at a particular time point in the cell cycle; it 
progressively increased to a peak level, then gradually decreased to nil.  Such fluctuation 
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was mainly attributed to the glucose-dependent SMAD1/SMAD4 pathway upstream.  At the 
peak level of HNF4α expression, an unknown glucose-independent pathway “stepped-in” to 
rapidly and transiently stabilize HNF4α or to strengthen HNF4α expression.  This was 
evident by an observation that the percentage of high-HNF4α nuclei changed very little in 
response to glucose deprivation or serum starvation, comparing with changes in the 
percentage of other nuclei showing moderate-to-weak HNF4α staining. 
   
3.4.7 HNF4α can be expressed in mitotic stress under serum starvation and during cell 
proliferation at 25mM glucose in standard DMEM  
HNF4α was not expressed during the mitotic phase of proliferating cells.  However, when 
sub-clone N was serum starved, 3% of the nuclei appeared to have “trapped” in the M phase, 
and among them, 51.4% showed co-staining of HNF4α (moderate-to-weak intensity only) 
and phospho-histone-H3.  This suggests that the SMAD4-HNF4α pathway could be 
conditionally activated even during the mitotic phase, when cells experience stress of serum 
starvation.   
 
Similarly, co-staining of HNF4α (weak and moderate intensity only) and phospho-histone-
H3 was also observed in proliferating cell sub-clone N in serum-medium at 25mM glucose 
(data not shown).  In proliferating cells in 10% serum, massive activation of HNF4 under 
normal DMEM (with artificially high 25mM glucose) compared with that in 1 or 5 mM 
Glucose DMEM (Figure 40) may have been due to excessive oxidative stress arising from 
rapid metabolism of glucose during proliferation.  If time was sufficient, It would be 
informative to also conduct immunofluorescence of cells under 25mM glucose DMEM with 
10% serum, and see whether such increase in HNF4 was attributed to an increase in 
overall moderate-to-weak nuclear HNF4 staining, or to those high-HNF4 nuclei
.  As shown in Figure 39, increase in moderate-to-weak HNF4 expression was due 
to metabolic stress when cells are deprived of serum (suppressed metabolism, quiescent G0 
state as marked by expression of p27 on western in Figure 35), and such stress response 
required at least 1mM glucose.  However, the cause of those high-HNF4 nuclei is 
unclear.  It would be tempting to investigate whether we would see an increase in high-
HNF4 nuclei of proliferating sub-clone N under 25mM glucose DMEM, relative to 
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Figure 39 (A) -  Co-immunofluorescence of HNF4α and Phospho-histone H3, of cell 
sub-clone N under starvation of serum or glucose or both.  Condition: cells were 
seeded on coverslips on Day0 in 10% serum normal DMEM; then on Day1, being 
washed twice with PBS, and replaced with serum free medium conditions as shown 
above, and on Day2 being fixed for confocal microscopy.  (B) – Percentage of cells 
that showed high nuclear HNF4α staining, moderate-to-weak HNF4α staining, and no  
HNF4α staining, for each condition tested.  Over 200 cells were counted and analyzed 
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Figure 40 (A) – immunoblot analysis of HNF4α expression in cell sub-
clone N, at 1mM, 5mM, and 25mM glucose medium, in the presence of 
10% serum.  Condition: Cells were seeded on Day0 in normal DMEM 
with 10% serum, then on Day1, washed twice with PBS, and replaced 
with 10% serum, DMEM with glucose concentration respectively at 
1mM, 5mM, and 25mM (normal DMEM concentration), and incubated 
for 16 hr before harvest. (B) Quantification of the immunoblot in (A), 



















glucose metabolism, potentially involving oxidative stress from the citric acid cycle, at a 
particular time point in the cell cycle.   
 
Nevertheless, since 25mM glucose wasmuch higher than the physiological range of glucose 
concentration, it would be of little relevance to conduct further investigation at this glucose 
concentration.    
  
3.4.8 Replicative stress induced by thymidine or Gemcitabine block cell cycle 
progression and upregulated HNF4α expression 
Since blockage of cell cycle progression at the G0 phase by serum starvation upregulated 
HNF4α expression, I more specifically asked whether replicative stress was one of the stress 
factors for activating the SMAD4-HNF4α pathway.  I found that treatment with excess 
thymidine (in 1mM glucose with 10% serum) upregulated HNF4α expression in sub-clone 
cell N (infected with a non-targeting shRNA), and proportionally less so in the SMAD4 
knocked-downs of sub-clone N (Figure 41).  This shows that when DNA replication was 
blocked by thymidine, HNF4α expression was also induced by SMAD4.  Although I was 
unable to find an usable antibody for a marker of the G1-S phase, decreased p27KIP levels 
indicated departure from the G0 phase of the cells.   
 
Next, I tested if cells could also respond to Gemcitabine by inducing HNF4α expression.  As 
discussed in section 1.1.7 of Introduction, Gemcitabine is the first ever therapy for the 
treatment of pancreatic cancer.  It is a nucleoside analogue in which the hydrogen atoms on 
the 2' carbon of deoxycytidine are replaced by fluorine atoms, thereby substituting for 
normal cytidine during DNA replication (reviewed by Rivera et al 2009).  Hence DNA-
replication is attenuated at the G1-S phase by the insertion of a faulty nucleoside 
(Gemcitabine), and eventually induced apoptosis.  
 
Similar to the thymidine-block experiment, HNF4α expression increased in response to 
incubation with 100nM Gemcitabine (Figure 42), the minimum amount to kill these mouse 
pancreatic cancer cells in 5 days in vitro, as determined by SRB assay (Figure 43).  
Conversely, at 500nM Gemcitabine, induction of HNF4α expression was less robust than at 
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Figure 41 (A) – Immunoblot analysis of changes in HNF4α levels in response to 
thymidine block at 1mM glucose, in cell sub-clone N infected by non-targeting shRNA 
(Nnt) and that infected by SMAD4-knockdown shRNAs (N41, N42). Condition: Cells 
were seeded on Day0 in normal DMEM with 10% serum, then on Day1, washed twice 
with PBS, and replaced with 1mM glucose DMEM serum free medium, plus the 
treatments as shown above, and incubated for 16 hr before harvest. (B) – Quantification 
of the immunoblot in (A), relative to Actin levels, using ImageJ.   
Figure 41 
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Figure 42 (A) -  Immunoblot analysis of changes in HNF4α levels in response 
to 100nM and 500nM Gemcitabine, and in the presence or absence of BMP 
receptor-inhibitors.  Condition: Cells were seeded on Day0 in normal DMEM 
with 10% serum, then on Day1, washed twice with PBS and replaced with 
1mM glucose DMEM serum free medium, plus the treatments as shown above, 
and incubated for 16 hr before harvest. (B) – Quantification of the immunoblot 
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Figure 43 
Figure 43 (A) – The “kill curve” by Gemcitabine of each of the seven cell sub-
clones, measured by SRB assay, over a 5-day incubation period with a range of 
Gemcitabine concentration at 10, 20, 40, 80, or 100nM.  (B) – Showing the 
seven sub-clones’ IC50, the concentration of Gemcitabine needed to reduce cell 
population to half of that of the control, which was treated with only PBS.  IC50 
calculation was performed by using Prism software; please note that sub-clones 
K and M were sensitive to Gemcitabine even at 10nM, so the IC50 value of them 
were not accurate. 























































X axis: Log Gemcitabine concentration (nM) 
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Hence, a titration experiment will be required to determine an optimal concentration 
(between 100nM to 500nM) of Gemcitabine that would cause maximal induction of HNF4α 
expression in these mouse pancreatic cancer cells over 16 hr incubation.  Furthermore, 
Gemcitabine-induced HNF4α expression could be suppressed by both Dorsomorphin and 
LDN193189, and this was also true in thymidine blocked sub-clone N (data not shown), 
suggesting that HNF4α was upregulated downstream of the BMP pathway while under 
replicative stress.  
 
I also compared the sensitivity to Gemcitabine of all seven mouse pancreatic cancer cell sub-
clones, using SRB assay.  Notably, in standard DMEM at 25mM glucose with 10% serum, 
the three HNF4α-expressing cell sub-clones E, N and T, had a moderately higher IC50 of 
Gemcitabine than the other cell sub-clones, suggesting that the BMP-SMAD1/SMAD4-
HNF4α pathway might have offered survival advantage in coping with cell cycle blockage 
and apoptosis caused by Gemcitabine.  Owing to time limit within the scope of the project, I 
was unable to further investigate into this potential relationship.  Especially, I would need to 
optimise a condition for cells to proliferate in serum medium at 1mM glucose for a long 
enough period of time, in order to observe cytotoxic effects induced by Gemcitabine.   
 
To sum up with the new information described above, the BMP-SMAD1/SMAD4-HNF4α 
pathway can be activated by replicative stress caused by Gemcitabine or excess thymidine, 
which blocked DNA replication at the G1-S phase.  However, HNF4α levels during 
“thymidine- or Gemcitabine-block” of cells were essentially lower than that when cells were 
serum starved.  This may be because serum starvation induced both metabolic and 
replicative stress to the cells, while thymidine block induced replicative stress only.   
 
In addition, HNF4α could also be upregulated in proliferating cells by high glucose 
concentration (25mM), and this implies a potential role of oxidative stress in HNF4α 
expression.  However, since 25mM glucose is much higher than the physiological 
concentration range of 1-to-5 mM, other methods should be used to induce oxidative stress 
in proliferating cells in serum-medium at 1mM glucose (this will be discussed in the 





3.4.9 HNF4α is overexpressed in early PanIN lesions 
Consistent with what is published in the literature, HNF4α is widely expressed in the normal 
pancreas in mouse.  Immunohistochemical staining of murine pancreatic tumour sections, 
from which the heterogeneous cell sub-clones were derived, revealed that HNF4α was 
overexpressed in epithelial tumour cells, but not in stromal cells (Figure 44).  In some less 
well-differentiated tumour regions, cells having positive nuclear HNF4α staining co-existed 
with cells not having nuclear HNF4α staining in a woven-like pattern, indicating possible 
dissociation and invasion of tumour cells into the surrounding stroma (Figure 44E).  Results 
from staining HNF4α in sections of Pdx1-Cre/ KrasG12D/+ mice indicated that HNF4α was 
already overexpressed in early PanIN lesions induced by mutant KRas.  Five out of five 
pancreatic tumours from Pdx1-Cre/ KrasG12D/+ mice show readily detectable HNF4α staining, 
and nuclear staining of SMAD4 was also observed in all corresponding lesions (Figure 45).  
Mutant p53 was not required for upregulation of HNF4α, as knockdown of mutant p53 in 
cell sub-clone N did not obviously affect HNF4α levels.   
 
Likewise, HNF4α was overexpressed in epithelial neoplasia and tumours in human 
pancreatic caner sections, but not in stromal cells, in 8 out of 8 cases examined (Figure 46).  
Unlike in the mouse model with both mutant KRas and mutant p53, HNF4α staining was not 
observed in any of the less well-differentiated regions in human pancreatic cancer sections.  
This may be due to the fact that transgenic mice are homogenously bearing the p53R172H 
mutant, which is known to have caused properties associated with invasion and metastasis.  
However, in human pancreatic cancer, there are a lot more variations among patients; p53 
may have been lost, or mutated, but not necessarily at codon-175.   
 
Unsurprisingly, staining of SMAD4 in consecutive sections of human pancreatic cancers 
revealed more diverged genetic differences between human cancers and the Pdx1 mouse 
model.  Around 50% cases demonstrated the co-presence of both SMAD4 and HNF4α in 
epithelial tumour cells (Figure 46), while the 50% cases had lost SMAD4, despite HNF4α 
being expressed (Figure 47).  In one case, SMAD4 was present in only some forms of the 
HNF4α-positive tumours or lesions, indicating that overexpression of HNF4α in human 
pancreatic cancer may be subjected to different upstream regulations.  This idea may be 
further supported by the fact that two human colorectal cancer cell lines, HT-29 and SW480, 




Scale bar = 50 μm 
Figure 44 - Immunohistochemistry of HNF4α on mouse pancreatic 
sections, photographs were taken using the 20x objective lens, except for 
(B) which was taken using the 10x objective lens.    (A) - Normal pancreas 
of a 12-week old adult mouse.  (B) - Low grade PanINs observed in a Pdx1-
Cre; LSL-KrasG12D mouse. (C) - High grade PanINs / tumours (Pdx1-Cre; 
LSL-KrasG12D) (D)- Tumours (Pdx1-Cre; LSL-KrasG12D; LSL-Tp53R172H). 
(E) Poorly differentiated regions in the tumour (Pdx1-Cre; LSL-KrasG12D; 
LSL-Tp53R172H) .    
Figure 44 
E 
* D and E are sections of the tumour (Pdx1-Cre; LSL-KrasG12D; LSL-Tp53R172H) 
from the mouse where the seven sub-clones were derived.  
Epithelial tumour cells 
Stromal cells  
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Scale bar = 50 μm 
Figure 45 - Immunohistochemistry of SMAD4 and HNF4α on consecutive 
paraffin sections of mouse pancreatic cancer.  Co-localization was found in 5 
out of 5 Pdx1-Cre; LSL-KrasG12D mice.  The pair of photographs on the top 
row were taken using the 10x objective lens, while the pair at the bottom 
















Figure 46 - Immunohistochemistry of SMAD4 and HNF4α on 
consecutive sections of human pancreatic adenocarcinoma (4 of the 
8 cases that show co-localization of SMAD4 and HNF4α).  (A): 
UB05-11932-1E  (B) UB04-17103-1d (C) UB05-11932-1E `(D) 
UB05-18166-1O.   Photographs were taken using the 20x objective 






















Figure 47, Immunohistochemistry of SMAD4 and HNF4α on 
consecutive sections of human pancreatic adenocarcinoma (another 4 of 
the 8 cases that show positive HNF4α but negative SMAD4 staining). 
ECMC patient sample number (A): UB06-1467-1J (B): UB05-21131 
(C): UB05-21131-1P, (D): UB05-18166-1O.  Photographs (A) were 
taken using the 4x objective lens; (B) and (D) were taken using the 10x 














suppressed HNF4α expression in three other SMAD4-intact cell lines tested (A549, lung 
carcinoma; HepG2, hepatocarcinoma; Caco2, colorectal cancer) (Figure 48).  This was in 
contrast to the mouse pancreatic cancer cell sub-clones, which showed near complete 
absence of HNF4α upon Dorsomorphin treatment (Figure 34A).   
 
To sum up, overexpression of HNF4α was an early event during the formation of pancreatic 
lesions as a consequence of KRasG12D mutation.  HNF4α continued to be irregularly 
expressed in epithelial cells throughout the progression from early PanINs to higher grade 
PanINs, and eventually to pancreatic adenocarcinomas.  HNF4α was also overexpressed in 
human pancreatic cancer, but in contrast to the mouse model, SMAD4 was not necessarily 
present, indicating that in human pancreatic cancer, there are likely additional regulatory 
levels of HNF4α expression, as well as more complicated genetic aberrations during 
carcinogenesis.  This is further supported by the observation that, in a series of human cancer 
cell lines endogenously expressing HNF4α, Dorsomorphin downregulated HNF4α only in 
some of the these cell lines, whereas Dorsomorphin can downregulate HNF4α levels in all 
three E, N and T murine pancreatic sub-clones.  
 
3.4.10 HNF4α was dispensable for proliferation in standard DMEM with serum 
In order to find out the biological function of HNF4α and the BMP pathway in these mouse 
pancreatic tumour cells, HNF4α was stably knocked down by three individual viral shRNAs 
(Figure 49).  Comparing with the non-targeting shRNA controls, all three HNF4α-positive 
cell sub-clones E, N and T, upon knockdown of HNF4α, did not show obvious changes in 
proliferation rate in complete medium (Figure 49).  Owing to limited time towards the end of 
my studentship, I could not further investigate whether or not HNF4α played a role in cell 
proliferation of sub-clones E, N and T under more physiologically relevant glucose 
conditions, such as 1mM and 5mM. 
  
3.4.11 HNF4α expressing cells appear more tolerant to stress under low glucose 
condition 
Because of the roles of HNF4α in controlling glucose metabolism, I asked whether or not 
HNF4α-positive tumour cells were more resistant to hypoglycaemic conditions in the 
absence of exogenous serum growth factors.  Of interest, cell sub-clone N could maintain a 
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(A) 
Figure 48 (A) – Immunoblot analysis of changes in HNF4α levels, in response to 
5μM Dorsomorphin, of five established human cancer cell lines that express 
HNF4α, respectively, A549 (lung cancer), HepG2 (hepatocarcinoma), Caco2, 
HT29, and SW480 (colorectal cancer).  Condition: Cells were seeded on Day0 in 
normal DMEM with 10% serum, then on Day1, replaced with the same but fresh 
serum medium with 5μM Dorsomorphin or DMSO, and incubated for 16 hr before 
harvest (B) – Quantification of the immunoblot in (A), relative to Tubulin levels, 
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Figure 49 (A) – Immunoblot analysis of knocking-down HNF4α in sub-clones E, N and T, 
using three individual viral shRNAs (a1, a3, a5), along with the control cells infected with 
non-targeting shRNA (nt).  (B) – SRB proliferation assay of the HNF4α-knocked-down sub-
clones, over 5 days in normal DMEM with 10% serum.  Condition: on Day0, 500 cells  
were seeded onto each well of a 96-well plate, repeated for 6 wells per knockdown/control, 
and setting up three identically seeded plates for harvesting protein (fixing cells for SRB 
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“healthy”, unstressed morphology for at least 2 days in 1mM glucose containing DMEM, 
showing little difference from that in 25mM glucose DMEM; except that the cell density 
became higher in 25mM glucose (Figure 50).  This suggested that higher glucose 
concentration resulted in more cell proliferation over two days.   
 
In contrast, cell sub-clones V and H did not appear to be able to tolerate a low 1mM glucose 
concentration, as they displayed a “stressed” morphology, and many detached from the 
displayed culture dish (Figure 51, 52).  However, V and H remained typical in morphology 
and confluency in 25mM glucose, suggesting that glucose was more likely the determinant 
of viability.  Hence the HNF4α-positive cell sub-clone N was more tolerant to low glucose 
conditions than HNF4α-negative cell subclones, such as V and H.   Recombinant BMP9 
neither relieved the “stress” morphology of V and H nor induced any changes in the 
morphology of N, suggesting that although BMP9 could trigger phospho-SMAD1/5/8 
responses in V and H, this was insufficient to provide support for their survival under 
hypoglycaemic conditions.   
 
To test whether or not HNF4α conferred sub-clone cell N with its ability to survive under 
low glucose conditions, I treated the cells with recombinant mouse TGFβ1, which I 
previously showed that it inhibited phosphorylation of SMAD1/5 and HNF4α expression 
(back in Figure 37C).  Cell sub-clones E, N and T responded to recombinant mouse TGFβ1 
with an apparently “stressed” morphology (Figure 53).  In contrast, V and H, in which there 
was intrinsic phosphorylation of SMAD2 and SMAD3, only showed modest morphological 
changes in response to recombinant mouse TGFβ1 (Figure 54).  As a control, I added SB-
431542, a TGFβ type-1 receptor inhibitor, and this relieved the “stress” morphology induced 
by recombinant mouse TGFβ1 on cell sub-clones E, N and T, and the inhibitor did restore 
phosphorylation of SMAD1 and HNF4α as shown on immunoblots (Figure 53).  As for the 
two phospho-SMAD1 expressing but HNF4α-low or negative cell sub-clones, K and M, they 
appeared stressed and more spindly-like (Figure 55), but not as severely as that was observed 
in cell sub-clones E, N and T.   
 
To sum up, the BMP-SMAD1/SMAD4-HNF4α pathway appeared to be important for cell 
sub-clones E, N and T to survive and proliferate (with usual morphology) under low glucose 
136
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Figure 50 - Phase contrast photographs (taken with a 10x objective lens) 
showing the morphologies of sub-clone N upon treatment with 
recombinant mouse BMP9 or with recombinant mouse TGFβ1 for 48 hr.  
Condition: cells were seeded in normal DMEM with 10% serum on 
Day0; then on Day1, cells were washed with PBS twice and replaced 
with normal DMEM or 1mM glucose-DMEM, serum free, plus 
respective treatments as shown above.  Photographs were taken on 
Day3.  
Figure 50 
scale bar = 50µm 
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Cell  sub-clone V 
Figure 51 - Phase contrast photographs (taken with a 10x objective lens) 
showing the morphologies of sub-clone V upon treatment with recombinant 
mouse BMP9 or with recombinant mouse TGFβ1 for 48 hrs.  Condition: cells 
were seeded in normal DMEM with 10% serum on Day0; then on Day1, cells 
were washed with PBS twice and replaced with normal DMEM or 1mM 
glucose-DMEM, serum free, plus respective treatments as shown above.  
Photographs were taken on Day3.  
Figure 51 
scale bar = 50µm 
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Cell sub-clone H 
Figure 52 - Phase contrast photographs (taken with a 10x objective lens) 
showing the morphologies of sub-clone H upon treatment with recombinant 
mouse BMP9 or with recombinant mouse TGFβ1 for 48 hrs.  Condition: cells 
were seeded in normal DMEM with 10% serum on Day0; then on Day1, cells 
were washed with PBS twice and replaced with normal DMEM or 1mM 
glucose-DMEM, serum free, plus respective treatments as shown above.  
Photographs were taken on Day3.  
Figure 52 
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Figure 53 
Figure 53 -Phase contrast photographs (taken with a 10x objective lens) 
showing the morphologies of sub-clones E, N and T incubated in 1mM 
Glucose DMEM, serum free.  Condition: cells were seeded in normal 
DMEM with 10% serum on Day0; then on Day1, cells were washed with 
PBS twice and replaced with 1mM glucose-DMEM, serum free, plus 
respective treatments (2.5ng/ml mouse recombinant TGFβ, 5μM SB431542).  
Photographs were taken on Day3.  
DM O 
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Figure 54 
Figure 54 - Phase contrast photographs (taken with a 10x objective lens) 
showing the morphologies of sub-clones V and H incubated in 1mM Glucose 
DMEM, serum free.  Condition: cells were seeded in normal DMEM with 
10% serum on Day0; then on Day1, cells were washed with PBS twice and 
replaced with 1mM glucose-DMEM, serum free, plus respective treatments as 
shown above (2.5 ng/ml mouse recombinant TGFβ, 5μM SB431542).  
Photographs were taken on Day3.  
   






Figure 55 – Phase contrast photographs (taken with a 10x objective lens) 
showing the morphologies of sub-clones K and M incubated in 1mM Glucose 
DMEM, serum free.  Condition: cells were seeded in normal DMEM with 
10% serum on Day0; then on Day1, cells were washed with PBS twice and 
replaced with 1mM glucose-DMEM, serum free, plus respective treatments as 
shown above (2.5 ng/ml mouse recombinant TGFβ, 5μM SB431542).  
Photographs were taken on Day3.  
Carrier BSA TGFβ
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and serum-deprived conditions, implying that HNF4α may play a role in survival or 
maintenance of a subset of pancreatic tumour cells.  
 
3.4.12 Summary of the novel SMAD4-HNF4α pathway   
HNF4 was expressed at a basal level in many cells of the normal pancreas, but was 
overexpressed in a subset of neoplastic cells as early as in PanIN lesions during 
tumorigenesis induced by mutant KRasG12D alone or by the presence of both mutant 
KRasG12D and mutant p53R172H.  HNF4α expression in cultured mouse pancreatic cancer cells 
was directly downstream of the BMP pathway, as knockdown of SMAD4 or SMAD1 in 
mouse pancreatic cancer cells shows correspondingly decreased HNF4α levels.  Notably, 
this pathway has been indirectly indicated by two previous studies using knockout mouse 
embryos (Sirard et al., 1998; Gu et al., 1999, discussed in Introduction 1.6.2).  
 
This SMAD4-HNF4α pathway was cell autonomous and required the presence of at least 
1mM glucose (at the point of cell seeding).  In proliferating cells, HNF4α appeared to be 
progressively increased to a peak level, then gradually decreased to nil within a particular 
time frame in the cell cycle.  Once HNF4α reached its peak level in the nucleus, an 
unknown, glucose-independent pathway rapidly and transiently stabilized HNF4α, before 
HNF4α levels went downhill.  On the other hand, in cells being blocked from cell cycle 
progression, the SMAD4-HNF4α pathway could be upregulated as long as stress persists, 
including metabolic stress under serum starvation, which was marked by expression of 
p27KIP1, and replicative stress, which resulted from blockage of DNA replication by 
thymidine or by Gemcitabine.   
 
Treatment with recombinant BMP9 induced HNF4α expression, while recombinant TGFβ1 
inhibited HNF4α and induced SMAD3 phosphorylation.  This suggests that BMP-and 
TGFβ-mediated pathways played a counteracting role in controlling expression of HNF4α.  
Loss of HNF4α expression upon TGFβ1 treatment causes an apparently stressed-phenotype 
in cell sub-clones E, N and T under serum starvation, but not in control conditions.  Along 
with HNF4α’s well documented roles in mediating glucose metabolism, these data suggest 
that HNF4α may promote the survival of cell sub-clones E, N and T when glucose is low and 
growth factors are scarce in the hypoxic intra-tumour environment of pancreatic 




When the BMP pathway was inhibited by Dorsomorphin (which suppresses ALK2, 3, 6) in 
sub-clone E, phospho-SMAD3 levels increased sharply (Figure 34A).  This suggests that 
activated BMPR1 (ALK2, 3, 6) may have an inhibitory effect on TGFR1 (ALK4, 5, 7)’s 
serine/threonine kinase activity, which was relieved upon inhibition by Dorsomorphin.  
Alternatively, activation of the BMP pathway may have suppressed the expression of TGF 
receptor kinases that phosphorylate SMAD3.  In contrast, sub-clones N and T did not appear 
to share a similar mechanism of flipping between phospho-SMAD1 and phospho-SMAD3.  
 
In fact, under 1mM glucose DMEM with 10% serum, all seven sub-clones showed strong 
phosphorylation of the BMP-SMADs (1/5/8), but not TGF-SMADs (2/3), as shown in 
Figure 37B and 38.  Only under artificially high 25mM glucose DMEM with 10% serum, 
could we see phosphorylation of TGF-SMADs (2/3),  as in Figure 31.  These suggest that 
when mouse pancreatic cancer cells were under 1mM glucose DMEM, and exposed to both 
TGF and BMP ligands in serum, the BMP pathway was preferentially activated.  When 
glucose was high at 25mM, phosphorylation of TGF-SMADs (2/3) started increase in sub-
clones V and H (Figure 31), which were their intrinsic “preferred pathway” in the absence of 
serum (Figure 37B).  So there are a pair of competitive mechanisms in which glucose boost 
the cells’ intrinsic pathway, in a glucose concentration-dependent manner; while growth 






4.1 On clonal heterogeneity and origin of cancer cells 
As a supplement to Introduction Chapter 1.8, nevertheless, it is important to note that 
isolation of the cell sub-clones does not indicate whether they were of monoclonal or 
polyclonal origin, or transformed through clonal evolution; they could have evolved during 
primary culture in vitro, too.  Since most if not all normal pancreatic cells are subjected to 
express KrasG12D and p53R172H under Pdx1-CRE, pancreatic cancers in this mouse model are 
more likely to be of polyclonal origin.  This also formed the basis of my project trying to 
identify heterogeneous cancer cell populations, and their molecular markers and properties.    
 
With the use of the Estrogen Receptor (ER)/Tamoxifen system, as well as fluorescent 
proteins, perhaps in the future more lineage genes will be examined for the types of 
pancreatic cells that are susceptible to transformation by mutant KrasG12D.  For example, 
somatostatin, glucagon, pancreatic polypeptide, and gherlin, which mark their corresponding 
pancreatic cell types, as shown in Figure 10.  If time was sufficient during the course of my 
project, karyotyping of chromosomes may also reveal more of the similarities and 
differences between the sub-clones, and if any of them retain some markers of their lineage 
origin.  This may answer, for example, whether sub-clones E, N and T were evolved from 
the same particular normal pancreatic compartment, and sub-clones V and H from another.  
 
4.2 Common features among subgroups of heterogeneous cell sub-clones  
HNF4α was expressed only in cell sub-clones E, N and T, which had intrinsic 
phospho-SMAD1.  In contrast, two of the HNF4α-negative cell sub-clones V and H, had 
intrinsic phospho-SMAD2 and phospho-SMAD3.  Such diversity implied two groups of 
cells respectively sharing common features, possibly evolved from two different ‘lineages’ 
in the normal pancreas during tumorigenesis driven by KrasG12D and p53R172H .   
 
In particular, both V and H transcribed the Gata6 gene (detected by QRT-PCR) and the 
WNT5A protein.  GATA6 expression has been reported to suppress HNF4α expression in 
the developing mouse embryo (Morrisey et al., 1998).  Interestingly, cell sub-clone K had 
both BMP- and TGFβ-mediated phospho-SMADs and it  weakly expressed HNF4α.  
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Although cell sub-clone M had intrinsic phospho-SMAD1, it did not express HNF4α, 
suggesting that additional pathways, genetic or epigenetic factors were required for the 
Hnf4α gene transcription.  This strengthens the idea that cell sub-clones E, N and T share 
more common genetic characteristics with one another.   
 
In view of this, it would be of interest to examine whether cell sub-clones E, N, and T, or the 
other subgroup of V and H, share common chromosome alterations.  It would also be of 
interest if time allowed me to conduct immunohistochemistry with phospho-Smad2 and 
Phospho-Smad1/5/8 antibodies, and to see how these two cell types are distributed in the 
normal pancreas and in the original tumour sections.  Because these would visualise in 
which pancreatic compartments or neoplastic lesions are the two groups of cells located, and 
hence the populations of cells that are susceptible to KrasG12D-induced transformation.   
 
4.3 The BMP-HNF4α pathway and low glucose conditions 
The HNF4α-positive cell sub-clones, E, N and T, could survive and proliferate in 
1mM-glucose-containing serum-free medium for at least for 2 days, whereas sub-clones V 
and H appeared to become ‘stressed’ on Day1 and completely detached from the culture dish 
bottom on Day2.  This indicates sub-clones V and H were less tolerant to stress under low 
glucose/serum starved conditions.   
 
Moreover, only 1mM glucose (at the point of cell seeding) was sufficient to fully activate the 
SMAD4-HNF4α pathway, which may be equivalent to hypoglycaemia in human tissues 
(assuming a similar definition in mouse).  This further suggests that HNF4α may be playing 
a pro-survival, stress-responsive role to buffer against “stress”.  Considering the fact that 
TGFβ1 is inhibitory to the BMP-HNF4α pathway, overexpression of TGFβ1 in the tumour 
may gradually select against these HNF4α-positive cells as clonal evolution progresses 
through the late stage tumour.  This would be consistent with the observation that 
HNF4α-positive cells are less often found in late stage, poorly differentiated human 
pancreatic tumour sections.  Reports in the literature have generally suggested that HNF4α 
more often acts as a tumour suppressor.  However, it could be that its presence may support 




4.4 HNF4α may be regulated by multiple pathways in vivo 
As discussed in Introduction, HNF4α is well documented as a direct cause of maturity onset 
diabetes of the young.  However, it is not known whether HNF4α expression in normal 
pancreatic cells is also regulated by the BMP-SMAD4 pathway.  In a mouse model, 
deletion of BMPR1A restricted to the insulin-expressing cells does not affect pancreas 
development, but it does perturb glucose homeostasis by decreased expressions of genes 
related to insulin secretion and metabolism (Goulley et al., 2007).  On the other hand, 
deletion of SMAD4 in the mouse pancreas (using Ptf1a-Cre) does not affect glucose 
tolerance, serum lipase or amylase levels in 10-week old mice (Bardeesy et al., 2006).  If 
both observations are assumed to be on a compatible basis, it would mean that HNF4α 
expression may be regulated by BMP-mediated non-SMAD-dependent pathways in normal  
pancreatic cells.  Alternatively, compensatory pathways may have been activated 
downstream of the BMP receptors in response to ablation of the SMAD4-HNF4α pathway.  
 
However, the most direct way to know whether HNF4α is downstream of SMAD4 in normal 
pancreatic cells, and in which cellular compartments in vivo, is to stain pancreas sections of 
SMAD4-null mice.  I have been seeking paraffin sections of Pdx/Ptf1a-Cre; Dpc4flox/flox 
pancreas, but so far without success.  Specifically, requests have been sent to Nabeel 
Bardeesy (Massachusetts General Hospital) - declined, Christopher Klug (University of 
Alabama at Birmingham) - materials no longer available, and Chu Xia Deng (National 
Institute of Health) – no reply.  
 
4.5 Potential roles of HNF4α in Warburg effect  
Most differentiated normal cells metabolize glucose to carbon dioxide by oxidation of 
glycolytic pyruvate in the mitochondrial tricarboxylic acid (TCA) cycle. This reaction 
produces NADH [nicotinamide adenine dinucleotide (NAD+), reduced], which then fuels 
oxidative phosphorylation to maximize ATP production, with minimal production of lactate 
(reviewed by Vander Heiden et al., 2009).  Otto Warburg found that unlike most normal 
tissues, cancer cells tend to “ferment” glucose into lactate (glycolysis), even in the presence 
of sufficient oxygen to support mitochondrial oxidative phosphorylation (diagram in Figure 
56A).  For example, lung tumours arising in the airways exhibit aerobic glycolysis even 
though these tumour cells are exposed to oxygen during tumorigenesis (Christofk et al., 



























Figure 56 (A) - An illustration of Warburg's effect in tumour cells as 
compared with normal metabolism in differentiated cells, taken from Vander 
Heiden et al., 2009.  (B) - Illustration of the known roles of HNF4α, this far, 




This ‘aerobic glycolysis’ of glucose to lactate generates only 2 ATPs per molecule of 
glucose, whereas oxidative phosphorylation generates up to 36 ATPs upon complete 
oxidation of one glucose molecule (Lehninger et al., 1993; reviewed by Vander Heiden et 
al., 2009).  Hence aerobic glycolysis is in fact much less efficient in generating ATP than 
oxidative phosphorylation, and the reasons or advantages for such a change in glucose 
metabolism remain uncertain.  Importantly, mitochondrial functions in many cancer cells 
are not impaired (Weinhouse et al., 1976; Fantin et al., 2006; Moreno-Sanchez et al., 2007; 
reviewed by Vander Heiden et al., 2009). 
 
HNF4α is potentially linked to the Warburg effect because it can regulate the transcription of 
genes involved in glucose entry and glycolysis in vitro and in vivo (Stoffel et al., 1997), 
particularly, the glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and pyruvate kinase (Stoffel et al., 1997).  GAPDH acts in one of the multi-step chemical 
reactions to convert glyceraldehyde-3-phosphate to Phosphoenolpyruvic acid (PEP), which 
is then converted to pyruvate.  Pyruvate kinase is the key enzyme that dictates whether 
pyruvate is to undergo fermentation to lactate or to enter the mitochondrial oxidative 
phosphorylation, in which cancer cells often favour the former path.   
 
4.6 HNF4α and its role in glucose metabolism  
HNF4α has well documented roles in the metabolic control of gene expression when insulin 
is low (Yoon et al., 2001; Rhee et al., 2003).  When fasting (low insulin), HNF4α induces 
gene expressions that promote gluconeogenesis (generation of glucose from 
non-carbohydrate carbon substrates such as lactate, glycerol, and glucogenic amino acids), 
such as phosphoenol pyruvate carboxykinase (PEPCK) and glucose-6-phosphatase 
(reviewed by Gonzalez 2008).  This requires the presence of an HNF4α-coactivator, namely 
PPARγ-coactivator-1-α (PGC-1α), which is upregulated by a cyclic-AMP cascade initially 
induced by glucagon.  In the absence of PGC-1α, HNF4α-induced expression of PEPCK 
and Glucose-6-Phosphatase is greatly decreased (reviewed by Gonzalez 2008).  PGC-1α 
also regulates other metabolic transcription factors, such as FOXO1 (reviewed by Gonzalez 
2008).   
 
Another study shows that in the absence of insulin, HNF4α synergizes with FOXO1 in 
activating transcription of the gene encoding Glucose-6-phosphatase, while FOXO1 
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conversely represses HNF4α from inducing transcription of the Glucokinase gene (Hirota et 
al., 2003, 2008; Ganjam et al., 2009).  Both of these HNF4α-dependent events are 
abrogated by treating cells with insulin, which stimulates translocation of FOXO1 to the 
cytosol (Hirota et al., 2008; Ganjam et al., 2009; reviewed by Barthel et al., 2005), and 
instead allow HNF4α to potentiate transcription of the Glucokinase/Hexokinase gene (Hirota 
et al., 2008; Ganjam et al., 2009).  Hence the reciprocal action of FOXO1 and HNF4α 
appeared to be an important determinant of the metabolic shift toward glycolysis, or the 
reverse process, gluconeogenesis (Figure 56B).    
 
Relating this published literature back to my mouse pancreatic cancer cell sub-clones, in 
1mM glucose (at the point of seeding cells) without serum, and therefore in a situation 
similar to fasting and low insulin, HNF4α and its co-activator, such as FOXO1, may induce 
increased expression of Glucose-6-phosphatase, which would facilitate gluconeogenesis to 
produce glucose from non-carbohydrate carbon sources, particularly as the need for energy is 
lower in the absence of serum mitogens.  However, the cells need to survive in this low 
glucose environment as long as possible, and there will be selection for survival.  Hence, 
HNF4α-mediated gluconeogenesis may offer an advantage for these HNF4α-expressing cell 
sub-clones (E, N and T) to survive. 
 
However, in the presence of serum, which contains insulin, FOXO1 would be inactivated 
and excluded from the nucleus, meaning that HNF4α induces transcription of Glucokinase, 
which phosphorylates glucose to glucose-6-phosphate and glycolysis.  Consumption of 
glucose by proliferating tumour cells will lower the glucose concentration in medium down 
to below 1mM glucose, the threshold for effective HNF4α expression, and this may explain 
the overall decrease in HNF4α levels in cycling cells.   
 
Furthermore, substitution of 1mM glucose with 1mM pyruvate did not cause an increase in 
HNF4α levels, suggesting that upregulation of HNF4α in response to serum starvation was 
independent of pyruvate and its downstream metabolism.  Hence, HNF4α was apparently 
linked to the series of metabolic reactions, that begin with uptake of glucose by its 
transporters to the generation of phosphoenolpyruvate (the precursor of pyruvate).  Perhaps 
once there is excess pyruvate, the need for glucose uptake and the immediate metabolism of 
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glucose to produce pyruvate, is no longer required, and thus high levels of HNF4α would no 
longer be required.   
 
4.7 HNF4α overexpression suggests inactivation of the LKB-AMPK pathway 
When malignant cells exhibit a shift from oxidative phosphorylation to ‘aerobic glycolysis’, 
ATP to AMP ratios declined, and accumulation of AMP activates AMP-activated protein 
kinase (AMPK), which in turn acts to shift the metabolic pathway back to oxidative 
phosphorylation (reviewed by Vander Heiden et al., 2009).  This causes opposition to 
abnormal proliferation signals resulting from oncogene expression (reviewed by Vander 
Heiden et al., 2009; reviewed by Cairns et al., 2011).  Activation of AMPK requires the 
upstream kinase Liver Kinase B1 (LKB1), which is encoded by the gene Stk11 (Lizcano et 
al., 2004).  LKB1 is a well-documented tumour suppressor, and it is frequently mutated in 
sporadic cases of non-small-cell lung cancer and cervical carcinoma (Ji et al., 2007; Wingo 
et al., 2009; reviewed by Cairns et al., 2011).  Somatic mutation of LKB1 is found in 
patients with Peutz–Jeghers syndrome, in which they develop benign gastrointestinal and 
oral cancer lesions and an increased risk of developing a broad range of malignancies (Jenne 
et al., 1998; reviewed by Cairns et al., 2011).   
 
AMPK has been shown to negatively regulate HNF4α (Leclerc et al., 2001; Hong et al., 
2003); hence it would be of interest to elucidate the relationship between LKB1-AMPK, 
HNF4α and cancer cell metabolism.  Importantly, heterozygous deficiency of LKB1 does 
lower phospho-AMPK levels and accelerate mouse pancreatic tumorigenesis in a mutant 
KRasG12D background (Morton et al., 2010).  In isolated islet cells from mice with 
widespread homozygous deletion of the AMPKα2 subunit, glucose stimulated insulin 
secretion is not affected (Viollet et al., 2003).  This possibly indicates that absence of 
AMPK in normal cells does not necessarily lead to deregulated HNF4α activity, as HNF4α 
can be regulated by a densely overlapping network of other HNFs and transcriptional 
co-factors (Odom et al., 2004).  Hence, the regulation and role of HNF4α is complex, and 






4.8 Drawbacks in subcutaneous or orthotopic injection experiments  
Tumours formed by injection of mouse pancreatic cancer cells to the subcutaneous layer or 
back to the pancreas did not resemble the original tumour’s microenvironment.  
Importantly, no HNF4α staining was detected on sections of subcutaneous tumours of cell 
sub-clones E, N and T.  This is also true for tumour sections from orthotopic injection, in 
which HNF4α is stained only in the remaining normal pancreatic cells surrounded by 
injected tumour cells.  Hence injections of cultured cells back to the mouse do not seem to 
be of value to study this BMP-SMAD1/SMAD4-HNF4α pathway, and this probably reflects 
how limited is this approach trying to study native signalling pathways of cancer using 
xenograft tumours.  Particularly, from what is published in the literature, xenograft has 
never been able to reproduce the full scope of heterogeneity or pathology in the original 
tumour, which argues strongly against the hypothesis that a few cancer stem cells eventually 
contribute to all cancer cell types in a tumour (reviewed by Visvader et al., 2008).  This is 
not surprising at all, considering how long it generally takes for tumours to evolve in their 
environment and acquire additional mutations, and to overcome internal selective pressure. 
 
4.9 Targeting ERK, and probably also Wnt, are not enough 
Despite the fact that inhibiting MEK could suppress anchorage independent proliferation of 
the seven mouse pancreatic tumour cell sub-clones, their proliferation on 2D-plastic culture 
dish was unaffected.  Consistently, David Tuveson’s group found that knocking down 
mutant KRasG12D in primary cells derived from the same mouse model only affects 
anchorage independent proliferation, but not 2D proliferation on tissue culture dishes 
(unpublished observation, reported during the 50th BACR conference in Edinburgh 2010), 
suggesting that cell adhesion is sufficient to provide signals for tumour cells to proliferate in 
a KRasG12D-independent manner.  Furthermore, in a multicentre phase-II study, the MEK 
inhibitor PD184352 (CI-1040), which was used in my study, had been found well tolerated 
in patients, but demonstrated little antitumor activity in pancreatic cancer patients (Rinehart 
et al., 2004).  However, such study could not rule out the possibility that delivery of 
PD184352 to the tumour was not sufficiently efficient, as pancreatic adenocarcinomas 
commonly bare poor vasculature (Olive et al., 2009). 
  
Likewise, inhibition of the canonical Wnt pathway only partially suppressed anchorage 
independent proliferation in cell sub-clones V and N, but not 2-dimensional proliferation.  
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Considering only two out of the seven murine pancreatic cancer cell sub-clones were 
sensitive to Wnt-inhibition under anchorage independent condition, targeting Wnt alone 
would probably be ineffective in suppressing the overall tumour growth attributed to a 
combination of cell sub-clones that are addicted to distinct, although possibly overlapping, 
cancer driver pathways.   
 
4.10 Notes on results presentation 
All experiments shown in this thesis are representative experiments that have been repeated 
at least once, and among them, experiments related to the initial characterization of the cell 
sub-clones and to the SMAD4-HNF4α pathway have been repeated at least twice.  
 
However, and ideally, data should have been collected and presented using an average of 
data from at least three independent experiments.  For example, in analysis of cell-sphere 
sizes in anchorage independent proliferation, the correct way to present data is to take the 
mean of the average sphere area from three independent soft-agar assays, and present this 
with an error bar showing the standard deviation of the three independent averages of colony 
area.  For western blot analysis, ideally,  quantification of band intensity using ImageJ 









5. FUTURE PERSPECTIVES 
 
5.1 Deletion of HNF4α in the Pdx1 lineage  
The most straightforward way to understand the role of HNF4α in pancreatic carcinogenesis 
is to knockout HNF4α in the pancreas using the Pdx1-Cre system.  Direct homozygous 
deletion of HNF4α in the mouse pancreatic β-cells (insulin positive cells) did not cause 
developmental defects but a diabetic phenotype (Gupta et al., 2005; Miura et al., 2006), but it 
is still not known whether deletion of HNF4α in the whole pancreas will cause 
developmental defects.  It will be necessary to generate a test strain of mice with the 
genotype Pdx1-Cre/ Hnf4αflox/flox. More precisely, use of the genotype of Pdx1-CreER/ LSL-
KrasG12D/+/ Hnf4αflox/flox, with or without LSL-Tp53R172H, in which Cre recombinase is 
activated only when the animal is treated with Tamoxifen, will provide controls over the 
timing of transgenic expressions, by controlling the time and space where gene deletion 
occurs.  This would avoid any acquired artefacts during developmental stages.  Tamoxifen is 
an antagonist of the estrogen receptor which is metabolised into compounds that bind the 
estrogen receptor (ER) but without activating it (Indra et al., 1999).  Alternatively, since 
heterozygous deficiency in HNF4α did not cause diabetes in mice, it may be worth testing 
whether decreased HNF4α expression will have an effect on the formation of KrasG12D-
induced PanIN lesions.   
 
5.2 Investigation into the glucose metabolic pathways that may involve HNF4α in 
pancreatic cancer 
Assuming that the HNF4α-positive cell sub-clones E, N and T have a different glucose 
metabolic status from the rest of the cell sub-clones, an immediate experiment of interest will 
be to check the transcription levels of important metabolic enzymes that are known to be 
direct targets of HNF4α, such as glucose-6-phosphatase and Glucokinase.  This may also 
provide insight on how glucose metabolism is coupled to secretion of BMP ligands and 
initiate an ‘autoloop’ pathway.  As discussed earlier in Introduction, HNF4α is closely 
integrated into the metabolic pathway of AMPK, which is known to suppress HNF4α 
expression (Figure 56B).  Chemical agonists of AMPK, such as Metformin and the 
chemically related Phenformin (reviewed by Vander Heiden et al., 2009) can be used to see 
if HNF4α is suppressed, and to simultaneously determine whether the BMP-






how the BMP-SMAD4 is coupled to the AMPK pathway via HNF4α in the pancreas, and in 
pancreatic cancer, is to stain for HNF4α, phospho-SMAD1/5/8 and phospho-SMAD2 on 
tissue sections of Pdx1-Cre; Lkb1flox/flox, and Pdx1-Cre; LSL-KrasG12D; Lkb1flox/flox (Morton et 
al., 2010).  Loss of LKB1 in the pancreas is sufficient to initiate cancer progression, and 
heterozygous deletion of Lkb1 accelerates KRasG12D-induced pancreatic cancer progression 
(Morton et al., 2010).  Since LKB1 is long known to be an upstream activator of AMPK, loss 
of LKB would mean decreased AMPK activity, and in turn allowing increased HNF4α 
expression.  If we could understand the methods those “tougher” cancer cells use to survive 
in idle under nutrients-scarce conditions, we may be able to clear them up early before they 
“wake up” and acquire metastatic potential.   
 
5.3 Further refinement of in-vitro experimental conditions needed in order to  
accurately study pancreatic caner cell metabolism.   
One drawback of using standard DMEM in tissue culture is its high glucose concentration 
(25mM).  It was supposed to maximise the energy provided to cells so as to maximise 
survival or proliferation, however, the accuracy to study cellular pathways and gene 
expressions under such unrealistically high glucose concentration is questionable.  If time 
were sufficient within the scope of my studentship, I would examine the cell sub-clones’ 
proliferation rate or survival using DMEM with glucose concentration at 1mM 
(hypoglycaemia-equivalent) and at 5mM (normal level equivalent), in the presence of 10% 
serum.  In this case, the medium may have to be refreshed daily in order to avoid over-
depletion of glucose in the medium.  I would also put the cells under hypoxic conditions in 
an nitrogen-adjusted incubator, due to the fact that pancreatic cancer is known to be poorly 
vascularized, and therefore the cancer cells within a tumour are likely to experience both low 
glucose and low oxygen supply.  
 
5.4 Which HNF4α promoter of the two is a BMP-SMAD target? 
As discussed earlier, there are multiple splice variants of HNF4α that can be transcribed by 
two independent promoters.  A report has shown that most cell types in the pancreas, no 
matter whether human or mouse, express a basal level of HNF4α, which in some of the cell 
types are mediated by promoter-1 and while in some others by promoter-2 (Jiang et al., 
2003).  The antibody that I have been using recognizes all variants of HNF4α, therefore, use 






available) will be more informative on how HNF4α is overexpressed during pancreatic 
carcinogenesis in a mutant KRasG12D background.  This may also reveal which cellular 
compartments and which cell type in the pancreas may have given rise to cancer cell sub-
clones E, N and T.  Alternatively, performing PCRs with oligonucleotides targeting 
promoter-specific regions of the HNF4α transcript will be complementary to check which of 
the two HNF4α promoters were active in cell sub-clones E, N and T.  It is not clear whether 
these splice variants possessed different functions or are redundant; most studies in the 
literature have so far been based on the two longest variants (including my study).  Hence, if 
normal pancreatic cells express different variants of HNF4α, or using a different promoter 
from that downstream of SMAD4 (“the embryonic promoter”). Moreover, overexpression of 
HNF4α was an early event as observed in immunohistochemistry in my study, we may be 
able to distinguish early neoplastic cells from normal pancreatic cells right at the tipping 
point of PanIN evolution.     
 
5.5 Roles of the BMP-SMAD1/5 pathway in pancreatic carcinogenesis  
Although BMP induces expression of HNF4α via SMAD1/5 and SMAD4, HNF4α is 
unlikely to be the only downstream target.  Previous mouse models have provided details on 
the roles of the TGFβ type-2 receptor and SMAD4 during carcinogenesis driven by mutant 
KRasG12D, however, the BMP pathway, which classically signals through SMAD1/5/8 and 
SMAD4, has not been specifically studied.  Deletion of SMAD4 only abolishes R-SMAD-
dependent pathways, and this may have shifted the activity to non-SMAD-dependent 
pathways.  Conversely, deletion of SMAD1/5/8 may shift the BMP pathway to the 
SMAD2/3 pathway or other non-SMAD-dependent pathways, and vice versa.  It is known 
that deletion of the BMP type-2 receptor in insulin-positive cells leads to diabetic mice in the 
KRasG12D background, hence it will also provide information on whether deregulated insulin 
secretion and glucose metabolism can accelerate pancreatic carcinogenesis induced by 
KRasG12D.  In addition, it would also be informative to stain sections of normal pancreas and 
pancreatic cancer, for phospho-SMAD1/5/8 and phosphos-SMAD2/3, and to compare 
whether activities of these two classes of SMADs have a distinctive pattern in different 
pancreatic compartments. 
 
5.6 Do the SMADs regulate HNF4α expression via binding to its promoter(s) ? 
If ablation of HNF4α in the adult pancreas has an effect on pancreatic cancer progression in 






regulated by the SMADs, for example, whether the SMADs directly bind to the promoter(s) 
of HNF4α.  To do so, chromatin immunoprecipitation (ChIP) can be performed, which 
involves cross-linking DNA to protein in cell lysates using formaldehyde, sonication to shear 
DNA into fragments of less than 1000 base pairs, purification with anti-SMADs-linked 
beads, and uncoupling DNA from protein using proteinase K.  DNA is eventually purified 
and used to run quantitative PCR with oligos designed to prime for mouse HNF4α sequences 
and HNF4α promoter sequences, respectively.   
 
For cell sub-clone N as an example, setup of ChIP samples would be as follows: 
Glucose Condition (DMEM) Treatment 
1mM Serum free BSA alone 
1mM Serum free BSA, TGFβ 
1mM Serum free  BSA, BMP9 
 
ChIP with SMAD4 antibody could be used to check whether SMAD4 binds HNF4α’s 
promoter(s) sequences, and whether such binding is suppressed by treatment with TGFβ, or 
enhanced by treatment with BMP9.  Then, use of SMAD1, SMAD2, and SMAD3 
antibodies, respectively, can unveil which additional R-SMAD plays a dominant role in 
binding to HNF4α’s DNA or promoter(s) sequences in BMP- or TGFβ-stimulated 
conditions.  SMADs-DNA binding can be quantified by running qPCR with samples 
immunoprecipitated with the same SMAD antibody under the three different conditions.  
Quantitative PCR can indicate relative SMAD-DNA binding activity under different 
conditions.  
 
Potential SMAD-binding sites in the promoters(s) of HNF4α could be first predicted by 
aligning the HNF4α promoter(s) against classical SMAD-binding sequences.  If such a 
potential binding site is confirmed by PCR with DNA from ChIP,  a reporter plasmid 
containing GFP or luciferase downstream of the identified SMAD-binding sequences can be 








ChIP often needs time for optimization of conditions, a potentially quicker method to “pre-
check” DNA-protein binding is to use Electrophoretic mobility shift assay (EMSA), in which 
the presence of protein-DNA complexes is reflected by an up-shift of bands on a SDS-
PAGE, comparing with the control band using DNA or RNA alone.  The gel can also be 
transferred onto nitrocellulose membrane to probe for the protein of interest by 
immunoblotting, such as SMAD4 in this case.  However, it only addresses whether the 
SMADs have the affinity to bind a DNA sequence in the running buffer, but not whether 









My PhD project provided evidence to establish for the first time:  
 
• Cancer (malignant tumour) cells in this Pdx1-Cre mouse model are highly 
heterogeneous, and this may also apply to many other mouse cancer models that are 
driven by a pan-organ-specific promoter.  We cannot simply study primary tumour cells 
as if they were homogeneous.  
 
• A connection between the BMP/TGFβ-SMAD4 pathway and glucose metabolism, which 
acts as a stress response in mouse pancreatic cancer cells.  Although both SMAD4 and 
HNF4α appeared to be tumour suppressors during early tumourigenesis, as suggested by 
some studies in the literature, this pathway may in turn provide survival advantage to 
some of the cancer cells in a poorly vascularized intra-tumour environment.   
 
• A developmental pathway (SMAD4-HNF4α) that appeared to have been “reactivated” 
during KRasG12D induced-transformation.  This implies potential similarities in signalling 
between gastrulation of the mouse embryo and PanIN formation in KrasG12D-expressing 
compartments, considering the well-documented importance of wild-type KRas during 
embryonic development.  
  
• HNF4α IHC can be used to mark epithelial pancreatic cancer cells on tumour sections, in 
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